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Abstract	  
Chronic	  Obstructive	  Pulmonary	  Disease	  (COPD)	  is	  a	  collective	  term	  for	  emphysema,	  
chronic	  bronchitis,	  and	  obstructive	  bronchiolitis,	  which	  is	  caused	  by	  chronic	  tobacco	  smoke	  
exposure.	   COPD	   is	   a	   multi-­‐system	   disease;	   skeletal	   muscle	   is	   one	   such	   system	   that	   is	  
dysfunctional	  in	  a	  significant	  proportion	  of	  COPD	  patients.	  Muscle	  weakness	  and	  wasting	  is	  
observed	   in	   COPD	   patients,	   with	   fibre	   type	   changes	   as	   well	   as	   fibre	   atrophy	   reported.	  
Skeletal	  muscle	  as	  a	  target	  for	  pharmacotherapy	  in	  COPD	  as	  exercise	  training	  improves	  life	  
expectancy	   and	   quality	   of	   life	   in	   patients.	   Loss	   of	   protein	   contributes	   to	  muscle	   atrophy;	  
however,	  the	  mechanisms	  and	  signalling	  pathways	  involved	  in	  protein	  degradation	  are	  not	  
fully	  understood.	  	  
Autophagy	   is	   a	   protein	   degradation	   pathway	   implicated	   in	   muscle	   atrophy.	  
Additionally,	  the	  TGF-­‐β	  superfamily	  member	  -­‐myostatin	  and	  FHL1	  are	  signalling	  molecules	  of	  
interest.	  The	  cytokine	  myostatin	  is	  a	  recognised	  inhibitor	  of	  muscle	  growth,	  whilst	  FHL1	  is	  an	  
adaptor	  protein	  usually	  associated	  with	  hypertrophy	   in	  muscle.	  The	  data	  presented	  herein	  
focuses	   on	   three	   aspects:	   the	   effect	   of	  myostatin	   on	   autophagy,	   the	   interaction	   between	  
myostatin	   and	   FHL1	   in	   atrophy	   and	   the	   effect	   of	   smoke	   exposure	   on	   autophagy.	  
Furthermore,	   the	   effects	   of	   other	   atrophy	   associated	   signalling	   molecules	   (growth	  
differentiation	   factor	   15,	   GDF-­‐15	   and	   angiotensin-­‐II,	   ang-­‐II)	   on	   these	   themes	   were	  
examined.	  	  
The	   data	   show	   that	   myostatin	   is	   a	   novel	   inducer	   of	   autophagy	   indicating	   that	  
myostatin	  can	   induce	  protein	  degradation	  through	  autophagy.	  FHL1	  augmented	  myostatin	  
induced	   signalling	   in	   vitro	   and	   in	   vivo,	   suggesting	   a	   potential	  mechanism	  by	  which	   type	   II	  
fibres	  are	  more	  susceptible	  to	  atrophy	  than	  others	  and	  helping	  to	  account	  for	  the	  fibre	  type	  
changes	  and	  atrophy	   in	  COPD.	  The	  role	  of	  smoke	  exposure	  of	  autophagy	  remains	  unclear;	  
however,	  GDF-­‐15	  may	   be	   involved	   in	  muscle	   atrophy.	   Ang-­‐II	   did	   not	   induce	   autophagy	   in	  
vivo	  and	  inhibition	  of	  angiotensin	  signalling	  had	  no	  effect	  on	  autophagy	  in	  COPD	  patients.	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1.1 Chronic	  Obstructive	  Pulmonary	  Disease	  (COPD)	  
	   COPD	  is	  an	  umbrella	  term	  encompassing	  chronic	  bronchitis,	  obstructive	  bronchiolitis,	  
and	   emphysema,	   which	   leads	   to	   the	   progressive	   limitation	   of	   airflow	   (breathlessness	   or	  
dyspnoea).	  Although	  COPD	  is	  treatable	  and	  preventable,	  it	   is	  not	  fully	  reversible.	  The	  main	  
risk	   factor	   in	   the	  developed	  world	   is	  exposure	   to	   tobacco	  smoke,	  but	  chronic	  exposure	   to	  
other	   noxious	   gases	   such	   as	   indoor	   pollutants	   from	   the	   combustion	   of	   biomass	   fuels,	  
occupational	   fumes	   as	   well	   as	   environmental	   pollutants	   are	   also	   risk	   factors	   in	   the	  
developing	  world	   (Rabe	   et	   al.,	   2007,	  Mannino	   and	  Buist,	   2007,	   Smith,	   2000,	   Rabe,	   2008).	  
COPD	  is	  currently	  the	  third	  leading	  cause	  of	  death	  worldwide	  (Lozano	  et	  al.,	  2012)	  and	  10%	  
of	  the	  global	  population	  is	  affected	  by	  COPD	  as	  a	  cause	  of	  mortality	  (Buist	  et	  al.,	  2007).	  The	  
pulmonary	   effects	   of	   COPD	   are	   due	   to	   an	   abnormal	   chronic	   inflammatory	   response	  
occurring	   in	   the	  peripheral	  airways	  and	   lung	  parenchyma.	  The	   infiltration	  of	   immune	  cells	  
and	   fibrosis	   ultimately	   leads	   to	   airway	   obstruction.	   Although	   there	   is	   no	   clear	   genetic	  
predisposition	   to	   COPD,	   it	   is	   thought	   that	   those	  with	   a	  α1-­‐anti-­‐trypsin	   deficiency	  may	   be	  
more	   susceptible	   to	   COPD,	   as	   α1-­‐anti-­‐trypsin	   inhibits	   neutrophil	   elastase,	   which	   targets	  
elastin	  contributing	  lung	  damage	  and	  resulting	  in	  fibrosis	  (Yoshioka	  et	  al.,	  1995,	  Eden,	  2010).	  	  
COPD	   is	   characterised	   by	   a	   reduction	   in	   FEV1	   (Forced	   Expiratory	   Volume	   in	   one	  
second),	  which	  is	  a	  measurement	  of	  lung	  function,	  (Rabe	  et	  al.,	  2007).	  The	  Global	  Initiative	  
for	  the	  prevention	  of	  Obstructive	  Lung	  Diseases	  (GOLD)	  has	  defined	  COPD	  in	  4	  stages,	  based	  
on	   percentage	   of	   predicted	   lung	   function	   with	   GOLD	   1	   classified	   as	   mild,	   GOLD	   2	   –	  
moderate,	   GOLD	   3-­‐	   severe	   and	   GOLD	   4	   classified	   as	   very	   severe	   (Vestbo	   et	   al.,	   2013).	  
Patients	  with	  COPD	  often	  have	  periods	  of	  worsening	  symptoms	  such	  as	  increased	  dyspnoea,	  
which	  are	  known	  as	  acute	  exacerbations	  of	  COPD	  (AECOPD).	  Exacerbations	  are	  thought	  to	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be	  caused	  by	  bacterial	  or	  viral	  infections,	  which	  require	  hospital	  admissions	  (Wedzicha	  and	  
Donaldson,	  2003,	  Serres	  et	  al.,	  1998).	  	  
1.1.1 Skeletal	  muscle	  dysfunction	  in	  COPD	  
COPD	   is	   increasingly	   recognised	   as	   a	   multi-­‐system	   disease,	   with	   a	   number	   of	   co-­‐
morbidities	   such	   as	   diabetes,	   cardiovascular	   disease,	   osteoporosis	   and	   skeletal	   muscle	  
dysfunction	   (Fabbri	   et	   al.,	   2008,	   Bolton	   et	   al.,	   2004,	   Barnes	   and	   Celli,	   2009,	   Rana	   et	   al.,	  
2004).	  Of	   these	  co-­‐morbidities,	   skeletal	  muscle	  dysfunction,	  which	   includes	   impairment	   in	  
muscle	  function	  as	  well	  as	  a	  loss	  of	  muscle	  bulk,	  is	  of	  particular	  importance.	  
Body	  weight	   loss	  has	  been	  reported	  to	  occur	   in	  as	  much	  as	  49%	  of	  patients	   in	  one	  
study	   (Schols	   et	   al.,	   1993a),	   with	   skeletal	   muscle	   atrophy	   occurring	   in	   15-­‐40%	   of	   COPD	  
patients	   and	   increasing	  with	  disease	   severity	   (Engelen	  et	   al.,	   1994,	   Seymour	  et	   al.,	   2010).	  
Patients	  with	  clinical	  muscle	  atrophy	  have	  a	  fat	  free	  mass	   index	  (FFMI	  –a	  measurement	  of	  
lean	  mass	  which	  includes	  muscle	  mass)	  of	  less	  than	  15kg	  m-­‐2	  for	  women	  and	  16kg	  m-­‐2	  for	  men	  
(Baarends	  et	  al.,	  1997).	  These	  FFMI	  values	  are	  based	  on	  disease	  specific	  calculations	  and	  are	  
2	  standard	  deviations	  from	  the	  mean	  FFMI	  for	  normal	  healthy	  age	  matched	  controls	  (Steiner	  
et	   al.,	   2002,	   Schols	   et	   al.,	   1993b).	   Body	   mass	   index	   (BMI)	   is	   often	   used	   as	   a	   marker	   of	  
atrophy,	  however,	  this	  has	  lead	  to	  an	  underestimate	  of	  the	  number	  of	  COPD	  patients	  with	  
muscle	  atrophy,	  as	   some	  patients	  may	  have	  a	  normal	  BMI	  despite	  having	  a	   reduced	  FFMI	  
(Vestbo	  et	  al.,	  2006),	  therefore	  atrophy	  is	  under	  diagnosed.	  Patients	  with	  a	  loss	  of	  fat	  free	  
mass	  (FFM)	  have	  a	  lower	  quality	  of	  life	  which	  includes	  loss	  of	  independence	  and	  a	  decrease	  
in	   comfort	   levels	   compared	   to	   patients	  with	   preserved	   FFM	   (Mostert	   et	   al.,	   2000).	   COPD	  
patients	   with	   low	   FFM	   also	   have	   increased	   dyspnoea	   and	   reduced	   exercise	   performance	  
(Bernard	  et	  al.,	  1998b,	  Gosselink	  et	  al.,	  1996,	  Hamilton	  et	  al.,	  1995).	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   Skeletal	  muscle	  weakness	  is	  another	  aspect	  of	  the	  muscle	  impairment	  in	  COPD,	  with	  
an	  overall	  prevalence	  of	  30%	  observed	   in	  one	  study	  of	  590	  patients,	  again	   increasing	  with	  
disease	  severity	  (Seymour	  et	  al.,	  2010).	  However,	  quadriceps	  weakness	  has	  been	  observed	  
at	  all	  GOLD	  stages	  as	  measured	  by	  a	  reduction	  in	  quadriceps	  maximal	  voluntary	  contraction	  
(QVMC)	   (Shrikrishna	   et	   al.,	   2012).	   COPD	   patients	   have	   up	   to	   a	   30%	   average	   reduction	   in	  
quadriceps	   strength	   in	   the	   advanced	   stages	   of	   COPD	   (Man	   et	   al.,	   2003b,	   Bernard	   et	   al.,	  
1998a,	  Man	  et	  al.,	  2005b,	  Hopkinson	  et	  al.,	  2004b).	  Quadriceps	  weakness	  has	  been	  shown	  
to	  be	  related	  to	  impaired	  quality	  of	  life	  (Simpson	  et	  al.,	  1992),	  exercise	  limitation	  (Gosselink	  
et	  al.,	  1996)	  and	  predicts	  survival	  more	  powerfully	  than	  FFM	  or	  FEV1	  (Swallow	  et	  al.,	  2007b).	  
In	   addition,	   the	   mid	   thigh	   cross	   sectional	   area	   (MTCSA)	   has	   been	   shown	   to	   inversely	  
correlate	  with	  mortality	  (Marquis	  et	  al.,	  2002).	  The	  skeletal	  muscle	  dysfunction	  that	  occurs	  
in	  COPD	  patients	  is	  not	  only	  a	  result	  of	  atrophy,	  as	  patients	  have	  a	  reduction	  in	  quadriceps	  
endurance,	   in	   addition	   to	   weakness	   (Coronell	   et	   al.,	   2004,	   Swallow	   et	   al.,	   2007a)	   as	   a	  
consequence	  of	  both	  atrophy	  and	  a	  shift	  in	  fibre	  proportions	  as	  discussed	  in	  section	  1.1.2.	  	  
	   Skeletal	  muscle	   dysfunction	   occurs	  more	   in	   the	   lower	   limbs,	   predominantly	   in	   the	  
locomotor	  muscles	  (Man	  et	  al.,	  2003a,	  Man	  et	  al.,	  2005a)	  such	  as	  the	  quadriceps,	  compared	  
to	  the	  upper	  limbs,	  with	  the	  relative	  preservation	  of	  the	  diaphragm	  (Levine	  et	  al.,	  1997).	  As	  
the	  quadriceps	  muscles	  are	  one	  of	  the	  main	  muscle	  groups	  used	  for	  walking,	  dysfunction	  in	  
these	  muscles	  causes	  a	  reduction	  in	  daily	  physical	  activity.	  Consequently,	  the	  quadriceps	  has	  
been	   the	  main	   focus	   of	   research	   as	   the	   site	   where	  weakness	   occurs.	   Leg	   discomfort	   has	  
been	  shown	  to	  be	  a	  more	  important	  factor	  in	  exercise	  limitation	  than	  dyspnoea	  in	  a	  physical	  
exercise	  study	  in	  COPD	  (Killian	  et	  al.,	  1992),	  suggesting	  that	  muscle	  dysfunction	  is	  a	  greater	  
impairment	   than	   lung	   function	   in	   exercise	   capacity.	   Additionally,	   common	   treatments	   for	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COPD	  such	  as	  bronchodilators	  or	   lung	  transplantation	  have	  no	  effect	  on	  exercise	  capacity,	  
despite	  improving	  lung	  function	  (Saey	  et	  al.,	  2003,	  Williams	  et	  al.,	  1992).	  
	   Although	   COPD	   is	   characterised	   as	   a	   lung	   disease,	   one	   study	   has	   shown	   that	  
quadriceps	   strength	   is	   a	   more	   accurate	   correlate	   of	   survival	   than	   FEV1	   (Swallow	   et	   al.,	  
2007a)	   furthermore,	  COPD	  patients	  with	  muscle	  wasting	   show	   significantly	   greater	   risk	  of	  
mortality	  than	  non-­‐wasted	  patients	  (Wagner,	  2008,	  Schols	  et	  al.,	  2005).	  	  Thus	  it	  is	  likely	  that	  
muscle	  wasting	  contributes	  to	  mortality.	  Muscle	  mass	  is	  a	  better	  correlate	  of	  survival	  than	  
lung	  function,	  consequently	  muscle	  is	  a	  useful	  target	  to	  treat	  COPD	  (MacNee,	  2013,	  Barnes	  
and	   Celli,	   2009).	   Targeting	   skeletal	   muscle	   is	   therefore	   increasingly	   becoming	   a	   standard	  
form	  of	  care	  for	  COPD	  since	  pulmonary	  rehabilitation	  or	  exercise	  training	  not	  only	  improves	  
quadriceps	   strength,	   exercise	   capacity	   and	   quality	   of	   life,	   but	   it	   is	   also	   associated	   with	  
increased	   survival	   in	   COPD	   patients	   (Bowen	   et	   al.,	   2000,	   Garcia-­‐Aymerich	   et	   al.,	   2006,	  
Troosters	   et	   al.,	   2000).	   Moreover,	   physical	   activity	   has	   been	   shown	   to	   be	   the	   strongest	  
predictor	  of	  all-­‐cause	  mortality	  in	  COPD	  (Waschki	  et	  al.,	  2011),	  thus	  these	  lines	  of	  evidence	  
suggest	  skeletal	  muscle	  as	  a	  useful	  target	  for	  COPD	  therapy.	  
1.1.2 Disuse	  and	  Fibre	  shift	  in	  COPD	  
Disuse	   is	   thought	   to	  be	  a	  major	   contributor	   to	  muscle	  dysfunction	   in	  COPD,	  which	  
contributes	   to	   ‘the	   spiral	   of	   disease’	   in	   COPD	   (Polkey	   and	   Moxham,	   2006).	   Poor	   lung	  
function	   in	   patients	   often	   leads	   to	   reduced	   physical	   activity	   levels	   as	   patients	   attempt	   to	  
avoid	   dyspnoea,	   and	   this	   disuse	   contributes	   to	   further	   muscle	   dysfunction	   resulting	   in	  
further	  reduction	  in	  levels	  of	  physical	  activity.	  Disuse	  and	  muscle	  dysfunction	  contribute	  to	  
the	  downward	  deterioration	  of	  the	  patient	  as	  the	  disease	  progresses	  (Polkey	  and	  Moxham,	  
2006).	   Exacerbations	   followed	   by	   periods	   of	   hospitalisation	   further	   worsen	   this	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deterioration,	  with	  quadriceps	  weakness	  occurring	  after	  just	  1	  week	  of	  admission	  (Spruit	  et	  
al.,	   2003).	   Pulmonary	   rehabilitation	   following	  discharge	   from	  AECOPD	  has	   been	   shown	   to	  
improve	  exercise	  capacity	  (Man	  et	  al.,	  2004).	  	  
Skeletal	  muscle	  is	  not	  a	  uniform	  tissue	  and	  is	  made	  of	  different	  fibre	  types	  that	  have	  
distinct	  contraction	  kinetics	  and	  utilise	  different	  metabolic	  pathways	  as	   their	  predominant	  
source	  of	  energy	  (as	  discussed	  in	  section	  1.2).	  Biopsies	  of	  quadriceps	  show	  that,	  in	  patients	  
with	  COPD,	   in	  addition	   to	   reduced	   fibre	  size,	   there	   is	  a	  shift	   in	   the	   fibre	   type	  composition	  
towards	  a	  predominantly	  type	  II	  fibre	  proportion,	  with	  reduced	  capillarity	  (Jobin	  et	  al.,	  1998)	  
and	  oxidative	  capacity	  (Jakobsson	  et	  al.,	  1990)	  that	  is	  usually	  indicative	  of	  disuse	  (Jakobsson	  
et	  al.,	  1990,	  Gosker	  et	  al.,	  2003,	  Gosker	  et	  al.,	  2007).	  This	  shift	  is	  not	  observed	  in	  all	  muscles,	  
with	  an	  opposite	  shift	   towards	  an	   increase	   in	  type	   I	   fibres	   in	  the	  diaphragm	  (Levine	  et	  al.,	  
1997).	   However,	   physical	   rehabilitation	   does	   not	   fully	   reverse	   the	   fibre	   type	   changes	   and	  
capillarity	  in	  COPD	  patients,	  suggesting	  that	  other	  factors	  are	  involved	  in	  muscle	  dysfunction	  
(Whittom	   et	   al.,	   1998).	   Several	   studies	   have	   also	   observed	   that	   type	   II	   fibres	   waste	   to	   a	  
greater	  extent	  than	  type	  I	   fibres	   in	  COPD	  associated	  muscle	  wasting	  (Gosker	  et	  al.,	  2002b,	  
Gosker	   et	   al.,	   2003).	   The	   change	   in	   fibre	   composition	   and	   type	   II	   atrophy	  may	   therefore	  
contribute	  to	  reduced	  force	  generation	  and	  muscle	  dysfunction	  observed	  in	  COPD.	  
1.2 	  Skeletal	  muscle	  
Skeletal	   muscle	   accounts	   for	   approximately	   40%	   of	   body	  mass.	   Skeletal	   muscle	   is	  
involved	   in	   many	   roles	   in	   the	   body;	   particularly	   generating	   force	   to	   provide	   movement,	  
maintaining	  posture	  as	  well	  as	  energy	  metabolism.	  Skeletal	  muscle	  consists	  of	  muscle	  fibres	  
arranged	  into	  bundles	  or	  fascicles	  by	  connective	  tissue,	  which	  are	  in	  turn	  grouped	  together	  
in	  connective	  tissue	  to	  form	  a	  whole	  muscle.	  A	  muscle	   fibre	   is	  a	   large	  multi-­‐nucleated	  cell	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consisting	  of	  thousands	  of	  myofibrils	  enclosed	  by	  a	  membrane	  called	  the	  sarcolemma.	  Each	  
myofibril	   can	   further	   be	   dissected	   into	   a	   series	   of	   functional	   units	   known	   as	   sarcomeres	  
consisting	  of	  myosin	  and	  actin	  filaments,	  which	  generate	  force	  upon	  contraction	  (Lieber	  and	  
Fridén,	  2000,	  MacIntosh	  et	  al.,	  2006).	  	  
The	  function	  of	  a	  skeletal	  muscle	  is	  determined	  by	  the	  proportion	  of	  different	  fibre	  
types	  in	  the	  muscle,	  which	  can	  be	  divided	  into	  four	  types	  in	  mammals-­‐	  type	  I,	  type	  IIA,	  type	  
IIX	   and	   type	   IIB.	   Each	   fibre	   type	   differs	   in	   contractility	   speed,	   energy	   metabolism,	   and	  
mitochondrial	  content.	  In	  addition,	  each	  fibre	  type	  expresses	  a	  distinct	  myosin	  heavy	  chain	  
isoform.	   Slow	   twitch	   type	   I	   fibres	   have	   a	   greater	   oxidative/aerobic	   capacity,	   increased	  
mitochondrial	   content	   and	  are	  defined	  by	   the	  expression	  of	   the	   slow	  myosin	  heavy	   chain	  
isoform	   MYH7.	   Type	   II	   fibres,	   in	   general,	   are	   fast	   twitch	   fibres,	   which	   have	   a	   more	  
glycolytic/anaerobic	  energy	  metabolism	  and	  decreased	  mitochondrial	  content.	  Type	  II	  fibres	  
have	   higher	   ATPase	   activity	   levels	   compared	   to	   type	   I	   and	   produce	   lactate	   during	   energy	  
production,	  thus	  are	  more	  easily	  fatigued	  (Scott	  et	  al.,	  2001).	  Type	  IIA	  expresses	  the	  myosin	  
heavy	  chain	  isoform	  MYH2,	  IIX	  expresses	  MYH1	  and	  IIB	  expresses	  MYH4,	  however,	  type	  IIB	  
is	   found	   in	   mice	   but	   not	   humans	   (Schiaffino	   and	   Reggiani,	   2011).	   This	   heterogeneity	   of	  
muscle	  fibre	  types	  permits	  muscle	  plasticity	  and	  changes	  in	  fibre	  type	  to	  accommodate	  the	  
changes	   in	   functional	   demand	   on	   the	   muscle	   (Costill	   et	   al.,	   1976).	   In	   disuse,	   atrophy	   is	  
associated	  with	  an	  increase	  in	  the	  proportion	  of	  type	  II	  fibres	  (Stein	  and	  Wade,	  2005),	  whilst	  
endurance	  training	  is	  associated	  with	  a	  fast	  to	  slow	  fibre	  type	  switch	  and	  increases	  fatigue	  
resistance	   (Costill	   et	   al.,	   1976,	   Holloszy	   and	   Booth,	   1976)	   whereas	   strength	   or	   resistance	  
training	  is	  associated	  with	  a	  slow	  to	  fast	  fibre	  type	  switch	  (Staron	  et	  al.,	  1994)	  .	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1.3 Muscle	  mass	  homeostasis	  	  
Skeletal	  muscle	  is	  highly	  adaptive;	  altering	  mass	  and	  fibre	  type	  proportion	  based	  on	  
functional	  needs.	  The	   regulation	  of	  muscle	  mass	   is	   therefore	  complex,	   involving	  pathways	  
that	  result	  in	  either	  hypertrophy	  (gain	  of	  muscle	  mass)	  or	  atrophy	  (loss	  of	  muscle	  mass).	  In	  
the	   normal	   adult,	  muscle	  mass	   is	   relatively	   constant	   and	   this	   homeostasis	   is	   achieved	   by	  
balancing	  the	  pathways	  that	  synthesise	  protein	  with	  those	  that	  cause	  protein	  degradation	  
(Mitch	  and	  Goldberg,	  1996).	  Changes	  in	  the	  rates	  of	  these	  processes	  result	  in	  a	  shift	  in	  the	  
homeostatic	   balance	   with	   a	   net	   increase	   or	   decrease	   in	   muscle	   mass.	   For	   example,	   in	  
atrophy,	  there	  can	  be	  an	  increase	  in	  both	  protein	  synthesis	  and	  protein	  degradation	  but	  the	  
increase	  in	  degradation	  is	  greater	  than	  the	  increase	  in	  protein	  synthesis.	   	  Conversely,	  both	  
protein	   degradation	   and	   synthesis	   can	   be	   suppressed	   but	   synthesis	   is	   suppressed	   to	   a	  
greater	   extent	   than	   degradation.	   	   It	   is	   the	   net	   effect	   of	   these	   changes	   that	   lead	   to	   the	  
changes	   in	   physiology.	   	   In	   COPD,	   muscle	   homeostasis	   is	   disrupted	   by	   the	   disease	   state	  
involving	   oxidative	   stress,	   systemic	   inflammation	   and	   growth	   cytokines,	   with	   further	  
complication	  from	  the	  medications	  such	  as	  corticosteroids,	  which	  may	  further	  contribute	  to	  
muscle	  wasting	  (Wust	  and	  Degens,	  2007,	  Kim	  et	  al.,	  2008a,	  Lynch	  et	  al.,	  2007).	  However,	  the	  
relative	  contribution	  of	  protein	  synthesis	  and	  protein	  degradation	   to	  muscle	  wasting	  have	  
yet	  to	  be	  accurately	  established.	  
1.3.1 Pathways	  involved	  in	  muscle	  growth	  
Hypertrophy	   is	   generally	   associated	  with	   an	   increase	  muscle	  mass.	   There	   are	   two	  
main	   processes	   involved	   in	   increasing	   muscle	   mass:	   protein	   synthesis	   and	   satellite	   cell	  
recruitment.	   Impairment	   in	   both	   these	   processes	   has	   been	   examined	   in	   COPD	   muscle	  
atrophy.	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1.3.1.1 Protein	  Synthesis	  
Protein	   synthesis	   is	   thought	   to	   be	   the	   main	   contributor	   in	   muscle	   growth	   and	  
hypertrophy	   (Goldspink	   et	   al.,	   1983,	   Bolster	   et	   al.,	   2004).	   An	   increased	   rate	   of	   protein	  
synthesis	   results	   in	   the	   synthesis	   of	   additional	   contractile	   filaments	   in	   the	   myofibre	   and	  
therefore	   greater	   force	   production	   during	   muscle	   contraction.	   Studies	   have	   examined	  
whether	   the	   rates	   of	   protein	   synthesis	   are	   lower	   in	  models	   of	   atrophy	   and	  COPD.	   In	   one	  
study,	   mice	   with	   induced	   atrophy	   from	   different	   stimuli	   including	   diabetes	   and	   fasting,	  
exhibited	   decreased	   gene	   expression	   of	   extracellular	   matrix	   proteins	   in	   the	   muscle	  
suggesting	   the	   loss	   of	   proteins	   during	   atrophy	   (Lecker	   et	   al.,	   2004).	   A	   few	   studies	   have	  
indicated	   that	   lower	   rates	   of	   protein	   synthesis	  may	   also	   contribute	   to	  muscle	   wasting	   in	  
COPD	  by	  measuring	   the	  excretion	  of	   stable	   isotope-­‐labelled	  essential	   amino	  acids	   such	  as	  
using	  13C-­‐leucine	  as	  tracers	  (Morrison	  et	  al.,	  1988,	  Engelen	  et	  al.,	  2000;	  Jagoe	  and	  Engelen,	  
2003).	   Although	   a	   few	   studies	   have	   reported	   increased	   whole	   body	   protein	   turnover	   in	  
COPD	   (Engelen	   et	   al.,	   2000,	   Kao	   et	   al.,	   2011);	   the	   rate	   of	   protein	   synthesis	   and	   protein	  
degradation	  may	  both	  be	   increased	   (Engelen	  et	  al.,	  2000),	   thus	   interpretation	  of	   the	  data	  
may	   be	   unclear.	   Protein	   synthesis	   may	   increase	   as	   a	   compensatory	   mechanism	   to	   the	  
increase	  in	  protein	  degradation.	  
1.3.1.2 Satellite	  cells	  
Satellite	  cells	  are	  progenitor	  cells	  committed	  to	  the	  myogenic	  cell	  lineage.	  Normally,	  
satellite	   cells	   are	  quiescent	  and	  are	   found	   in	   the	   space	  between	   the	   sarcolemma	  and	   the	  
basal	  lamina.	  However,	  upon	  muscle	  injury,	  satellite	  cells	  activate	  and	  migrate	  to	  the	  injury	  
site	   to	   proliferate	   and	   fuse	  with	   the	  damaged	  myofibre	   to	   repair	   the	  muscle	   (Hawke	   and	  
Garry,	  2001).	  In	  order	  to	  replenish	  the	  satellite	  cell	  pool,	  satellite	  cells	  divide	  asymmetrically,	  
i.e.	   a	   subpopulation	   of	   cells	   return	   to	   their	   original	   location	   and	   resume	   quiescence	   thus	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maintaining	   their	   regenerative	   capacity	   (Hawke	   and	   Garry,	   2001).	   Although	   satellite	   cells	  
have	  a	  role	  in	  the	  growth	  of	  fibres	  during	  postnatal	  growth,	  the	  contribution	  of	  satellite	  cells	  
to	  hypertrophy	   in	  adult	  muscle	   is	  still	  unclear	   (O'Connor	  and	  Pavlath,	  2007,	  McCarthy	  and	  
Esser,	  2007).	  
However,	   recently,	   it	   has	   been	   suggested	   that	   impaired	   satellite	   cell	   function	  may	  
lead	  to	  poor	  regeneration,	  thus	  contributing	  to	  atrophy	  (Kudryashova	  et	  al.,	  2012).	  In	  COPD,	  
an	  increased	  number	  of	  centralised	  nuclei	  (as	  a	  marker	  of	  activated	  satellite	  cells	  that	  have	  
moved	   into	   the	   myofibre	   during	   regeneration)	   was	   observed	   in	   patients	   with	   preserved	  
muscle	  mass	   compared	   to	   low	  muscle	  mass	   and	   controls,	   suggesting	   that	   COPD	   patients	  
who	   lose	  muscle	  mass	  have	  a	   lower	   regenerative	   capacity	   than	   those	  who	  maintain	   their	  
muscle	  (Thériault	  et	  al.,	  2012).	  Furthermore,	  a	  significant	  decrease	   in	  telomere	   length	  was	  
also	  observed	  in	  COPD	  muscle	  compared	  to	  controls	  indicating	  that	  more	  satellite	  cells	  may	  
be	  senescent,	  and	  therefore	  unable	  to	  repair	  muscle	  damage.	  
1.3.2 Pathways	  involved	  in	  muscle	  degradation	  
As	  there	  is	  a	  net	   increase	  in	  protein	  degradation	  in	  atrophy,	  many	  of	  the	  studies	  in	  
muscle	   atrophy	   have	   focussed	   on	   protein	   degradation.	   There	   are	   a	   number	   of	   pathways	  
involved	  in	  protein	  degradation:	  the	  ubiquitin	  proteasome	  system	  (UPS),	  apoptosis	  and	  the	  
autophagy-­‐lysosomal	  pathway.	  
1.3.2.1 Ubiquitin	  proteasomal	  system	  (UPS)	  
The	  most	  studied	  protein	  degradation	  process	   is	   the	  UPS,	  which	  targets	  mis-­‐folded	  
or	  damaged	  intracellular	  proteins.	  In	  this	  system,	  proteins	  are	  tagged	  for	  degradation	  by	  the	  
covalent	  linkage	  of	  ubiquitin	  chains	  in	  a	  process	  called	  ubiquitination.	  Several	  enzymes	  are	  
involved	   the	   process	   of	   ubiquitination:	   E1	   ubiquitin-­‐activating	   enzyme,	   E2	   ubiquitin-­‐
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conjugating	  enzyme	  and	  the	  E3	  ubiquitin	  ligase.	  The	  E1	  enzyme	  activates	  ubiquitin	  in	  an	  ATP	  
dependent	  manner,	  and	  the	  activated	  ubiquitin	  is	  then	  transferred	  to	  the	  E2	  enzyme.	  The	  E2	  
enzyme	  then	  complexes	  with	   the	  E3	  enzyme,	  and	   transfers	   the	  ubiquitin	   to	   the	  E3	  bound	  
protein	  substrate	  (Hochstrasser,	  1995,	  Glickman	  and	  Ciechanover,	  2002).	  This	  occurs	   in	  an	  
iterative	  manner	  resulting	  in	  multiple	  ubiquitin	  molecules	  added	  to	  the	  target	  protein.	  Once	  
poly-­‐ubiquitinated,	   the	   tagged	   protein	   is	   then	   proteolytically	   degraded	   by	   the	   26S	  
proteasome.	   	  The	  specificity	  of	  the	  UPS	  pathways	   is	  due	  to	  the	  E3	  ubiquitin	   ligases,	  which	  
bind	  to	  specific	  classes	  of	  protein	  substrate.	  Two	  muscle	  specific	  E3	  ubiquitin	  ligases,	  Muscle	  
Ring	  Finger-­‐1	  (MuRF1)	  and	  atrogin-­‐1,	  have	  been	  dubbed	  atrogenes,	  as	  they	  are	  consistently	  
up-­‐regulated	   in	   disease	   models	   that	   induce	   atrophy	   (Lecker	   et	   al.,	   2004).	   Atrogin-­‐1	   is	   a	  
member	   of	   the	   Skp1,	   Cullin	   and	   F-­‐box	   (SCF)	   protein	   family	   that	   complexes	   together	   to	  
confer	  ubiquitin	  ligase	  activity	  (Gomes	  et	  al.,	  2001).	  Atrogin-­‐1	  preferentially	  targets	  muscle	  
specific	  transcription	  factors	  such	  as	  MyoD.	  MuRF-­‐1	  contains	  a	  RING	  finger	  domain,	  which	  
confers	  its	  ubiquitin	  ligase	  activity	  (Spencer	  et	  al.,	  2000),	  and	  targets	  structural	  proteins	  such	  
as	   myosin	   heavy	   chain	   proteins	   (Clarke	   et	   al.,	   2007,	   Foletta	   et	   al.,	   2011).	   Mutations	   in	  
atrogin-­‐1	   and	   MuRF-­‐1	   that	   result	   in	   loss	   of	   function	   have	   attenuated	   muscle	   atrophy	   in	  
response	  to	  various	  atrophic	  stimuli	  (Gomes	  et	  al.,	  2001,	  Bodine	  et	  al.,	  2001a).	  
The	   activation	   of	   proteasomal	   degradation	   in	  muscle	  wasting	   and	   COPD	   has	   been	  
studied	  widely	   (Mitch	  and	  Goldberg,	   1996,	  Ottenheijm	  et	   al.,	   2006,	  Bodine	  et	   al.,	   2001a).	  
Increased	  proteasomal	  degradation	  has	  been	   linked	   to	  atrophy	  as	   increased	  expression	  of	  
atrogin-­‐1	  and	  MuRF-­‐1	  has	  been	  observed	  in	  COPD	  patients	  with	  muscle	  wasting	  (Doucet	  et	  
al.,	   2007).	   In	   addition,	   the	   protein	   expression	   of	   Forkhead	   Box	   O	   (FoxO)	   transcription	  
factors,	  and	  NEDD4,	  another	  E3	   ligase,	   is	  also	   increased	   in	  COPD	  patient	  biopsies	  (Plant	  et	  
al.,	  2010,	  Koncarevic	  et	  al.,	  2007).	  The	  UPS	  is	  also	  thought	  to	  work	  in	  conjunction	  with	  the	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autophagy/lysosome	   pathway	   suggesting	   degradation	   pathways	   synergise	   in	   muscle	  
atrophy	  (Zhao	  et	  al.,	  2007).	  
1.3.2.2 Apoptosis	  
Apoptosis,	   also	   known	   as	   programmed	   cell	   death,	   is	   initiated	   by	   either	   external	  
ligands	   (such	   as	   Tumour	   Necrosis	   Factor-­‐α,	   TNF-­‐α	   and	   Fas	   ligand,	   FasL)	   binding	   to	   death	  
receptors	   in	   the	  plasma	  membrane	  or	  by	   internally	   released	  factors	  such	  as	  cytochrome	  c	  
from	  the	  mitochondria	  (Adhihetty	  and	  Hood,	  2003).	  These	  factors	  then	  initiate	  a	  proteolytic	  
cascade	   in	   which	   caspases	   sequentially	   cleave	   and	   activate	   other	   caspases.	   For	   example,	  
caspase	  3	   cleaves	  procaspase	  6	   resulting	  activated	   caspase	  6,	  which	   then	   cleaves	   lamin	  A	  
(Fan	  et	  al.,	  2005).	  Once	  activated,	  caspases	  then	  cleave	  cytosolic	  and	  nuclear	  target	  proteins	  
in	  the	  cell	   including	  nuclear	   lamins	  and	  DNase	   inhibitors.	  The	  caspases	  are	   instrumental	   in	  
the	   breakdown	   of	   cells,	   bringing	   about	   the	   distinct	   morphological	   features	   that	   define	  
apoptosis	  such	  as	  plasma	  membrane	  blebbing,	  nuclear	  breakdown,	  DNA	  fragmentation,	  and	  
the	  formation	  of	  vesicular	  apoptotic	  bodies	  containing	  cellular	  contents	  (Kerr	  et	  al.,	  1972).	  	  
Although	   apoptosis	   is	   normally	   associated	   with	   development,	   and	   differentiated	  
striated	  muscle	  is	  highly	  apoptosis	  resistant,	  apoptosis	  has	  been	  shown	  to	  occur	  in	  a	  subset	  
of	  myonuclei	   during	   atrophy,	  whilst	   the	   rest	   of	   the	   fibre	   remains	   intact	   (Liu	   and	   Ahearn,	  
2001).	  However,	  another	  study	  has	  shown	  that	  the	  apoptotic	  cells	  induced	  by	  atrophy	  were	  
derived	   from	   satellite	   cells	   and	   not	   from	   the	   myonuclei	   from	   the	   fibre	   (Bruusgaard	   and	  
Gundersen,	   2008).	   A	   further	   study	   showed	   that	   apoptosis	   in	   skeletal	   muscle	   leads	   to	  
atrophy	  not	  cell	  death	  (Vescovo	  et	  al.,	  2000).	  In	  COPD,	  increased	  apoptosis	  was	  observed	  in	  
patients	  with	  a	  low	  BMI	  (Agustí	  et	  al.,	  2002).	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1.3.2.3 Autophagy-­‐lysosomal	  pathway	  
The	   literal	   meaning	   of	   autophagy	   translated	   from	   Greek	   is	   to	   eat	   oneself	   (‘auto’	  
oneself	   and	   ‘phagy’	   to	   eat).	   Several	   forms	   of	   autophagy	   have	   been	   identified,	   including	  
chaperone-­‐mediated	   autophagy	   (a	   specific	   form	   requiring	   Heat	   shock	   proteins),	  
microautophagy	  (the	  direct	  engulfment	  of	  material	  by	  the	  lysosome)	  and	  macroautophagy.	  
Macroautophagy,	  hereafter	  referred	  to	  as	  autophagy,	  is	  the	  bulk	  degradation	  of	  membrane	  
encapsulated	  cytoplasmic	  material	  by	  the	  lysosome.	  	  	  
In	   eukaryotic	   cells,	   autophagy	   begins	   with	   the	   formation	   of	   a	   double-­‐layered	  
isolation	  membrane	  or	  phagophore,	  which	  forms	  around	  cytoplasmic	  material	  such	  as	  long-­‐
lived	   proteins	   and	   whole	   organelles	   (Figure	   1,	   (Glick	   et	   al.,	   2010,	   Meléndez	   and	   Levine,	  
2009).	   	  The	  origin	  of	   the	   isolation	  membrane	   is	   still	  unclear	   (Hamasaki	  et	  al.,	  2013,	  Tooze	  
and	  Yoshimori,	  2010).	  The	  cargo	  of	  the	  autophagosome	  can	  be	  selectively	  or	  non-­‐selectively	  
engulfed	  by	  mechanisms	  that	  depend	  on	  ubiquitin	  and	  MAP1	  LC3B	  	  (microtubule-­‐associated	  
protein	  1	  light	  chain	  3	  B,	  otherwise	  known	  as	  LC3B)	  (Shaid	  et	  al.,	  2013).	  The	  LC3-­‐interacting	  
region	  (LIR)	  motif	  in	  LC3B	  is	  thought	  to	  interact	  with	  adaptor	  proteins	  such	  as	  p62	  to	  select	  
cargo	   (Johansen	  and	  Lamark,	  2011).	  As	   the	  phagophore	  expands,	   the	  edges	  of	   the	  double	  
membrane	   fuse	   together,	   sequestering	   the	   cytoplasmic	   material	   inside	   the	   double	  
membrane	   and	   forming	   an	   autophagosome.	   The	   autophagosome	   then	   fuses	   with	   a	  
lysosome	  forming	  an	  autolysosome.	  The	  acid	  hydrolases	  within	  the	  lysosome	  then	  degrade	  
the	  material	  within	   the	   autophagosome	   into	   constituent	   parts	   such	   as	   amino	   acids,	   fatty	  
acids	  and	  sugars,	  which	  are	  exported	  out	  of	  the	  autophagosome.	  The	  component	  parts	  are	  
either	   recycled	   in	   the	   cell	   to	   make	   other	   organelles	   and	   proteins	   or	   used	   as	   an	   energy	  
source.	  Autophagy	  is	  regulated	  by	  a	  distinct	  group	  of	  proteins	  known	  as	  autophagy	  related	  
gene	   (Atg)	   proteins	   which	   are	   functionally	   conserved	   in	   higher	   eukaryotes	   and	   include	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several	  ubiquitin	  like	  proteins	  (LC3,	  Gamma-­‐Amino	  Butyric	  Acid	  Receptor-­‐Associated	  Protein	  
like	   1	   –Gabarapl1	   and	   Atg12,	   Table	   1)	   (Levine	   and	   Kroemer,	   2008).	   Autophagosome	  
expansion	  and	  elongation	  requires	  two	  different	  ubiquitin	  like	  conjugation	  systems,	  in	  which	  
Atg12	  is	  covalently	  linked	  to	  Atg5	  and	  LC3	  linked	  to	  phosphatidylethanolamine	  (PE).	  
	   The	  process	  of	  autophagy	  is	  dynamic	  and	  in	  a	  state	  of	  constant	  flux,	  thus	  measuring	  
autophagy	   is	   challenging,	   particularly	   as	   autophagosomes	   are	   constantly	   turned	   over.	  
However,	  LC3B	  (or	  Atg8	  in	  yeast)	  is	  a	  specific	  protein	  that	  is	  present	  throughout	  the	  process;	  
from	   phagophore	   formation	   to	   lysosomal	   fusion	   (Yoshimori,	   2004,	   Kabeya	   et	   al.,	   2000).	  
Three	  isoforms	  of	  LC3	  exist	   in	  mammalian	  cells:	  LC3A,	  LC3B	  and	  LC3C,	  though	  only	  LC3B	  is	  
associated	  with	  the	  autophagosome	  (Barth	  et	  al.,	  2010).	  LC3	  is	  synthesised	  as	  a	  pro-­‐peptide	  
(proLC3)	  and	  twenty	  two	  amino	  acids	  of	  proLC3	  are	  cleaved	  at	  the	  carboxyl-­‐terminus	  by	  the	  
cysteine	  protease	  Atg4b	  to	  expose	  a	  glycine	  residue	  forming	  LC3-­‐I	  (Kabeya	  et	  al.,	  2000).	  LC3-­‐
I	  is	  located	  in	  the	  cytoplasm	  and	  undergoes	  a	  series	  of	  ubiquitin-­‐like	  reactions	  (as	  mentioned	  
previously),	   which	   result	   in	   the	   conjugation	   of	   PE	   to	   LC3-­‐I	   forming	   LC3-­‐II.	   The	   lipid	  
conjugation	  anchors	  and	  integrates	  LC3-­‐II	  into	  the	  autophagosome	  membrane	  on	  the	  inside	  
and	   outside,	   which	   aids	   the	   formation	   of	   the	   autophagosome	   (Glick	   et	   al.,	   2010).	   As	   the	  
autophagosomes	  degrade,	   accordingly	   LC3-­‐II	   levels	   also	  decrease.	   Thus,	   the	   synthesis	   and	  
degradation	  of	  LC3-­‐II	  provide	  readouts	  to	   levels	  of	  autophagy,	  and	  this	   is	  one	  of	   the	  most	  
commonly	  used	  methods	  of	  autophagy	  measurements	  (Barth	  et	  al.,	  2010,	  Mizushima	  et	  al.,	  
2010).	  
Autophagy	  is	  a	  constitutively	  active	  housekeeping	  process	  that	  occurs	  at	  a	  low	  basal	  
level	   in	  most	  cells	   in	  order	   to	  maintain	  homeostasis,	   remove	  cellular	  debris,	  as	  well	  as	   re-­‐
generate	   metabolic	   precursors	   (Ravikumar	   et	   al.,	   2010,	   Levine	   and	   Kroemer,	   2008,	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Mizushima	   et	   al.,	   2008).	   This	   basal	   autophagy	   is	   vital	   in	   a	   number	   of	   processes	   such	   as	  
regulation	   of	   innate	   and	   adaptive	   immunity,	   cytoskeleton	   re-­‐modelling	   and	   microbe	  
clearance	   (Deretic	   and	   Levine,	   2009,	   Ravikumar	   et	   al.,	   2010,	   Levine	   and	   Kroemer,	   2008).	  
Autophagy	   is	  up-­‐regulated	  above	  the	  basal	  rate	  upon	  physiological	  stress	  such	  as	  hypoxia,	  
nutrient	   starvation	   and	   also	   in	   response	   to	   hormonal	   stimulation	   and	   infection.	   Equally,	  
autophagy	   is	   suppressed	   during	   certain	   diseases	   such	   as	   cancer,	   neurodegenerative	   and	  
infectious	  disease	  as	  well	  as	  aging	  (Levine	  and	  Kroemer,	  2008).	  	  
	   Autophagy	   is	   also	   implicated	   in	  muscle	   homeostasis,	   removing	   protein	   aggregates	  
and	  abnormal	  or	  damaged	  organelles	  that	  would	  otherwise	  lead	  to	  toxicity	  and	  dysfunction	  
in	   muscle.	   Indeed	   autophagy	   has	   been	   implicated	   in	   a	   number	   of	   genetic	   myopathies	  
including	  X-­‐linked	  myopathy	  with	  excessive	  autophagy,	  Pompe	  disease,	   in	  which	  defective	  
lysosomal	  degradation	  leads	  to	  autophagosome	  accumulation,	  and	  Danon	  disease,	  in	  which	  
lysosomes	   cannot	   form	   and	   fuse	   with	   autophagosomes	   again	   leading	   to	   autophagosome	  
accumulation	  (Kundu	  and	  Thompson,	  2008,	  Nishino,	  2003).	  
	  Recently,	  research	  efforts	  have	  focussed	  on	  the	  involvement	  of	  autophagy	  in	  muscle	  
atrophy,	   particularly	   as	   autophagy	   also	   breaks	   down	   myofibrillar	   proteins,	   which	   may	  
contribute	   to	   fibre	   wasting.	   Lysosomal	   degradation	   may	   contribute	   to	   increased	   protein	  
breakdown	  in	  muscle	  wasting	  (Furuno	  et	  al.,	  1990,	  Bechet	  et	  al.,	  2005).	  However,	  deletion	  
of	   essential	   autophagy	   genes,	   Atg7	   and	   Atg5	   specifically	   in	  muscle,	   leads	   to	   atrophy	   and	  
myopathy	  owing	  to	  the	  accumulation	  of	  protein	  aggregates	  (Masiero	  et	  al.,	  2009,	  Masiero	  
and	  Sandri,	  2010,	  Raben	  et	  al.,	  2008).	  Studies	  have	  shown	  that	  the	  autophagy-­‐lysosome	  and	  
ubiquitin-­‐proteasome	   pathways	   may	   be	   regulated	   independently	   by	   the	   same	   protein	  
FoxO3,	  indicating	  that	  both	  pathways	  work	  concurrently	  with	  each	  other	  in	  muscle	  atrophy	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(Zhao	  et	  al.,	  2007,	  Mammucari	  et	  al.,	  2007a).	  Evidently,	  autophagy	  has	  an	  important	  role	  in	  




Figure	  1	  Schematic	  representation	  of	  autophagy	  
A	   double	   membrane	   forms	   elongates	   to	   form	   a	   phagophore,	   before	   fusing	   to	   form	   an	  
autophagosome,	   encapsulating	   cytoplasmic	   material.	   Fusion	   with	   a	   lysosome	   forms	   an	  
autolysosome,	   and	   the	   encapsulated	  material	   is	   degraded	   into	   constituent	   parts.	   Scheme	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Table	  1	  ATG	  genes	  involved	  in	  autophagy	  
Table	   of	   functions	   of	   human	   ATG	   genes,	   interacting	   proteins	   and	   yeast	   homolog	   genes.	  
Table	  continued	   in	  Appendix	  Table	  18.	  Adapted	  from	  Kundu	  and	  Thompson,	  2008.	   (Kundu	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1.4 Signalling	  systems	  and	  molecules	  that	  regulate	  muscle	  mass	  
1.4.1 Hypertrophy	  signalling	  
Hypertrophy	  signalling	  may	  be	  aberrant	  in	  COPD	  contributing	  to	  muscle	  dysfunction.	  
Pathways	   that	   induce	   protein	   transcription	   and	   translation	   have	   been	   examined	   and	  
alterations	   in	   the	   levels	   of	   proteins	   associated	   with	   these	   pathways	   may	   contribute	   to	  
decreased	  protein	  synthesis	  and	  thereby	  muscle	  atrophy.	  
1.4.1.1 IGF-­‐1	  -­‐AKT	  signalling	  and	  activity	  
Insulin	  like	  growth	  factor-­‐1	  (IGF-­‐1)	  is	  an	  anabolic	  hormone,	  which	  augments	  protein	  
synthesis	  and	  inhibits	  protein	  degradation	  (Sacheck	  et	  al.,	  2004).	  Over	  expression	  of	  IGF-­‐1	  in	  
muscle	   is	  associated	  with	  an	   increase	   in	  muscle	  mass	  and	  strength	   in	  mice	  (Musaro	  et	  al.,	  
2001).	   In	   humans,	   IGF-­‐1	   has	   also	   been	   shown	   to	   increase	   upon	   resistance	   training	   in	   the	  
elderly	  (Singh	  et	  al.,	  1999)	  and	  endurance	  exercise	  in	  the	  young	  (Nishida	  et	  al.,	  2010).	  	  IGF-­‐1	  
activates	   phosphoinositide-­‐3-­‐kinase	   (PI3K),	   which	   phosphorylates	   and	   activates	   AKT.	   	   The	  
importance	   of	   AKT	   in	  muscle	   hypertrophy	   is	   exemplified	   by	   studies	   showing	   that	   specific	  
overexpression	  of	  AKT	   in	   skeletal	  muscle	  causes	  hypertrophy	  with	   increased	   fibre	  mass	   in	  
mice	  (Blaauw	  et	  al.,	  2009,	  Lai	  et	  al.,	  2004).	  
A	  major	   target	  of	  AKT	   is	  mTOR	   (mammalian	   Target	  of	  Rapamycin)	   (Rommel	   et	   al.,	  
2001),	   which	   it	   phosphorylates	   and	   activates.	   There	   are	   two	   forms	   of	   distinct	   protein	  
complexes;	   mTORC1	   which	   increases	   protein	   synthesis	   through	   up-­‐regulation	   of	   p70S6k	  
(70kDa	   ribosomal	   S6	   protein	   kinase)	   and	   inhibition	   of	   4EBP1,	  whilst	  mTOC2	   inhibits	   FoxO	  
transcription	   factors	   and	   the	   downstream	   targets	   of	  MurF1	   and	   atrogin-­‐1	   (Sandri,	   2008).	  
Furthermore,	  activated	  AKT	  can	  exert	  its	  effects	  independent	  of	  mTOR,	  by	  inhibiting	  another	  
repressor	  of	  protein	  synthesis,	  glycogen	  synthase	  kinase-­‐3β	  (GSK-­‐3β)	  (Vogiatzis	  et	  al.,	  2007).	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The	  combined	  effects	  of	   IGF-­‐1	  on	   these	   two	  complimentary	  mTORC	  pathways	   increase	   its	  
hypertrophic	  effect.	  	  
	   In	  COPD	  patients,	  levels	  of	  circulating	  IGF-­‐1	  are	  reduced;	  furthermore	  circulating	  IGF-­‐
1	  is	  associated	  with	  BMI	  and	  thigh	  circumference	  (Ye	  et	  al.,	  2012).	  IGF-­‐1	  levels	  are	  reduced	  
in	  patients	  with	  atrophy	   compared	   to	   those	  with	  preserved	  muscle	  mass	   (Vogiatzis	   et	   al.,	  
2010).	   Furthermore,	   levels	   of	   IGF-­‐1	  were	   increased	   in	   patients	   participating	   in	   pulmonary	  
rehabilitation	  and	  the	  increase	  in	  IGF-­‐1	  was	  associated	  with	  increased	  exercise	  capacity	  and	  
fibre	  size	  (Vogiatzis	  et	  al.,	  2007).	  In	  addition,	  a	  splice	  variant	  of	  IGF-­‐1	  mechano-­‐growth	  factor	  
(MGF)	   which	   is	   specifically	   induced	   upon	   mechanical	   stretch	   and	   leads	   to	   hypertrophy,	  
(Goldspink	   et	   al.,	   1983)	   was	   also	   up-­‐regulated.	   However,	   the	   evidence	   implicating	  
involvement	   of	   IGF-­‐1	   in	   muscle	   atrophy	   is	   not	   consistent,	   two	   studies	   have	   reported	   an	  
increase	   in	   IGF-­‐1	   expression	   in	   COPD	   quadriceps	   compared	   to	   controls	   (Debigare	   et	   al.,	  
2008,	   Donaldson	   et	   al.,	   2013,	   Lewis	   et	   al.,	   2012),	   whilst	   another	   has	   reported	   increased	  
phospho-­‐AKT	  levels	  in	  patients	  with	  atrophy	  (Doucet	  et	  al.,	  2007).	  The	  authors	  suggest	  that	  
increased	   IGF-­‐1	  mRNA	   levels	  may	  be	  due	   to	   a	   failed	   compensatory	   synthesis	   response	   to	  
restore	  muscle	  mass	   during	   atrophy	   (Doucet	   et	   al.,	   2007).	   These	   differences	   in	   apparent	  
expression	   levels	   of	   IGF-­‐1	   in	   COPD	   may	   have	   resulted	   from	   differences	   in	   the	   patient	  
phenotypes	  or	  may	  suggest	  that	  altered	  IGF-­‐1	  levels	  are	  not	  fundamental	  to	  development	  of	  
muscle	  wasting	  in	  COPD.	  
1.4.2 Atrophy	  
The	  role	  of	  signalling	  molecules	  and	  pathways	  involved	  in	  atrophy	  in	  COPD	  has	  been	  
explored	   to	   a	   greater	   degree	   than	   those	   regulating	   hypertrophy.	   There	   are	   a	   number	   of	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mechanisms	   by	  which	  muscle	  wasting	   occurs;	   systemic	   inflammation	   and	   oxidative	   stress	  
have	  been	  shown	  to	  be	  increased	  in	  patients	  with	  COPD	  (Gan	  et	  al.,	  2004).	  	  	  
1.4.2.1 Inflammation	  	  
The	   large	   insult	   of	   inflammation	   in	   the	   lung	   is	   thought	   to	   spill	   over	   and	   lead	   to	  
systemic	   inflammation	   (Barnes	   and	   Celli,	   2009)	   and	   to	   this	   end	  much	   of	   the	   research	   in	  
COPD	   has	   focussed	   on	   the	   inflammatory	   pathway.	   Increased	   levels	   of	   pro-­‐inflammatory	  
cytokines	   IL-­‐6	  and	   IL-­‐8,	  TNF-­‐α	  and	  C-­‐reactive	  protein	   (Di	  Francia	  et	  al.,	  1994,	  Schols	  et	  al.,	  
1996)	   in	   the	   circulation	   are	   associated	   with	   decreased	   muscle	   strength	   and	   exercise	  
tolerance.	   The	   nuclear	   factor	   kappa-­‐B	   (NF-­‐κB)	   pathway	   is	   one	   inflammatory	   system	  
activated	  by	  TNF-­‐α.	  	  
The	   NF-­‐κB	   transcription	   factor	   family	   include	   the	   p65	   and	   p50	   subunits,	   which	  
dimerise	  together	  in	  different	  combinations	  to	  activate	  transcription.	  The	  NF-­‐κB	  complex	  is	  
held	  inactive	  by	  its	  inhibitor,	  IκB	  (Inhibitor	  of	  NF-­‐κB),	  in	  the	  cytosol.	  Activation	  of	  the	  TNF-­‐α	  
receptor	   by	   ligand	   binding	   activates	   IκB	   Kinase	   (IKK),	   which	   phosphorylates	   IκBα.	   This	  
phosphorylation	  releases	  NF-­‐κB	  and	  targets	  the	  IκB	  for	  degradation.	  Once	  released	  from	  the	  
IκB	  complex,	  NF-­‐κB	  translocates	  to	  the	  nucleus	  where	  it	  binds	  to	  target	  enhancer	  elements	  
in	  promoters,	   increasing	  gene	   transcription	  of	   inflammatory	  mediators	   such	  as	  TNF-­‐α	  and	  
Interferon-­‐γ	  (IFN-­‐γ)	  (DiDonato	  et	  al.,	  1997,	  Baldwin,	  2001).	  Amongst	  the	  genes	  activated	  by	  
NF-­‐κB	  in	  muscle	  are	  MuRF-­‐1	  and	  those	  in	  other	  degradation	  pathways.	  	  
NF-­‐κB	  activation	  has	  been	   implicated	  as	  a	  key	  step	   in	  muscle	  wasting,	  by	   inhibiting	  
myogenesis	   and	   repair	   as	   well	   as	   activating	   the	   ubiquitin-­‐proteosome	   degradation	   and	  
inflammation	  pathways	  (Cai	  et	  al.,	  2004,	  Langen	  et	  al.,	  2001).	   Inhibition	  of	  NF-­‐κB	  in	  C2C12	  
myotubes	  prevented	  wasting	  (Li	  and	  Reid,	  2000).	  Mourkioti	  et	  al.	  have	  shown	  that	  deletion	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of	   IKK2,	   a	   catalytic	   subunit	   of	   IKK,	  maintains	  muscle	  mass	   and	   promotes	   regeneration	   of	  
muscle	   (Mourkioti	   et	   al.,	   2006).	   Furthermore,	   NF-­‐κB	   has	   been	   shown	   to	   be	   activated	   by	  
physical	  inactivity	  (Hunter	  et	  al.,	  2002)	  in	  a	  BCl3	  dependent	  manner.	  In	  COPD,	  initial	  studies	  
supported	   the	   theory	   that	   inflammation	  contributed	   to	  muscle	  mass	   loss,	  with	  a	   reported	  
increase	   in	   muscle	   p65	   levels	   in	   patients	   with	   a	   low	   BMI	   (Agusti	   et	   al.,	   2004).	   However,	  
recent	   studies	   have	   shown	   inconsistent	   changes	   in	   levels	   of	   inflammatory	   mediators	   in	  
wasted	  patients.	  Some	  studies	  have	  failed	  to	  find	  an	  increase	  in	  inflammatory	  mediators	  in	  
the	  muscle	  of	  COPD	  patients	  (Barreiro	  et	  al.,	  2008,	  Crul	  et	  al.,	  2007),	  whilst	  one	  study	  found	  
increased	   levels	   in	   phosphorylated	   IκB	   in	   low	   FFM	   patients	   compared	   to	   those	   with	  
preserved	  mass	  (Vogiatzis	  et	  al.,	  2010).	  Data	  from	  within	  the	  group	  has	  shown	  no	  change	  in	  
levels	   of	   IκB-­‐α	   or	   phosphorylated	   IκB-­‐α	   in	   COPD	   patients	   compared	   to	   controls	   (data	  
unpublished).	  However,	  the	  relative	  effects	  of	  NF-­‐κB	  may	  be	  dependent	  on	  disease	  status.	  
For	   example,	   Donaldson	   et	   al.	   recently	   showed	   that	   plasma	   levels	   of	   muscle-­‐specific	  
microRNAs	   were	   associated	   with	   quadriceps	   nuclear	   p50	   but	   not	   p65	   in	   early	   disease,	  
suggesting	  that	  inactivity	  was	  increasing	  muscle	  turnover	  (Donaldson	  et	  al.,	  2013).	  	  In	  later	  
disease,	   this	   association	   did	   not	   exist	   and	   the	   plasma	   microRNAs	   were	   associated	   with	  
cytokine	  levels	  suggesting	  a	  role	  for	  classical	  inflammatory	  signalling.	  One	  interpretation	  of	  
these	   findings	   is	   that	   the	   relative	   contribution	   of	   inactivity	   and	   inflammation	   in	   muscle	  
wasting	   changes	   during	   the	   disease	   process.	   Inflammatory	   cytokines	   may	   also	   induce	  
muscle	   atrophy	   by	   pathways	   in	   addition	   to	   the	   UPS;	   for	   example,	   TNF-­‐α	   also	   induces	  
apoptosis	  in	  skeletal	  muscle	  cells	  (Stewart	  et	  al.,	  2004)	  and	  inhibits	  muscle	  regeneration	  by	  
suppressing	  MyoD	  (Langen	  et	  al.,	  2004).	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1.4.2.2 Oxidative	  stress	  and	  Cigarette	  Smoke	  
Oxidative	   stress	   may	   be	   another	   contributing	   factor	   in	   muscle	   mass	   loss	   via	   the	  
generation	   of	   reactive	   oxygen	   species	   (ROS),	   which	   are	   oxygen	   free	   radicals.	   The	   main	  
sources	  of	  ROS	  are	  thought	  to	  be	   from	  mitochondria	  when	  oxygen	   is	  not	   fully	   reduced	  by	  
the	   electron	   transport	   chain	   (Giuliani	   and	  Cestaro,	   1997),	   and	   from	  nicotinamide	   adenine	  
dinucleotide	  phosphatase	  (NADPH)	  oxidase	  in	  activated	  immune	  cells	  in	  muscle	  (Whitehead	  
et	   al.,	   2010).	   The	   ROS	   generated	   include	   superoxides,	   singlet	   oxygen,	   peroxides	   and	  
hydroxyl	   radicals	   which	   cause	   damage	   to	   various	   molecules	   within	   the	   cell	   including	  
carbonyl	  modifications	  to	  proteins,	  lipid	  peroxidation	  and	  DNA	  damage	  (Zhang	  et	  al.,	  1990).	  
Antioxidants	  (or	  free	  radical	  scavengers)	  such	  as	  reduced	  glutathione,	  vitamin	  E,	  superoxide	  
dismutase	  and	  glutathione	  peroxidase	  within	  the	  cell	  normally	  inactivate	  these	  oxidants	  (Ji,	  
1996,	  Clarkson,	  1995,	  Sen	  et	  al.,	  1994).	  Oxidative	  stress	  occurs	  due	  to	  an	  imbalance	  between	  
oxidant	   and	   antioxidant	   levels,	   and	   may	   lead	   to	   increased	   degradation	   of	   carbonylated	  
proteins	  (Nagasawa	  et	  al.,	  1997,	  Dean	  et	  al.,	  1997),	  increased	  membrane	  permeability	  (Sen	  
et	  al.,	  1994)	  and	  apoptotic	  cell	  death	  (Stangel	  et	  al.,	  1996).	  	  
Cigarette	  smoke	  has	  been	  shown	  to	   induce	  oxidative	  stress	   (Barreiro	  et	  al.,	  2010a)	  
and	  consistent	  with	  this,	  patients	  with	  COPD	  have	  increased	  oxidative	  stress	   in	  the	  muscle	  
(Barreiro	  et	  al.,	  2008),	  that	  is	  further	  exacerbated	  by	  exercise	  (Couillard	  et	  al.,	  2003).	  COPD	  
patients	  are	  also	  reported	  to	  have	  reduced	  antioxidant	  levels	  compared	  to	  controls	  (Gosker	  
et	  al.,	  2005)	  	  and	  increased	  systemic	  oxidative	  stress	  (Mercken	  et	  al.,	  2005).	  The	  increase	  in	  
oxidative	  stress	  in	  COPD	  patients	  may	  also	  be	  due	  to	  the	  occurrence	  of	  hypoxemia	  (Tashkin	  
et	  al.,	  2008)	  as	  hypoxic	   tissues	  may	  produce	   less	  antioxidants	   (Giuliani	  and	  Cestaro,	  1997)	  
and	   re-­‐oxygenation	   of	   hypoxic	   tissues	   may	   induce	   ROS	   production	   (Ferrari	   et	   al.,	   1993).	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Consistent	  with	  this,	  COPD	  patients	  with	  hypoxemia	  have	  increased	  oxidative	  stress	  at	  rest	  
and	  after	  exercise	  compared	  with	  non-­‐hypoxemic	  patients	  (Koechlin	  et	  al.,	  2005a).	  
1.4.2.3 Angiotensin-­‐II	  (ang-­‐II)	  
The	  renin-­‐angiotensin	  system	  (RAS)	  is	  another	  signalling	  system	  of	  interest	  in	  muscle	  
atrophy,	   due	   to	   the	   pathologic	   role	   it	   has	   in	   diabetes,	   renal	   disease	   and	   cardiovascular	  
disease	  (Dzau,	  1988,	  Schernthaner	  et	  al.,	  1984),	  which	  are	  often	  accompanied	  by	  increased	  
ang-­‐II	   levels	   and	  muscle	   atrophy	   (Tan	   and	   Fearon,	   2008,	  Masson	   et	   al.,	   1998,	   Roig	   et	   al.,	  
2000).	  The	  RAS	  is	  initiated	  by	  cleavage	  of	  angiotensinogen	  by	  renin,	  producing	  angiotensin-­‐I	  
(ang-­‐I).	  The	  inactive	  precursor,	  angiotensin	  I,	   is	  then	  converted	  to	  angiotensin-­‐II	  (ang-­‐II)	  by	  
Angiotensin	   Converting	   Enzyme	   (ACE)	   (Henriksen	   and	   Jacob,	   2003).	   Ang-­‐II	   then	   binds	   to	  
either	  ang-­‐II	  type	  1	  (AT1)	  receptors	  or	  ang-­‐II	  type	  2	  (AT2)	  receptors	  which	  instigate	  distinct	  
signalling	  pathways	  (Carter	  et	  al.,	  2005).	  Through	  AT1	  receptors,	  ang-­‐II	  mediates	  salt/water	  
retention	   and	   increased	   vascular	   tone,	   whereas	   through	   AT2	   receptors	   ang-­‐II	   can	   cause	  
opposing	  vasodilatory	  effects.	  Although	  both	  receptors	  are	  expressed	  in	  the	  lung,	  only	  AT1	  
receptors	  are	  expressed	  in	  adult	  skeletal	  muscle	  (Malendowicz	  et	  al.,	  2000).	  	  
The	  RAS	  has	  recently	  been	  recognised	  as	  an	  important	  signalling	  pathway	  in	  muscle	  
atrophy;	   ang-­‐II	   has	   been	   shown	   to	   affect	   the	   IGF	   system,	   the	   UPS	   and	   inflammation	   in	  
skeletal	  muscle	   (Hanif	   et	   al.,	   2010).	   Ang-­‐II	   causes	   atrophy	   in	   animal	  models	   (Brink	   et	   al.,	  
1996,	   Song	   et	   al.,	   2005),	   by	   increasing	   protein	   degradation	   via	   the	   UPS.	   In	   mice,	   the	  
cachectic	  effects	  of	  ang-­‐II	  can	  be	  prevented	  by	  muscle	  specific	  IGF-­‐1	  over-­‐expression	  (Song	  
et	   al.,	   2005),	   suggesting	   that	   ang-­‐II	   disrupts	   IGF-­‐1	   signalling	   to	   mediate	   its	   effects.	  
Furthermore,	  blocking	  AKT	  signalling	  with	  a	  dominant	  negative	  AKT	  and	  over-­‐expression	  of	  a	  
constitutively	   active	   FoxO1	   block	   the	   ability	   of	   IGF-­‐1	   to	   inhibit	   ang-­‐II	   induced	   atrophy	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(Yoshida	  et	  al.,	  2010).	  Ang-­‐II	  has	  been	  shown	  to	   induce	  wasting	   in	  myotubes	  by	   increasing	  
protein	   degradation	   via	   the	   UPS	   and	   to	   inhibit	   protein	   synthesis	   (Sanders	   et	   al.,	   2005,	  
Russell	   et	  al.,	   2006).	  Ang-­‐II	   is	   also	  a	  potent	  activator	  of	  oxidative	   stress	   in	   smooth	  muscle	  
and	  endothelial	   cells	   (Zhang	  et	  al.,	  1999b,	  Griendling	  et	  al.,	  1994)	  and	  has	  been	  shown	  to	  
induce	  oxidative	  stress	  in	  skeletal	  muscle,	  suggesting	  that	  it	  may	  also	  contribute	  to	  muscle	  
wasting	  (Wei	  et	  al.,	  2008,	  Zhao	  et	  al.,	  2006b)	  via	  ROS	  production	  from	  the	  NADPH	  oxidases	  
and	  mitochondria	  (Sukhanov	  et	  al.,	  2011).	  
Ang-­‐II	   may	   also	   mediate	   its	   effects	   via	   another	   pathway,	   since	   it	   also	   stimulates	  
thrombospondin,	   a	   major	   activator	   of	   TGF-­‐β	   signalling,	   which	   has	   been	   shown	   to	   inhibit	  
muscle	  regeneration	  and	  to	  promote	  fibrosis	  (Allen	  and	  Boxhorn,	  1989,	  Allen	  and	  Boxhorn,	  
1987,	  Li	  et	  al.,	  2004).	  Thus,	  ang-­‐II	  may	  mediate	   its	  deleterious	  effects	  on	  muscle	  via	  TGF-­‐β	  
signalling.	   Cohn	   et	   al	   2007	   observed	   that	   increased	   TGF-­‐β	   activity	   prevents	   muscle	  
regeneration	   in	  mouse	  models	   of	  Marfan	   syndrome	   and	  Duchenne’s	  muscular	   dystrophy,	  
and	   using	   an	   AT1	   receptor	   blocker	   (Losartan)	   antagonised	   TGF-­‐β	   signalling	   and	   allowed	  
muscle	   regeneration	   and	   the	   restoration	   of	   muscle	   function	   and	   structure	   (Cohn	   et	   al.,	  
2007).	  	  
Another	   approach	   used	   to	   inhibit	   ang-­‐II	   signalling	   is	   through	   ACE	   inhibition.	   ACE	  
inhibitors	   were	   initially	   used	   as	   a	   treatment	   for	   cardiovascular	   diseases	   (Bicket,	   2002),	  
however;	   recently,	   ACE	   inhibitors	   have	   also	   been	   used	   to	   treat	   sarcopenia	   in	   the	   elderly,	  
with	  ACE	   inhibition	  reported	  to	  decrease	  functional	  decline	  and	  disability,	   increase	  muscle	  
strength,	   and	   improve	   muscle	   function	   (Sumukadas	   et	   al.,	   2007,	   Carter	   et	   al.,	   2005)	  
(Gambassi	  et	  al.,	  2000,	  Onder	  et	  al.,	  2002,	  Fransen	  et	  al.,	  2003).	  In	  addition,	  polymorphisms	  
in	  ACE	  have	  been	  shown	   to	   relate	   to	  muscle	   strength	   in	  COPD	  patients	   (Hopkinson	  et	  al.,	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2004a).	   Clearly,	   there	   is	   potential	   for	   ACE	   inhibition	   to	   improve	  muscle	   function	   in	   COPD	  
patients.	  	  	  
1.4.2.4 Myostatin	  
One	  particular	  signalling	  molecule	  of	  interest	  is	  myostatin,	  which	  has	  been	  suggested	  
to	  have	  a	  significant	  role	  in	  muscle	  wasting	  in	  COPD	  (Thomas	  et	  al.,	  2000,	  McFarlane	  et	  al.,	  
2006,	  Man	  et	  al.,	  2010).	  Myostatin	  (also	  known	  as	  growth	  differentiation	  factor	  8,	  GDF-­‐8)	  is	  
a	  member	   of	   the	   TGF-­‐β	   superfamily	   and	   a	  well-­‐known	   and	   important	   inhibitor	   of	  muscle	  
growth	  (McPherron	  and	  Lee,	  1997,	  Lee	  and	  McPherron,	  1999).	  McPherron	  et	  al.	  discovered	  
myostatin	   in	   1997,	   by	   showing	   that	   the	   myostatin	   null	   mice	   exhibited	   a	   double	   muscle	  
phenotype	   with	   both	   fibre	   hypertrophy	   and	   hyperplasia,	   and	   a	   concurrent	   decrease	   in	  
adipose	   tissue	   (McPherron	   et	   al.,	   1997).	   There	   are	   also	   naturally	   occurring	   mutations	  
resulting	  in	   loss	  of	  function	  of	  myostatin	  found	  in	  animals	  such	  as	  Bully	  Whippet	  dogs	  and	  
Belgian	  Blue	  cows,	  which	  also	  exhibit	  a	  similar	  double-­‐muscle	  phenotype	  (Kambadur	  et	  al.,	  
1997,	   Mosher	   et	   al.,	   2007).	   Recently,	   a	   loss-­‐of-­‐function	   mutation	   in	   myostatin	   has	   been	  
found	  in	  a	  human	  child,	  which	  has	  resulted	  in	  an	  abnormal	  increase	  in	  strength	  and	  muscle	  
bulk	  for	  the	  child’s	  age	  (Schuelke	  et	  al.,	  2004).	  	  
	   Myostatin	   is	   an	   expressed	   cytokine,	   which	   can	   act	   in	   both	   an	   auto	   and	   paracrine	  
manner.	  Myostatin	   expression	   is	   limited	   to	   the	   skeletal	  muscle	   during	   embryogenesis,	   to	  
regulate	  proliferation	  and	  differentiation	  of	  myoblasts	   (McPherron	  et	  al.,	  1997).	  However,	  
myostatin	  is	  not	  limited	  to	  skeletal	  muscle	  in	  adulthood,	  where	  it	  is	  expressed	  in	  the	  heart,	  
adipose,	  and	  mammary	  gland	  (Sharma	  et	  al.,	  1999).	  Myostatin	   is	  secreted	  in	  a	   latent	  form	  
attached	   to	   a	   latency	   association	   protein	   (LAP),	   which	   is	   cleaved	   during	   myostatin	  
maturation	   (Lee	   and	  McPherron,	   2001).	   The	   LAP	   pro-­‐peptide	   can	   bind	   and	   inactivate	   the	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mature	  myostatin	   (Yang	  et	   al.,	   2001).	  Once	   activated,	  myostatin	   binds	   to	   activin	   receptor	  
type	   II	   (ActRII)	   either	   Act	   RIIA	   or	   Act	   RIIB,	   leading	   to	   recruitment	   and	   dimerisation	   with	  
activin	   type	   I	   receptors,	   either	   activin	   receptor-­‐like	   kinase	   (ALK)	   ALK-­‐4	   or	   ALK-­‐5	  
(Rebbapragada	   et	   al.,	   2003).	   In	   the	   canonical	   signalling	   pathway,	   myostatin	   binding	   and	  
receptor	   dimerisation	   lead	   to	   activation	   of	   the	   serine/threonine	   receptor	   kinase	   and	  
phosphorylation	   of	   receptor	   Small	   Mothers	   Against	   Decapentaplegic	   (SMAD)	   proteins	  
(SMAD2/3).	  Phosphorylated-­‐SMAD2/3	  binds	  to	  SMAD4,	  forming	  a	  complex	  that	  translocates	  
from	   the	   cytoplasm	   to	   the	   nucleus,	   where	   it	   binds	   to	   DNA	   and	   activates	   transcription	   of	  
target	   genes.	  Myostatin	   also	   signals	   through	   the	   non-­‐canonical	  mitogen-­‐activated	   protein	  
kinase	   (MAPK)	  pathway	   via	   TGF-­‐β	   activated	   kinase	   (TAK1),	   resulting	   in	  p38	  activation	  and	  
leading	  to	  down	  regulation	  of	  myogenesis	  (Philip	  et	  al.,	  2005).	  
Since	   its	  discovery,	  myostatin	  has	  been	  a	  central	   factor	   in	  muscle	  atrophy	  research	  
with	  intense	  efforts	  to	  identify	  the	  mechanisms	  by	  which	  myostatin	  regulates	  muscle	  mass,	  
as	  well	  as	  to	  generate	  and	  evaluate	  therapeutics	  that	  target	  myostatin.	  These	  studies	  have	  
shown	   that	   myostatin	   reduces	   muscle	   mass	   by	   inhibiting	   myoblast	   proliferation	   and	  
differentiation	   (Taylor	   et	   al.,	   2001,	   Langley	   et	   al.,	   2002)	   and	   by	   up-­‐regulating	   the	  
degradation	   of	   transcription	   factors	   involved	   in	   muscle	   synthesis	   and	   protein	   synthesis	  
(McFarlane	  et	  al.,	  2006,	  Trendelenburg	  et	  al.,	  2009,	  Lokireddy	  et	  al.,	  2011).	  Myostatin	  also	  
affects	  protein	  degradation,	  as	  it	  induces	  wasting	  by	  induction	  of	  MuRF1	  (McFarlane	  et	  al.,	  
2006)	   and	   inhibits	   IGF-­‐1	   induced	   hypertrophy	   via	   AKT	   (Morissette	   et	   al.,	   2009,	  
Trendelenburg	  et	  al.,	  2009).	  Several	  studies	  have	  shown	  that	  TGF-­‐β	  activates	  autophagy	  in	  a	  
number	  of	  cell	  lines	  (Ding	  et	  al.,	  2010,	  Kiyono	  et	  al.,	  2009,	  Gajewska	  et	  al.,	  2005);	  however,	  
it	  is	  unknown	  whether	  myostatin	  stimulates	  autophagy	  in	  skeletal	  muscle.	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Myostatin	  levels	  are	  increased	  in	  a	  number	  of	  chronic	  diseases	  such	  as	  cancer,	  AIDS,	  
and	  heart	  failure	  (Lenk	  et	  al.,	  2009,	  Gonzalez-­‐Cadavid	  et	  al.,	  1998),	  where	  muscle	  wasting	  is	  
a	   significant	   co-­‐morbidity	   as	  well	   as	   a	   number	   of	   atrophy	   situations,	   including	   acute	   and	  
chronic	   disuse	   atrophy,	   uni-­‐lateral	   limb	   casting,	   and	   sarcopenia	   (Gustafsson	   et	   al.,	   2010,	  
Reardon	  et	  al.,	  2001,	  Yarasheski	  et	  al.,	  2002).	  Furthermore,	  increased	  myostatin	  levels	  have	  
been	  observed	  in	  muscle	  unloading	  caused	  by	  lower	  limb	  suspension	  in	  mice	  (Carlson	  et	  al.,	  
1999,	  Wehling	  et	  al.,	  2000).	  
	  Myostatin	   is	  thought	  to	  act	   in	  a	  fibre	  specific	  manner,	  as	  myostatin	  null	  mice	  have	  
an	   increased	   proportion	   of	   glycolytic	   fibres	   (Hennebry	   et	   al.,	   2009),	   suggesting	   a	   role	   for	  
myostatin	   in	   fibre-­‐specific	   atrophy.	   Interestingly,	   disuse	   atrophy	   is	   associated	  with	   type	   II	  
fibre	   atrophy	   (Jespersen	   et	   al.,	   2011)	   and	   given	  myostatin	   levels	   are	   increased	   in	   disuse;	  
increased	  myostatin	  may	  provide	  a	  possible	  mechanism.	  	  
Muscle	   atrophy	   in	   COPD	   is	   also	   associated	   with	   type	   II	   fibre	   atrophy,	   again	  
suggesting	  a	  potential	  role	  for	  myostatin	  in	  the	  mechanism	  of	  atrophy.	  Consistent	  with	  such	  
a	   role	   in	   COPD	  associated	  wasting,	   increased	  myostatin	   levels	   have	  been	  observed	   in	   the	  
skeletal	  muscle	   of	   smokers	   compared	   to	   non-­‐smokers	   (Petersen	   et	   al.,	   2007),	   implicating	  
myostatin	  in	  COPD	  related	  muscle	  atrophy.	  Increased	  myostatin	  mRNA	  levels	  were	  observed	  
in	  COPD	  patients	  (Plant	  et	  al.,	  2010).	  Further	  to	  this,	  a	  study	  conducted	  by	  Dr	  William	  Man	  
has	   shown	   that	   myostatin	   mRNA	   levels	   in	   quadriceps	   of	   COPD	   patients	   were	   inversely	  
associated	  with	  quadriceps	  strength,	  daily	  physical	  activity	  and	  quadriceps	  endurance	  (Man	  
et	  al.,	  2010).	  Although	   there	  are	  currently	  a	  number	  of	  drugs	   targeting	  myostatin	  activity,	  
the	  mechanism	  of	   action	  of	  myostatin	   in	  muscle	   atrophy	   and	  COPD	  associated	   atrophy	   is	  
still	  not	  understood.	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1.4.2.5 Four	  and	  A	  Half	  Lim	  Domain	  (FHL)	  Protein	  1	  
Another	   signalling	  molecule	   involved	   in	  muscle	  mass	   regulation	   is	   Four	   and	   a	   half	  
LIM	  domain	  protein	  1	  (FHL1).	  As	  the	  name	  implies,	  FHL	  proteins	  contain	  an	  N-­‐terminal	  half	  
LIM	  domain	  succeeded	  by	  four	  complete	  LIM	  domains	  and	  each	  LIM	  domain	  is	  characterised	  
by	   double	   zinc	   finger	   domains	   which	   aid	   protein:protein	   interactions	   (Morgan	   and	  
Madgwick,	  1999).	  FHL	  proteins	  are	  involved	  a	  diverse	  range	  of	  biological	  functions	  including	  
regulation	   of	   transcription,	   differentiation,	   signalling	   scaffolds,	   as	   well	   as	   cytoskeletal	  
organisation.	   FHL	   proteins	   have	   a	   diverse	   range	   of	   functions	   due	   to	   their	   ability	   to	   bind	  
other	   proteins	   and	   to	   shuttle	   between	   the	   cytoskeleton	   and	   nucleus	   (Schmeichel	   and	  
Beckerle,	   1994,	  Morgan	  and	  Madgwick,	   1999).	  Of	   the	   FHL	  protein	   family,	   FHL1,	   FHL2	  and	  
FHL3	  are	  more	  highly	  expressed	  in	  striated	  muscle	  (Morgan	  and	  Madgwick,	  1999)	  with	  FHL2	  
highly	  expressed	  in	  cardiac	  rather	  than	  skeletal	  muscle	  (Chan	  et	  al.,	  1998)	  whereas	  FHL1	  and	  
FHL3	   have	   the	   opposite	   expression	   profile.	   Mutations	   in	   FHL1	   cause	   several	   hereditary	  
myopathies	  including	  X-­‐linked	  myopathy	  postural	  muscle	  atrophy	  (XMPMA),	  where	  postural	  
muscle	   atrophy	   occurs	   along	   with	   generalised	   hypertrophy	   and	   X-­‐linked	   Scapuloperoneal	  
myopathy	  (Quinzii	  et	  al.,	  2008,	  Windpassinger	  et	  al.,	  2008).	  FHL	  proteins	  are	  involved	  in	  the	  
regulation	  of	  muscle	  mass	  and	  phenotype	  by	  acting	  as	  both	  transcriptional	  co-­‐activators	  and	  
repressors.	   They	   are	   expressed	   differentially	   in	   muscle	   tissue,	   thus	   suggesting	   that	   FHL	  
proteins	  contribute	  to	  muscle	  specific	  gene	  expression.	  	  
FHL1	   has	   been	   shown	   to	   regulate	   differentiation	   in	   postnatal	   skeletal	   muscle.	   In	  
vitro,	  increasing	  FHL1	  expression	  resulted	  in	  cell	  spreading,	  migration	  and	  elongation	  during	  
differentiation	   (McGrath	   et	   al.,	   2003,	   Robinson	   et	   al.,	   2003).	   Over-­‐expression	   of	   FHL1	   in	  
mice	  causes	  increased	  myoblast	  fusion	  and	  hypertrophy	  in	  myotubes	  and	  leads	  to	  a	  switch	  
to	  a	  more	  oxidative	  fibre	  type	  (Cowling	  et	  al.,	  2008).	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In	  COPD	  quadriceps,	   FHL1	  mRNA	  expression	  correlates	  with	   type	   IIA	  myosin	  heavy	  
chain	   (MHC)	  expression	   (Lewis	  et	  al.,	  2010).	   Furthermore,	  FHL1	  expression	  also	  correlates	  
with	  inactivity	  and	  weakness	  in	  COPD	  patients	  (Lewis	  et	  al.,	  2010,	  Riddoch	  Contreras	  et	  al.,	  
2008).	  As	  disuse	  plays	  an	   significant	   role	  muscle	  dysfunction	   in	  COPD	   (Degens	  and	  Alway,	  
2006),	  and	  COPD	  is	  also	  associated	  with	  a	  fibre	  type	  switch	  in	  the	  muscle	  to	  more	  glycolytic	  
fibre	   type,	   these	   lines	   of	   evidence	   suggest	   that	   FHL1	  may	   be	   important	   in	   regulating	   the	  
muscle	  phenotype	  changes	  observed	  in	  COPD.	  	  
Additionally,	  FHL1	  has	  been	  shown	  to	  interact	  with	  and	  potentiate	  TGF-­‐β	  signalling	  in	  
human	  embryonic	  kidney	  293T	  cells	  (Ding	  et	  al.,	  2009),	  raising	  the	  possibility	  that	  FHL1	  may	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1.5 Hypotheses:	  
• Myostatin	  activates	  autophagy	  in	  skeletal	  muscle	  
• FHL1	  augments	  myostatin	  signalling	  in	  skeletal	  muscle	  
• Cigarette	  smoke	  affects	  autophagy	  in	  mice	  




The	   overarching	   theme	   of	   this	   thesis	   is	   to	   examine	   the	   role	   of	   autophagy	   and	  
myostatin	  in	  atrophy	  signalling	  in	  skeletal	  muscle	  in	  relation	  to	  COPD.	  The	  role	  of	  autophagy	  
in	   skeletal	   muscle	   atrophy	   in	   COPD	   has	   yet	   to	   be	   fully	   explored;	   and	   myostatin	   is	   of	  
particular	  interest	  given	  its	  role	  in	  the	  regulation	  of	  muscle	  mass.	  As	  discussed	  above,	  TGF-­‐β	  
has	  been	  shown	  to	  induce	  autophagy,	  thus	  myostatin	  may	  also	  induce	  autophagy	  in	  skeletal	  
muscle.	  FHL1	  has	  been	  shown	  to	  potentiate	  TGF-­‐β	  induced	  SMAD	  signalling	  thus	  indicating	  
that	  FHL1	  may	  also	  potentiate	  myostatin	  signalling.	  Lastly,	  the	  role	  of	  cigarette	  smoke	  and	  
COPD	  on	  autophagy	  will	  be	   further	  explored	  and	  added	  to	  this,	   the	  effect	  ang-­‐II	   signalling	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2.1 Chemicals	  and	  Solutions	  
All	  materials	  supplied	  by	  Sigma	  (UK)	  unless	  otherwise	  stated.	  
2.1.1 Plasmid	  Preparation	  
2.1.1.1 1%	  Luria	  Broth	  (LB)	  agar	  plates	  	  
2.5g	  of	  agar	  powder	  was	  suspended	  in	  250ml	  of	  LB	  media	  (25g	  LB	  powder	  in	  1l	  dH2O	  
with	  the	  pH	  adjusted	  to	  7.2	  and	  autoclaved),	  and	  the	  mixture	  was	  autoclaved.	  Once	  cooled	  
to	  approximately	  below	  60oC,	  the	  appropriate	  antibiotic	  was	  added	  for	  selection.	  For	  each	  
100mm	  petri	  dish,	  approximately	  20ml	  of	   LB	  agar	  was	  used,	  and	   the	  agar	  was	  allowed	   to	  
set.	  	  
2.1.1.2 Ampicillin	  antibiotic	  solution	  	  
A	  stock	  solution	  at	  10mg/ml	  was	  made	  by	  dissolving	  0.05g	  of	  ampicillin	  in	  5ml	  dH2O.	  
This	  stock	  solution	  was	  diluted	  1:100	  to	  a	  working	  concentration	  of	  100µg/ml.	  
2.1.1.3 Bacterial	  Transformations	  
1µl	  of	  plasmid	  DNA	  was	  added	   to	  40µl	   JM109	  competent	  cells	   (Promega,	  UK),	  and	  
incubated	  on	  ice	  for	  15	  min.	  The	  cells	  were	  heat	  shocked	  for	  90	  s	  at	  42oC	  then	  placed	  on	  ice	  
for	  2	  min.	  500µl	  of	  2x	  (Yeast	  extract	  Tryptone)	  YT	  was	  added	  and	  the	  bacterial	  solution	  was	  
incubated	   at	   37oC	   for	   45	   min	   with	   horizontal	   shaking	   at	   300rpm	   to	   allow	   cells	   to	   grow.	  
Subsequently,	   200µl	   of	   the	   resulting	   solution	   was	   spread	   on	   LB	   agar	   plates	   containing	  
100µg/ml	  ampicillin	  using	  sterile	  conditions.	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2.1.1.4 10x	  Tris	  Borate	  EDTA	  (TBE)	  buffer	  	  
For	  10x	  stock	  solution,	  108g	  of	  Trizma®	  Base	  was	  dissolved	   in	  1l	  dH2O,	  with	  55g	  of	  
Boric	  Acid	  and	  9.3g	  of	  EDTA	  in	  a	  final	  volume	  of	  1l	  of	  dH2O.	  For	  use,	  this	  10x	  stock	  solution	  
was	  diluted	  to	  0.5x	  with	  dH2O.	  
	  
2.1.2 Fixing	  and	  Staining	  Cells	  for	  Microscopy	  
2.1.2.1 4%	  Paraformaldehyde	  	  
4g	  of	  PFA	  was	  added	   to	  80ml	  dH2O,	  and	  heated	   to	  60oC	   to	  dissolve	   the	  PFA.	  Then	  
sodium	  hydroxide	   (NaOH)	  was	  added	  dropwise	   to	  completely	  dissolve	   the	  PFA.	  The	  pH	  of	  
the	  solution	  was	  adjusted	  to	  neutral	  with	  5M	  HCl,	  before	  10ml	  of	  10x	  Phosphate	  Buffered	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2.1.3 Solutions	  for	  Western	  Blotting	  
	  
2.1.3.1 2x	  NP40	  lysis	  buffer	  
300mM	  NaCl,	  20mM	  Trizma®	  Base,	  10mM	  EDTA	  and	  2%	  Igepal-­‐NP40	  were	  added	  to	  
500ml	  dH2O.	  The	  pH	  was	  adjusted	  to	  7.3	  before	  the	  addition	  of	  protease	  and	  phosphatase	  
inhibitor	  cocktails	  (1%)	  (Sigma).	  	  For	  western	  blot	  analysis,	  2x	  NP40	  was	  diluted	  1:1	  with	  2x	  
SDS	  protein	  sample	  buffer.	  
2.1.3.2 2x	  SDS	  protein	  sample	  buffer	  	  
The	  buffer	  consisted	  of	  4%	  SDS,	  20%	  Glycerol,	  10%	  Stacking	  gel	  buffer	  (1M	  Trizma®,	  
pH6.8)	   and	   10%	   mercaptoethanol	   (added	   just	   before	   use),	   and	   a	   trace	   amount	   of	  
bromophenol	  blue	  and	  adjusted	  to	  a	  final	  volume	  of	  50ml	  with	  dH2O.	  
2.1.3.3 Resolving	  Gel	  
For	   LC3-­‐II	   protein	   analysis	   15%	   resolving	   gels	   were	   used.	   A	   15%	   resolving	   gel	  
consisted	   of	   1.83ml	   of	   dH2O,	   2.5ml	   of	   acrylamide/methylene	   bisacrylamide	   solution	  	  
(National	   Diagnostics,	   UK,	   w/v	   30%),	   0.6ml	   of	   1.5M	   Trizma®	   (pH8.8,	   final	   concentration	  
0.37M),	  50µl	  of	  SDS	  (10%),	  25µl	  Ammonium	  Persulphate	  (APS)	  (10%)	  and	  2.5µl	   (N’,	  N’,	  N’,	  
N’-­‐Tetramethylethylenediamine)	   TEMED.	   For	   FHL1	   protein	   analysis,	   10%	   gels	   were	   used,	  
which	  consisted	  of	  2ml	  of	  dH2O,	  1.6ml	  of	  acrylamide,	  1.25ml	  of	  1.5M	  Trizma®	  (pH8.8)	  and	  
the	  same	  volumes	  of	  SDS,	  TEMED	  and	  APS.	  This	  mixture	  was	  poured	  in	  between	  1mm	  thick	  
glass	   plates	   then	   covered	   with	   400µl	   of	   water-­‐saturated-­‐butanol	   to	   ensure	   the	   top	   of	  
resolving	  gel	  sets	  in	  a	  straight	  line.	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2.1.3.4 Stacking	  Gel	  
Once	  the	  resolving	  gel	  was	  set,	  the	  butanol	  was	  removed	  and	  the	  resolving	  gel	  was	  
washed	  with	  dH2O	  three	  times.	  The	  stacking	  gel	  mixture	  consisted	  in	  1.1ml	  of	  dH2O,	  0.42ml	  
of	   acrylamide,	   0.63ml	   of	   1M	   Trizma®,	   25µl	   of	   10%	   SDS,	   12.5µl	   of	   10%	   APS	   and	   2.5µl	   of	  
TEMED.	  A	  10-­‐well	  plastic	  comb	  was	  added	  to	   the	  stacking	  mixture	  and	  the	  gel	  was	   left	   to	  
polymerise.	  
2.1.3.5 Running	  buffer	  10x	  
In	  1l	  of	  dH2O,	  30.3g	  of	  Trizma®	  Base	  was	  dissolved	  with	  10g	  of	   SDS	  and	  140.4g	  of	  
glycine.	  Once	  dissolved,	  the	  pH	  was	  adjusted	  to	  8.3	  with	  5M	  HCl.	  
2.1.3.6 Transfer	  buffer	  10x	  
24.7g	  of	  Trizma®	  base	  was	  dissolved	  into	  1l	  of	  dH2O	  with	  112.6g	  of	  glycine.	  20%	  (v/v)	  
methanol	  was	  added	  to	  the	  solution	  after	  dilution	  to	  1x	  with	  dH2O.	  
2.1.3.7 Tris	  Buffered	  Saline-­‐	  Tween	  (TBS-­‐T)	  10x	  
For	  a	  2l	  solution,	  48.4g	  of	  Trizma®	  base,	  and	  160g	  NaCl	  were	  added	  to	  1.8l	  of	  dH2O,	  
the	  pH	  was	  adjusted	  to	  7.6	  before	  20ml	  of	  Tween-­‐20	  was	  added.	  The	  volume	  of	  the	  solution	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2.2 Methods	  
2.2.1 Cell	  culture	  and	  DNA	  transfection	  
2.2.1.1 Cell	  culture	  
All	  cell	  culture	  reagents	  supplied	  by	  Life	  Technologies	  (UK)	  unless	  otherwise	  stated.	  
Murine	   skeletal	   myoblasts	   (C2C12)	   cells	   were	   maintained	   in	   Dulbecco’s	   Modified	  
Eagle	  Medium	   (DMEM)	  which	  was	   supplemented	  with	  10%	   (v/v)	   FBS	   (DMEM	  +	  10%	  FBS),	  
penicillin	  (100U/ml)	  and	  streptomycin	  (100U/ml)	  at	  37oC	  with	  5%	  CO2.	  Cells	  were	  kept	  sub-­‐
confluent	   and	   were	   sub-­‐cultured	   every	   2-­‐3	   days	   with	   trypsinisation	   (1:6)	   (Martin	   et	   al.,	  
2000).	  Cells	  were	  passaged	  10-­‐15	  times.	  
2.2.1.2 DNA	  transfection	  
1.25	   x	   104	   cells	   were	   seeded	   in	   to	   a	   24-­‐well	   plate.	   The	   following	   day,	   cells	   were	  
examined	   by	   light	   microscopy	   to	   ensure	   they	   were	   between	   60-­‐80%	   confluent	   before	  
transfection.	  0.4µg	  of	  plasmid	  DNA	  was	  added	  to	  20µl	  of	  Opti-­‐MEM,	  which	  was	  then	  mixed	  
with	  2µl	  of	  Lipofectamine	  reagent	  (Invitrogen,	  UK)	   in	  20µl	  of	  Opti-­‐MEM	  for	  each	  well.	  The	  
mixture	  was	  incubated	  at	  room	  temperature	  for	  15	  min,	  before	  165µl	  of	  serum-­‐free	  DMEM	  
was	  added	   to	   the	  mixture	  per	  well	  and	  mixed	  by	   inversion.	  Cells	  were	  washed	   twice	  with	  
serum-­‐free	  DMEM	  before	  200µl	  of	  the	  final	  reaction	  mixture	  was	  added	  to	  each	  well.	  Cells	  
were	  then	  kept	  at	  37oC,	   in	  5%	  CO2	  for	  4.5	  h	  before	  the	  transfection	  mixture	  was	  removed	  
and	  replaced	  with	  DMEM	  +	  10%	  FBS	  for	  12	  h.	  The	  plasmids	  used	  for	  transfections	  are	  listed	  
in	  Table	  2.	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Table	  2	  Table	  of	  plasmids	  used	  










Plasmid	   Gene	   Vector	   Origin	  
pCDNA.3	   Empty	  vector	   -­‐	   Promega	  
p(CAGA)12-­‐luc	   Luciferase	   pGL3	   P.	  Kemp	  
pRL-­‐TK	   Luciferase	   pRL	   Promega	  
p-­‐EGFP-­‐LC3	   LC3	   pEGFP-­‐C1	   T.	  Yoshimiri	  
pC-­‐FHL1	   FHL1	   pCDNA	   E.	  Amirak	  
pC-­‐	  FHL3	   FHL3	   pCDNA	   A.	  Lewis	  
pCAGGS-­‐FHL1	   FHL1	   pCAGGS	   D.	  Lori	  
pCAGGS	  Myostatin	   Myostatin	   pCAGGS	   D.	  Lori	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2.2.1.3 Luciferase	  Assays	  
The	   Dual	   Luciferase	   Reporter	   Assay	   (DLR	   TM)	   system	   (Promega,	   UK)	   uses	   a	   firefly	  
(Photinus	   pyralis)	   reporter	   luciferase	   vector	   (in	   this	   case	   p(CAGA)12)	   and	   a	   control	   Renilla	  
(Renilla	  reniformis)	   luciferase	  reporter	  (pRL-­‐TK).	  The	  amount	  of	  the	  two	  luciferase	  proteins	  
produced	  was	  measured	  sequentially	  from	  each	  sample	  thus	  the	  reporter	  luciferase	  activity	  
could	   be	   normalised	   to	   the	   control	   Renilla	   luciferase	   activity	   to	   account	   for	   transfection	  
efficiency.	   	  
For	   luciferase	   assays,	   cells	   were	   seeded	   in	   24-­‐well	   plates	   at	   a	   density	   of	   1.25x104	  
cells,	  with	  each	  well	  transfected	  with	  0.2µg	  p(CAGA)12,	  0.1µg	  pRL-­‐TK	  and	  either	  0.1µg	  of	  pC-­‐
FHL1	  or	  pC-­‐FHL3.	  The	  following	  day	  after	  transfection,	  cells	  were	  serum	  starved	  for	  7	  h,	  then	  
treated	  with	  either	  TGF-­‐β1	  or	  myostatin	  (R&D	  Systems,	  UK)	  at	  the	  concentrations	  stated	  in	  
Chapter	  5	  for	  16	  h	  before	  assessment	  of	  luciferase	  activity.	  Cells	  were	  washed	  with	  ice-­‐cold	  
1x	  PBS	  twice	  and	  then	  lysed	  with	  125µl	  of	  1x	  Passive	  Lysis	  Buffer	  (Promega,	  UK)	  and	  placed	  
under	  agitation	  using	  	  a	  lateral	  shaker	  for	  15	  min.	  	  10µl	  of	  the	  lysate	  solution	  was	  added	  to	  a	  
96-­‐well	  white	   polystrene	   plate	   (Costar,	  UK)	   before	   50µl	   of	   luciferase	   substrate	   (Promega)	  
was	  added	  and	  firefly	   luciferase	  activity	  was	  measured	  by	  reading	  light	  emission	  at	  420nm	  
using	  a	  spectrophotometer.	  The	  firefly	  luciferase	  activity	  was	  then	  quenched	  with	  50µl	  of	  1x	  
Stop	   and	   Glo	   solution	   (Promega,	   UK)	   before	   the	   control	   Renilla	   luciferase	   activity	   was	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2.2.1.4 Myotube	  diameter	  experiments	  
	   2x105	   cells	  were	   seeded	   in	   a	   6-­‐well	   plate	   in	  DMEM	  +	   10%	   FBS.	   The	   following	   day,	  
cells	  were	  transfected	  with	  a	  total	  of	  2μg	  DNA	  consisting	  of	  0.5μg	  pCAGGS-­‐GFP	  and	  either	  
1.5μg	   pC-­‐FHL1	   or	   1.5μg	   pcDNA	   (i.e.	   1:3	   ratio)	   in	   80μl	   Optimem.	   In	   a	   separate	   micro-­‐
centrifuge	   tube	   8μl	   of	   lipofectamine	  was	   added	   to	   80μl	   Optimem,	   and	   the	   two	   solutions	  
were	   mixed	   together	   i.e.	   160μl	   per	   well.	   660μl	   of	   serum	   free	   DMEM	   added	   to	   each	  
transfection	  mix	  and	  then	  800μl	  of	   this	  mix	  was	  added	  to	  cells.	  After	  4.5h	   incubation,	   the	  
medium	   was	   replaced	   with	   DMEM	   +	   10%	   FBS.	   Cells	   were	   allowed	   to	   become	   confluent	  
(approximately	  3	  days)	  and	  media	  was	  replaced	  with	  fresh	  DMEM	  +	  10%	  FBS	  every	  2	  days.	  
The	   media	   was	   then	   replaced	   with	   DMEM	   supplemented	   with	   2%	   horse	   serum	   (GE	  
healthcare,	   UK)	   (DMEM	   +	   2%	   HS)	   for	   7	   days	   to	   fully	   differentiate	   the	   myoblasts	   into	  
myotubes,	  during	  which	   the	  media	  was	  replaced	  with	   fresh	  DMEM	  +	  2%	  HS	  every	  2	  days.	  
After	  differentiating	  for	  7	  days	  in	  total,	  the	  medium	  was	  then	  replaced	  with	  DMEM	  +	  2%	  HS	  
with	   either	   myostatin	   (R&D	   Systems,	   UK),	   GDF-­‐15	   (Insight	   Biotechnology,	   UK)	   or	   vehicle	  
control	   (0.1%	  BSA	   and	  20mM	  HCl)	   and	   grown	   for	   4	   days.	   After	   48	   and	   96	  h	   of	   exposure,	  
myotubes	   were	   identified	   in	   randomly	   selected	   views	   at	   10x	  magnification	   and	   captured	  
using	  a	  Hamamatsu	  C4742-­‐95-­‐12ERG	  camera	  attached	   to	  a	  Zeiss	  Axiovert	  200	  microscope	  
with	  an	  emission	  filter	  470nm	  to	  capture	  GFP	  fluorescence.	  pCAGGS-­‐GFP	  was	  co-­‐transfected	  
into	   the	   cells	   so	   that	  myotubes	   that	  were	   selected	   are	  more	   likely	   to	   also	   express	   either	  
FHL1-­‐pcDNA	  or	  pcDNA.	  In	  addition,	  the	  diameter	  of	  the	  myotubes	  could	  be	  measured	  more	  
accurately	   in	   a	   GFP-­‐expressing	   myotubes	   as	   there	   is	   a	   greater	   contrast	   with	   the	   dark	  
background	   compared	   to	   bright	   field	   images.	   In	   each	   treatment	   group,	   20-­‐25	   randomly	  
selected	   images	   were	   captured,	   and	   myotubes	   within	   the	   image	   were	   quantified.	   The	  
myotube	  diameter	  was	  ascertained	  by	  averaging	  the	  shortest	  distance	  across	  the	  myotube	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at	   five	   points	   along	   the	   length	   of	   the	  myotube	   in	   Image	   J	   (National	   Institutes	   of	   Health,	  
USA).	  	  
	  
2.2.1.5 Cell	  Fluorescence	  Microscopy	  
	   1.25x104	   cells	   were	   seeded	   on	   to	   13mm	   glass	   coverslips	   placed	   in	   12-­‐well	   plates.	  
Cells	  were	   transfected	  with	   0.8μg	   p-­‐EGFP-­‐LC3	   (kindly	   provided	   by	  Dr	   Tamotsu	   Yoshimori)	  
using	   lipofectamine	   as	   described	   previously	   (Favot	   et	   al.,	   2005).	   The	   following	   day,	   cells	  
were	   treated	   with	   serum-­‐free	   DMEM,	   DMEM	   containing	   20ng/ml	   myostatin	   or	   10ng/ml	  
TGF-­‐β1	  or	  with	  serum-­‐free	  Earle’s	  Balanced	  Salt	  Solution	  (EBSS)	  for	  0,	  0.5,	  1	  and	  1.5	  h.	  Cells	  
were	  then	  washed	  twice	  with	  1x	  PBS,	  and	  fixed	  for	  10	  min	  with	  250μl	  4%	  PFA	  before	  being	  
washed	  with	  1x	  PBS.	  The	  nuclei	  were	  stained	  with	  4’,	  6-­‐diamino-­‐2-­‐phenylindole	  (DAPI,	  stock	  
concentration	  at	  5mg/ml	  diluted	  to	  1:10000	  in	  1x	  PBS).	  The	  coverslips	  were	  removed	  from	  
the	  wells,	   inverted	  and	  mounted	  with	  15μl	  Fluoromount®	  onto	  frost-­‐free	  glass	  slides.	  Cells	  
were	  viewed	  using	  a	  Hamamatsu	  C4742-­‐95-­‐12ERG	  camera	  attached	  to	  a	  Zeiss	  Axiovert	  200	  
microscope	   and	   images	   were	   captured	   with	   Improvision	   Volocity®	   software	   using	   x100	  
magnification	  with	   an	   oil	   immersion	   lens	   and	   analysed.	   Images	  were	   under	   brightfield	   as	  
well	   as	   using	   an	   emission	   filter	   at	   470nm	   to	   capture	   GFP	   fluorescence	   and	   at	   365nm	   to	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2.2.2 Tissue	  Staining	  
Mouse	  sections	   from	  electroporation	  experiment	   in	  Chapter	  4	  were	  processed	  and	  
sectioned	  by	  myself	  as	  detailed	  in	  Section	  2.2.11.2.	  	  
	  
2.2.2.1 Fibre	  type	  staining	  
	   Sections	  of	  mouse	  muscle	  tissue	  were	  retrieved	  from	  storage	  at	  -­‐80oC	  and	  allowed	  to	  
air	  dry	  for	  30	  min	  and	  a	  circle	  was	  drawn	  using	  an	  Immunopen	  (Calbiochem,	  UK)	  around	  the	  
section.	  Sections	  were	  rinsed	  with	  0.05%	  v/v	  Tween-­‐20	  in	  1x	  PBS	  (PBS-­‐T)	  then	  incubated	  in	  
1%	  PBST	  for	  15	  min	  and	  then	  incubated	  in	  5%	  non-­‐fat	  milk,	  0.5%	  Tween-­‐20	  v/v	  in	  1x	  PBS	  for	  
30	  min	  to	  block	  unspecific	  binding.	  Sections	  were	  washed	  with	  0.05%	  v/v	  PBS-­‐T	  three	  times	  
for	  5	  min.	  Sections	  were	  then	  incubated	  with	  rat	  anti-­‐laminin	  alpha	  2	  (Abcam,	  UK,	  see	  Table	  
4	  for	  all	  antibody	  concentrations)	  for	  1	  h	  at	  4oC	  before	  washing	  three	  times	  with	  0.05%	  PBS-­‐
T.	  Sections	  were	  further	   incubated	  with	  Alexa	  568	  goat	  anti-­‐rat	   (Invitrogen,	  UK)	  and	  again	  
washed	  three	  times	  with	  0.05%	  PBS-­‐T.	  The	  final	  incubation	  with	  the	  fluorophore-­‐conjugated	  
fibre	   type	   antibodies	   BA-­‐D5	   anti	   type	   I,	   SC-­‐71	   anti-­‐	   type	   IIA,	   and	   BF-­‐F3	   anti	   type	   IIB	   as	  
performed	  at	  4oC	  overnight	  with	  the	  sections	  protected	  from	  light	  from	  this	  stage	  onwards.	  
The	   sections	  were	   subsequently	  washed	   three	   times	  with	  0.05%	  PBS-­‐T	  and	  allowed	   to	  air	  
dry	   before	   sealing	   with	   Fluoromount	   (Sigma,	   UK)	   and	   coverslips.	   For	   the	   FHL1	   immuno-­‐
staining,	  a	  similar	  protocol	  was	  used,	  omitting	  the	  laminin	  stain,	  with	  FHL1	  antibody	  (Aviva	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2.2.2.2 Fibre	  Imaging	  of	  Electroporated	  Mice	  
	   Fibre	   type	   images	   for	   the	   FHL1	   over-­‐expression	   group	   were	   captured	   on	   the	  
Hamamatsu	   C4742-­‐95-­‐12ERG	   camera	   attached	   to	   a	   Zeiss	   Axiovert	   200	   microscope	   and	  
images	  were	  captured	  using	  x10	  magnification	  EC	  Plan-­‐Neofluar	  10x	  0.30	  Ph1	  and	  tiled	  using	  
Volocity®	  software.	  Subsequently,	  fibre	  type	  images	  for	  the	  myostatin	  +	  FHL1	  and	  myostatin	  
group	  were	  captured	  on	  a	  Zeiss	  Axio	  Observer	   inverted	  microscope	  with	  a	   fully	  motorised	  
stage,	  controlled	  by	  Zen	  acquisition	  software.	  The	  Zeiss	  Axio	  Observer	  microscope	  uses	  an	  
LED	   light	   source,	   allowing	   faster	   channel	   switching	   and	   thus	   faster	   low	   lighting	   imaging	  
compared	   to	   the	   Zeiss	   Axiovert	   200,	   thus	   this	   microscope	   was	   used	   to	   image	   the	   other	  
groups	  for	  speed.	  Images	  were	  captured	  with	  EC	  Plan-­‐Neofluar	  10x/0.30	  Ph1	  objective	  lens	  
and	  the	  tiles	  were	  stitched	  together	  with	  Zen	  software	  based	  on	  the	  red	  channel	  to	  align	  the	  
tiles.	  Filters	  used	  for	  fibre	  typing	  are	  listed	  in	  Table	  3.	  	  
	  
Table	  3	  Filters	  used	  in	  fibre	  type	  imaging	  
Table	  of	  the	  filters	  used	  for	  fibre	  tying	  and	  excitation	  and	  emission	  wavelengths.	  
Excitation	  λ	   Emission	  λ	   Name	  of	  Filter	  
BP	  365/12	   447/60	   Zeiss	  Filter	  Set	  01	  (DAPI)	  
BP	  470/40	   525/50	   Zeiss	  Filter	  Set	  10	  (FITC)	  	  
BP	  562/40	   624/40	   Texas	  Red,	  mCherry	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2.2.3 Sample	  preparation	  for	  western	  blotting	  
2.2.4 Cell	  protein	  lysates	  preparation	  	  
2.2.4.1 LC3-­‐II	  analysis	  in	  cells	  
	   For	   treatments,	   9x105	   cells	  were	   seeded	   into	   6cm	  wide	   dishes.	   The	   following	   day,	  
fresh	  DMEM	  +	  10%	  FBS	  was	  placed	  on	   the	   cells	   2	  h	  prior	   to	   treatment	   to	  minimise	  basal	  
autophagy	  and	  nutrient	  depletion.	  To	  treat	  the	  cells,	  this	  medium	  was	  replaced	  with	  serum-­‐
free	  DMEM	  alone,	  serum-­‐free	  DMEM	  containing	  either	  20ng/ml	  Myostatin	  or	  10ng/ml	  TGF-­‐
β1	   or	   1µM	   Rapamycin	   (Sigma,	   UK).	   Cells	   were	   treated	   for	   0.5,	   1.5,	   3	   or	   16	   h	   prior	   to	  
harvesting	   for	  protein	  extraction.	  Cells	  were	   lysed	   in	  500μl	  2x	  NP40	   lysis	  buffer	  before	  2x	  
SDS	  protein	  sample	  buffer	  was	  added	  for	  a	  1:1	  dilution	  and	  frozen	  on	  dry	  ice.	  Samples	  were	  
stored	  at	  -­‐80oC	  before	  western	  analysis.	  
	  
2.2.4.2 Muscle	  lysis	  and	  homogenisation	  
	   Tissue	  was	  lysed	  and	  homogenised	  using	  a	  Stretton	  Scientific	  Precellys	  24®	  (Stretton,	  
UK).	  The	  tissues	  were	  placed	  in	  tubes	  containing	  1.4mm	  ceramic	  beads	  (CDK-­‐14)	  along	  with	  
the	  200µl	  of	  2x	  NP40	  lysis	  buffer	  and	  applied	  to	  the	  Precellys	  machine,	  which	  uses	  a	  bead	  
beating	   process	   as	   the	   machine	   moves	   through	   a	   figure	   of	   ‘8’	   motion	   to	   lyse	   and	  
homogenise	   the	  muscle.	   For	   human	  muscle	   preparation,	   the	   frozen	   tissue	   samples	   were	  
placed	   in	   the	  ceramic	  bead	  containing	   tubes	  with	   the	  NP-­‐40	  buffer	  and	  2	   x	  20	   s	   cycles	  at	  
5500rpm	  were	  used.	  	  
For	   mouse	  muscle,	   mouse	   gastrocnemius	   was	   removed	   from	   the	   RNA	   Later	   (RLT)	   buffer	  
(Qiagen,	  UK),	  and	  placed	   into	   the	  ceramic	  beaded	   tubes	  containing	  200µl	  2x	  NP40	  buffer.	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The	  mouse	  samples	  were	  exposed	  to	  4	  x	  15	  s	  cycles	  at	  5500rpm.	  The	  muscle	  samples	  were	  
then	  spun	  at	  9000rpm	  for	  5	  min	  to	  pellet	  any	  uncrushed	  material.	  The	  protein	  lysates	  were	  
placed	  into	  fresh	  micro-­‐centrifuge	  tubes	  and	  stored	  at	  -­‐80oC	  until	  quantification.	  
	  
2.2.5 Protein	  quantification	  
	   2µl	  of	  protein	  lysates	  was	  diluted	  in	  the	  appropriate	  volume	  of	  dH2O	  (1:60	  to	  dilute	  
out	   the	   NP40	   which	   interacts	   with	   the	   Bradford’s	   reagent).	   10µl	   of	   the	   diluted	   protein	  
lysates	  was	  added	   to	  90µl	  of	  Bradford’s	   reagent	   in	  a	  clear	  96-­‐well	  plate.	  The	  mixture	  was	  
incubated	   for	   15	  min	   at	   room	   temperature.	   The	   change	   in	   absorption	   due	   to	   the	   varying	  
concentration	  of	  protein	  was	   then	  measured	  by	   reading	   the	  absorption	  at	  620nm	  using	  a	  
spectrophotometer	   (Micro-­‐plate	   reader,	   Biorad,	   UK).	   The	   absorption	   at	   620nm	   is	  
proportional	   to	  the	  amount	  of	  protein	   in	   the	   lysates.	  The	  concentration	  was	  subsequently	  
calculated	  using	  a	  standard	  curve	  prepared	  from	  known	  amounts	  of	  bovine	  serum	  albumin	  
(BSA).	  Samples	  were	  diluted	  to	  a	  stock	  of	  3mg/ml	  with	  dH2O	  and	  then	  diluted	  1:1	  with	  2x	  
sample	  buffer.	  
	  
2.2.6 Western	  blotting	  procedures	  
	   Protein	  lysates	  were	  analysed	  using	  SDS	  polyacrylamide	  gel	  electrophoresis	  (PAGE).	  
For	  LC3-­‐II	  quantification,	  protein	  lysates	  were	  separated	  using	  15%	  (v/v)	  SDS	  PAGE	  gels	  and	  
run	   at	   120V	   for	   approximately	   1.5	   h.	   	   Following	   electrophoresis,	   gels	   were	   cut	   into	   two	  
horizontally	   at	   the	   25kDa	   marker.	   The	   PolyVinylidenediFluoride	   (PVDF)	   membrane	   was	  
immersed	   in	  methanol	  prior	   to	  use	   then	  equilibrated	  with	  1x	   transfer	  buffer.	   The	  portion	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containing	  <25kDa	  proteins	   (i.e.	   25-­‐10kDa)	  was	   transferred	  onto	  PVDF	  membrane	  using	  a	  
semi-­‐dry	  blotter	   (Bio-­‐Rad,	  Ely)	   at	  14V	   for	  20	  min.	  The	  portion	   containing	  >25kDa	  proteins	  
(100-­‐25kDa)	  was	  transferred	  for	  1	  h.	  For	  FHL1	  blots,	  10%	  (v/v)	  SDS	  PAGE	  were	  gels	  were	  run	  
at	  120	  V	  for	  approximately	  1	  h	  and	  membranes	  were	  transferred	  whole	  for	  1h.	  Membranes	  
were	  blocked	  in	  5%	  (w/v)	  TBS-­‐T	  fat-­‐free	  milk	  for	  1	  h	  at	  room	  temperature.	  After	  three	  5	  min	  
washes	  with	  TBS-­‐T,	  blots	  were	   incubated	   in	  primary	  antibody	  overnight	  at	  4oC	   (antibodies	  
used	  are	   listed	  in	  Table	  4).	  After	  washing,	  the	  membranes	  were	  incubated	  with	  the	  horse-­‐
radish	   peroxidase	   (HRP)	   conjugated	   secondary	   antibody	   for	   1	   h	   at	   room	   temperature,	  
before	   washing	   as	   described	   previously.	   Protein	   levels	   were	   detected	   using	   chemi-­‐
luminescence	  (ECL	  plus,	  GE	  Healthcare,	  UK)	  and	  light	  sensitive	  film.	  Films	  were	  then	  scanned	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Table	  4.	  Table	  of	  Antibodies	  Used	  
Table	  of	  antibodies	  used	  for	  western	  blotting	  and	  immunofluorescence	  staining.	  
Antibody	   Species	  Raised	  in	   Company	  
Concentration	  
(v/v)	  
LC3	   Mouse	   Nanotools	   1:300	  
α-­‐tubulin	   Goat	   Invitrogen	   1:3000	  
FHL1	   Rabbit	   Aviva	  Biosystems	   1:100	  
α	  2	  Laminin	   Rat	   Abcam	   1:200	  
Mouse	  HRP	   Rabbit	   Abcam	   1:4000	  
Goat	  HRP	   Rabbit	   Dako	   1:3000	  
BA-­‐D5	  (anti-­‐type	  I)	  Alexa	  
Fluor	  350	  
Mouse	  
D	  Wells	  	  
(Gregorevic	  et	  al.,	  2008)	  
1:300	  
SC-­‐71	  (anti-­‐type	  IIB)	  
Alexa	  Fluor	  594	  
Mouse	  
D	  Wells	  
(Gregorevic	  et	  al.,	  2008)	  
1:900	  




(Gregorevic	  et	  al.,	  2008)	  
1:600	  
Anti	  rabbit	  488	   Goat	   Invitrogen	   1:250	  
Anti	  goat	  488	   Chicken	   Invitrogen	   1:1000	  
Anti	  rat	  568	   Goat	   Invitrogen	   1:200	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2.2.7 RNA	  extraction	  
2.2.7.1 RNA	  extraction	  from	  tissue	  
	   For	   tissue,	   muscle	   samples	   up	   to	   a	   weight	   of	   0.2g	   were	   placed	   in	   CK-­‐14	   ceramic	  
beaded	   tubes	   (Stretton	   Scientific,	   UK)	   containing	   500µl	   of	   TRIzol®	   (Invitrogen)	   and	  
homogenised	   with	   the	   Precellys	   24	   (Peqlab,	   Erlangen,	   Germany).	   Human	   tissue	   was	  
homogenised	  with	  2x	  20	  sec	  cycles	  at	  5500rpm,	  and	  mouse	  tissue	  was	  crushed	  with	  2x	  15	  
sec	  cycles	  at	  5500rpm.	  The	  samples	  were	  then	  centrifuged	  at	  8000rpm	  for	  3	  min	  at	  4oC	  to	  
remove	   insoluble	  material.	  The	  resulting	  RNA	  containing	  supernatant	  was	   transferred	   into	  
fresh	   micro-­‐centrifuge	   tubes	   and	   100µl	   of	   chloroform	   was	   added	   before	   vortexing.	   The	  
mixture	  was	   left	   at	   room	   temperature	   for	   2	  min	   to	   allow	   the	   phases	   to	   separate	   before	  
centrifugation	  (10,000rpm,	  15	  min,	  4oC).	  The	  centrifugation	  ensures	  phase	  separation	  of	  the	  
mixture,	   where	   the	   lower	   red	   phenol/	   chloroform	   phase	   is	   distinctly	   separated	   from	   the	  
RNA	   containing	  upper	   colourless	   aqueous	  phase	  by	   the	  pink	  protein	   interphase.	   The	  RNA	  
containing	  upper	  aqueous	  phase	  was	  transferred	  to	  fresh	  micro	  centrifuge	  tubes,	  and	  250µl	  
of	  iso-­‐propanol	  was	  added	  and	  left	  to	  incubate	  on	  ice	  for	  10	  min	  to	  precipitate	  the	  RNA	  from	  
the	  solution.	  The	  samples	  were	  then	  centrifuged	  (10,000	  rpm,	  10	  min,	  4oC)	  to	  pellet	  the	  RNA	  
and	  the	  supernatant	  was	  removed.	  The	  resulting	  opaque	  RNA	  pellet	  was	  washed	  twice	  with	  
75%	   ethanol	   and	   re-­‐suspended	   in	   30µl	   RNase-­‐free	   dH2O	   and	   stored	   at	   -­‐80oC.	   RNA	  
concentration	   was	   quantified	   using	   a	   Nanodrop™	   (absorption	   read	   at	   260nm,	   Nanodrop	  
ND1000,	  Wilmington,	  USA).	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2.2.7.2 RNA	  extraction	  from	  cells	  
	   5x104	  cells	  were	  seeded	  in	  12-­‐well	  plate	  in	  DMEM	  +	  10%	  FBS.	  The	  following	  day,	  cells	  
were	  ‘fed’	  for	  2	  h	  with	  fresh	  serum	  containing	  media	  prior	  to	  treatment	  with	  either	  TGF-­‐β,	  
Myostatin,	  GDF-­‐15,	  ang-­‐II	  or	   rapamycin	   in	  serum-­‐free	  media,	   for	  3	  or	  16	  h.	  After	   this,	   the	  
media	  was	   removed	   and	   cells	   lysed	   by	   the	   addition	   of	   500μl	   TRIzol®	   reagent	   (Invitrogen)	  
with	  vigorous	  scraping.	  The	  cell	  lysate	  was	  transferred	  to	  micro-­‐centrifuges	  tubes	  and	  100μl	  
of	  chloroform	  was	  added	  before	  proceeding	  through	  the	  protocol	  as	  described	  above.	  	  
2.2.7.3 DNAse	  Treatment	  
	   For	  electroporated	  mice	  and	  smoke	  exposed	  mice,	  RNA	  samples	  were	  treated	  with	  
DNase	  I	  (Qiagen,UK)	  to	  remove	  genomic	  DNA.	  2.5μl	  DNase	  I	  stock	  solution	  and	  10μl	  RNAse-­‐
free	  DNA	  Digestion	  Buffer	   (Qiagen)	  was	  added	  to	  87.5μl	  RNA	  solution	   (contaminated	  with	  
genomic	  DNA)	  for	  a	  final	  reaction	  volume	  of	  100μl.	  The	  mixture	  was	  incubated	  at	  37oC	  for	  
30	  min,	  before	  400μl	  of	  TRIzol	  was	  added	  to	  inhibit	  the	  DNase	  reaction.	  The	  RNA	  was	  then	  
re-­‐extracted	  with	  the	  same	  protocol	  described	  in	  section	  2.2.7.1.	  
	  
2.2.8 cDNA	  synthesis	  
	   150ng	  of	  RNA	  in	  11µl	  of	  dH2O	  was	  heated	  for	  10	  min	  at	  65oC	  and	  placed	  on	  ice	  for	  2	  
min.	  A	  reaction	  mixture	  consisting	  of	  4µl	  5x	  Buffer,	  0.5µl	  10mM	  dNTPs,	  0.5µl	  pdN6	  (random	  
hexamers,	   Promega),	   0.5µl	   RNAse	   inhibitor,	   1µl	   (0.1M)	   DTT,	   0.5µl	   Superscript™	   reverse	  
transcriptase	  (Invitrogen)	  and	  2µl	  dH2O	  was	  made	  and	  9µl	  of	  this	  mixture	  was	  added	  to	  the	  
RNA.	  The	  mixture	  was	  incubated	  at	  42oC	  for	  2	  h,	  and	  then	  diluted	  to	  200µl	  with	  dH20.	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2.2.9 PCR	  for	  Primer	  optimisation	  SYBR	  Green	  Taq	  	  
	   The	  primers	  used	  have	  been	  described	  previously	  (Table	  5,	  Table	  6).	  For	  previously	  
published	   primers,	   primers	   were	   validated	   using	   PCR	   to	   ensure	   the	   amplicons	   were	   the	  
correct	  size.	  The	  reaction	  contained	  12.5µl	  2x	  SYBR	  Green	  Taq	  Jump	  Start	  mix,	  2.5µl	  200µM	  
Primer	  mix	  of	  Forward	  and	  Reverse	  primers,	  7µl	  dH2O	  and	  3µl	  DNA	  template.	  An	  ABI	  7500	  
fast	   real-­‐time	  PCR	   system	   cycler	   (Appied	  Biosystems,	  UK)	  was	   used	   to	   perform	  a	   thermal	  
profile	  of	  50oC	  for	  2	  min,	  95oC	  for	  10	  min	  followed	  by	  40	  cycles	  of	  95oC	  for	  15	  s,	  60oC	  for	  1	  
min	  (Ellis	  et	  al.,	  2004).	  The	  resulting	  PCR	  products	  were	  separated	  by	  electrophoresis	  on	  a	  
1.5%	  (w/v)	  agarose	  gel	  containing	  ethidium	  bromide,	  and	  the	  gels	  imaged	  under	  UV	  light	  to	  
check	  the	  sizes	  of	  the	  amplicons	  to	  ensure	  no	  primer	  dimers	  were	  made.	  
	  
2.2.10 	  Quantitative	  real-­‐time	  PCR	  (qPCR)	  
	   qPCR	   was	   performed	   using	   a	   reaction	  mixture	   containing	   10µl	   SYBR®	   Green	   Jump	  
start™	  Taq	  2µl	  Primers	  (200pM,	  reverse	  and	  forward),	  0.2µl	  ROX	  reference	  dye,	  4.8µl	  dH2O,	  
and	  3µl	   cDNA.	  All	   reactions	  were	  performed	   in	   triplicate	  using	   an	  ABI	   7500	   fast	   real-­‐time	  
PCR	  system	  cycler	  (Applied	  Biosystems,	  UK)	  and	  a	  thermal	  profile	  of	  50oC	  for	  2	  min,	  95oC	  for	  
10	  min	  followed	  by	  40	  cycles	  of	  95oC	  for	  15	  s,	  60oC	  for	  1	  min	  (Ellis	  et	  al.,	  2004).	  Each	  PCR	  was	  
performed	  in	  duplicate	  to	  obtain	  an	  averaged	  Ct	  values.	  For	  experiments	  with	  myostatin	  and	  
TGF-­‐β	  SYBR	  Green	  Jump	  Start	  Taq	  was	  used.	  For	  all	  other	  qPCR	  data,	  QuantiFast	  SYBR	  Green	  
Taq	  (Qiagen,	  UK)	  was	  used	  with	  a	  thermal	  profile	  of	  95oC	  for	  5	  min,	  95oC	  for	  10	  s;	  60oC	  30	  s	  
was	   used	   for	   faster	   quantitation.	   qPCR	   data	   were	   analysed	   by	   determining	   the	   cycle	  
threshold	  (Ct).	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Table	  5	  Mouse	  qPCR	  primers	  	  
Table	  of	  mouse	  qPCR	  primers	  used	  and	  source	  of	  sequence	  
Gene	   Forward	  primer	  (5’	  to	  3’)	   Reverse	  primer	  (5’	  to	  3’)	  	   Reference	  
Beclin	   GGCCAATAAGATGGGTCTGA	   CACTGCCTCCAGTGTCTTCA	  
(Zhao	  et	  al.,	  2007)	  
Atg4b	   ATTGCTGTGGGGTTTTTCTG	   AACCCCAGGATTTTCAGAGG	  
Atg12l	   GGCCTCGGAACAGTTGTTTA	   CAGCACCGAAATGTCTCTGA	  
Ulk2	   CAGCCCTGGATGAGATGTTT	   GGATGGGTGACAGAACCAAG	  
Gabarapl1	   CATCGTGGAGAAGGCTCCTA	   ATACAGCTGGCCCATGGTAG	  
Lc3b	   CGTCCTGGACAAGACCAAGT	   ATTGCTGTCCCGAATGTCTC	  
Murf1	   CGGGCAACGACCGAGTGCAGACGATC	   CCAGGATGGCGTAGAGGGTGTCAAAC	   P	  Kemp	  
Atrogin1	   TCAGCCTCTGCATGATGTTC	   TGGGTGTATCGGATGGAGAC	   (Raffaello	  et	  al.,	  2010)	  
Rplpo	   GGACCCGAGAAGACCTCCTT	   TGCTGCCGTTGTCAAACACC	   P	  Kemp	  
Gapdh	   ACTCCACTCACGGCAAATTCA	   CGCTCCTGGAAGATGGTGAT	   (Chin	  et	  al.,	  2010)	  
Myostatin	   CGGACGGTACATGCACTAATATTTC	   GAGGGGAAGACCTTCCATGAC	   P	  Kemp	  
Tgfb1	   TGGAGCAACATGTGGAACTC	   GTCAGCAGCCGGTTACCA	  
(Yang	  and	  Kaartinen,	  
2007)	  
Pai-­‐1	   GACACCCTCAGCATGTTCATC	   AGGGTTGCACTAAACATGTCAG	   (Dong	  et	  al.,	  2005)	  
Vegf-­‐c	   GGGAAGAAGTTCCACCATCA	   ATGTGGCCTTTTCCAATACG	   (Zhang	  et	  al.,	  2007)	  	  
Smad7	   TCGGACAGCTCAATTCGGAC	   GGTAACTGCTGCGGTTGTAA	   (Fukasawa	  et	  al.,	  2004)	  
Cyr61	   GGATGAATGGTGCCTTGC	   GTCCACATCAGCCCCTTG	   P	  Kemp	  
Bad	   GGCTTGAGGAAGTCCGATCC	   TCCATGATGACTGTTGGTGGC	  
(Volle	  et	  al.,	  2007)	  	  
Bax	   TGGAGCTGCAGAGGATGATTG	   CACGGAGGAAGTCCAGTGTC	  
Myh	  Myhc-­‐a	   TGTGATAGCCTTCTTGGCCT	   AGCAGGAGCTGATTGAGACC	   (Rossi	  et	  al.,	  2010)	  	  
Myhc-­‐IIa	   CAGCTTGTTGACCTGGGACT	   TTGGTGGATAAACTCCAGGC	   P	  Kemp	  
Myhc-­‐IIb	   GTTTGTCCACCAAGTCCTGC	   TAGGGTGAGGGAGCTTGAAA	   (Raffaello	  et	  al.,	  2010)	  	  	  
	  Myhc-­‐IIx	   AGCTTGTTGACCTGGGACTC	   ACCTTGTGGACAAACTGCAA	   P	  Kemp	  
	  Myod1	   GTGGAGATGCGCTCCACTAT	   CTCTGATGGCATGATGGATT	   P	  Kemp	  
Myogenin	  	  	   ACCCAGCCTGACAGACAATC	   CCAACCCAGGAGATCATTTG	   (Frangini	  et	  al.,	  2013)	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Table	  6	  Human	  qPCR	  primers	  	  
Table	  of	  human	  qPCR	  primers	  used	  and	  source	  of	  sequence	  
Gene	   Forward	  primer	  (5’	  to	  3’)	   Reverse	  primer	  (5’	  to	  3’)	  	   P	  Kemp	  
RPLPO	   TCTACAACCCTGAAGTGC	  TTGATATC	   GCAGACAGACACTGGCAACATT	   P	  Kemp	  
MYOSTATIN	   ACATGAACCCAGGCACTGGT	   GGTTGTTTGAGCCAATTTTGC	   (Man	  et	  al.,	  2010)	  	  
PAI-­‐1	   CTCTCTCTGCCCTCACCAAC	   GTGGAGAGGCTCTTGGTCTG	  
(Zhao	  et	  al.,	  
2006a)	  	  
BECLIN1	   CAAGATCCTGGACCGTGTCA	   TGGCACTTTCTGTGGACATCA	  
(Young	  et	  al.,	  
2009)	  	  
ATG4B	   GCCGAGATTGGAGGTG	   GCCTATGGACTTGCCTTC	  
ATG12	   CCCCGTCTTCCGCTGCAGTT	   TCGTGTTCGCTCTACTGCCCACT	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2.2.11 	  Gene	  Over-­‐Expression	  In	  Vivo	  
2.2.11.1 Electroporation	  
	  (All	   in	  vivo	  work	  conducted	  by	  Professor	  Dominic	  Wells	  under	  the	  project	  licence	  70/6700	  
at	  the	  Royal	  Veterinary	  College,	  London)	  
	   Twelve	   female	   CD1	   mice,	   which	   were	   approximately	   7-­‐8	   weeks	   old	   were	   used.	  
Approximately	   1.5	   h	   prior	   to	   electroporation,	   both	   legs	   were	   shaved	   with	   a	   hair	   clipper	  
under	   general	   anaesthesia	   consisting	   of	   an	   intraperitoneal	   dose	   fentanyl/ﬂuanisone	   and	  
midazolam	   mixture	   (4ml/kg,	   respectively,	   Hypnorm,	   Janssen	   Animal	   Health,	   UK	   and	  
Hypnovel,	   Roche,	   UK)	   before	   the	   tibialis	   anterior	   (TA)	   was	   pre-­‐treated	   with	   25μl	   bovine	  
hyaluronidase	  at	  a	  concentration	  of	  0.04U/μl	  (H-­‐4272)	  (McMahon	  et	  al.,	  2001).	  Mice	  were	  
left	   to	   recover	   for	   2	   h	   at	   37oC	   before	   proceeding	   with	   the	   plasmid	   injection	   and	  
electroporation.	  Mice	  were	  injected	  with	  25µg	  of	  plasmid	  (at	  a	  concentration	  of	  1μg/μl)	  into	  
the	  TA	  were	  anaesthetised	  with	  5%	   isofluorane,	   (maintained	  under	  anaesthesia	  with	  2%).	  
	  Then	  the	  electrodes,	  coated	  in	  electro-­‐conductive	  cream,	  were	  placed	  firmly	  around	  the	  TA,	  
and	  a	  voltage	  of	  175	  V/cm	  was	  applied	  in	  ten	  20	  ms	  square-­‐wave	  pulses	  at	  a	  frequency	  of	  
1Hz	  using	  a	  BTX	  ECM	  830	  electroporator	  (BTX	  Harvard	  Apparatus,	  USA)	  (Gollins	  et	  al.,	  2003).	  
After	  electroporation,	   the	  mice	  were	   left	   to	   recover	   at	  37oC.	   For	   all	   injections	  a	  29-­‐gauge	  
syringe	  needle	  was	  used.	  Four	  mice	  were	  in	  each	  group	  and	  each	  group	  was	  electroporated	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Table	  7	  Table	  of	  Plasmids	  and	  Volumes	  electroporated	  into	  each	  group	  
Group	   Left	  TA	   Right	  TA	  
Group	  1	   25µl	  Myostatin	   25µl	  Empty	  vector	  (pCAGGS)	  
Group	  2	   25µl	  FHL1	   25µl	  Empty	  vector	  (pCAGGS)	  
Group	  3	   25µl	  Myostatin	   25µl	  FHL1	  /	  25µl	  Myostatin	  (50µl	  total	  volume)	  
	   	  
Following	  electroporation,	  the	  mice	  recovered	  fully	  and	  showed	  no	  signs	  of	  altered	  
behaviour	  afterwards.	  Mice	  were	  fed	  with	  normal	  chow	  and	  given	  water	  ad	  libitum.	  After	  2	  
weeks,	   the	   mice	   were	   sacrificed	   by	   cervical	   dislocation.	   TA	   muscles	   were	   harvested	   and	  
placed	  upright	  on	  to	  small	  pieces	  of	  cork	  with	  a	  small	  amount	  of	  OCT	  at	  the	  bottom	  to	  fix	  
the	   bottom	   of	   the	   TAs	   onto	   cork	   and	   snap	   frozen	   in	   liquid	   nitrogen	   cooled	   iso-­‐pentane.	  
Gastrocnemius	  muscles	  were	  also	  excised	  and	  weighed.	  
2.2.11.2 Sectioning	  
	   TA	  muscles	  were	  sectioned	  vertically	  from	  the	  top	  towards	  the	  cork	  at	  the	  bottom.	  
The	   cryostat	  was	  maintained	  at	  20oC,	  with	  a	   knife	   angle	  of	  5o	   and	  was	  used	   to	   cut	  10µm	  
thick	   sections	   and	   sections	   were	   grouped	   into	   12	   evenly	   spaced	   levels	   (Gollins	   et	   al.,	  
2003)(Figure	   2).	   A	   representative	   section	   from	   each	   of	   the	   12	   levels	   was	   captured	   onto	  
frost-­‐free	  glass	  slides,	  and	  this	  was	  repeated	  for	  12	  slides.	  The	  subsequent	  30	  sections	  from	  
each	   level	  were	  then	  collected	   into	  micro-­‐centrifuge	  tubes	  and	  stored	  at	   -­‐80oC	  for	  protein	  
and	  mRNA	  analysis.	  The	  slides	  were	  allowed	  to	  air	  dry	   for	  30	  min	  before	  storage	  at	   -­‐80oC	  
until	   use.	   This	   method	   of	   sectioning	   without	   embedding	   in	   OCT	   allowed	   the	   use	   of	   the	  
samples	   for	   both	   RNA	   and	   protein	   analysis;	   additionally,	   a	   representative	   section	   of	   each	  
‘level’	  could	  be	  captured	  for	  histological,	  protein	  and	  mRNA	  analysis.	  Sectioning	  using	  this	  
method	  is	  particularly	  important	  as	  the	  TA	  has	  been	  electroporated,	  thus	  some	  parts	  of	  the	  
TA	  may	   be	  more	   highly	   transfected	   than	   others.	   By	   sectioning	   the	   samples	   this	  way,	   the	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‘level’	  of	   the	  TA	  where	  gene	  expression	   is	  highest	   can	  be	   found,	  and	   thus	  analysis	   can	  be	  
targeted	  to	  this	  ‘level’.	  
Figure	  2	  Schematic	  of	  TA	  sectioning	  	  
The	  entire	  TA	  was	  sectioned	  into	  12	  levels,	  with	  each	  level	  collected	  on	  slides	  for	  histological	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2.2.12 	  GSK	  Smoke	  Exposure	  Model	  
Mice	  were	   exposed	   to	   smoke	   as	   described	   in	   (Harrison	   et	   al.,	   2008)	   by	  GSK,	  USA.	  
Four	  month	   old	   female	   C57BL/6	  mice	   (Jackson	   Laboratory,	   USA)	   were	   exposed	   to	   whole	  
cigarette	  smoke	  from	  3R4F	  cigarettes	  (College	  of	  Agriculture,	  Reference	  Cigarette	  Program,	  
University	   of	   Kentucky,	   USA),	   for	   2	  h/day,	   5	  days/week,	   for	   19	   months	   via	   a	   nose	   only	  
method.	   It	   is	   thought	   that	   the	  nose	  only	  method	  more	  closely	   resembles	  human	  smoking	  
than	  the	  whole	  body	  method	  where	  the	  mice	  are	  placed	  in	  smoking	  chambers	  with	  smoke	  
pumped	  into	  the	  chambers	  (Wright	  et	  al.,	  2008,	  Stevenson	  and	  Birrell,	  2011).	  The	  smoking	  
device	   consisted	  of	  a	  Baumgartner-­‐Jager	  CSM	  2070i	  machine	   (CH	  Technologies	   Inc.,	  USA),	  
which	  uses	  a	  circular	  head	  to	  hold	  30	  cigarettes	  to	  revolve	  at	  one	  revolution	  per	  minute,	  this	  
machine	  is	  used	  to	  mimic	  human	  smoking.	  From	  each	  cigarette,	  a	  2	  s,	  35ml	  puff	  of	  smoke	  
was	  taken	  per	  minute,	  resulting	  in	  1l	  of	  smoke.	  The	  1l	  of	  smoke	  air	  was	  then	  mixed	  with	  24l	  
of	  normal	  air	  to	  give	  a	  4%	  concentration	  of	  smoke.	  	  
The	   smoke	   exposure	   apparatus	   consisted	   of	   a	   tower	   to	   which	   mice	   housed	   in	  
separate	  compartments	  were	  attached	   (Figure	  3).	  The	  mice	  were	  placed	   in	  compartments	  
under	  restraint	  to	  restrict	  movement	  and	  to	  ensure	  the	  mice	  breathe	  nasally	  through	  holes	  
in	  the	  compartments.	  Small	  holes	  were	  positioned	  in	  the	  tower	  corresponding	  to	  where	  the	  
compartments	  contacted	  the	  smoking	  tower.	  The	  compartments	  were	  positioned	  on	  to	  the	  
tower	  corresponding	   to	  holes	   in	   the	   tower,	   so	   they	  mice	  place	   their	  noses	   into	   the	   tower	  
and	  breathe	   in	   the	  pumped	   in	   smoke	  air.	   There	  were	   three	  groups,	   consisting	  of	  20	  mice	  
exposed	  to	  cigarette	  smoke,	  18	  mice	  exposed	  to	  normal	  air	  in	  the	  smoking	  apparatus	  and	  8	  
mice	  left	  in	  normal	  cages	  were	  used	  as	  a	  control	  for	  the	  smoke	  exposure	  model.	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After	  19	  months	  of	  exposure,	  mice	  were	  culled,	  and	  the	  gastrocnemii	  were	  excised.	  
One	   gastrocnemius	   from	   each	   mouse	   was	   frozen	   in	   OCT	   using	   liquid	   nitrogen	   cooled	  
isopentane,	   whilst	   the	   other	   gastrocnemius	   was	   frozen	   in	   RLT	   buffer	   (Qiagen,	   UK)	   until	  
analysis.	  For	  RNA	  extraction,	  gastrocnemius	  samples	  were	  defrosted	  and	  removed	  from	  the	  
RLT	  buffer,	  before	  extraction	  in	  TRIzol	  using	  the	  Precellys	  homogeniser	  as	  described	  above.	  
The	  gastrocnemii	   frozen	   in	  OCT,	  were	  cut	   into	  10μm	  thick	   sections	  and	  haematoxylin	  and	  
eosin	  stained	  by	  Miss	  Lorraine	  Lawrence.	  	  
	  
Figure	  3	  Diagram	  of	  cigarette	  smoke	  exposure	  apparatus	  used	  by	  GSK,	  USA.	  
Diagram	  of	  how	  the	  mice	  were	  exposed	  to	  cigarette	  smoke	  at	  GSK.	  Mice	  were	  placed	  under	  
restraint	   in	   cages	   attached	   to	   a	   tower.	   Small	   openings	   for	   the	   mouse	   nose	   in	   the	   cages	  
corresponded	  to	  openings	  in	  the	  tower,	  so	  the	  mice	  could	  only	  breathe	  nasally.	  A	  4%	  smoke	  










	   74	  
2.2.13 	  ACE	  Inhibition	  (Fosinopril	  Trial)	  
	   A	  double-­‐blind,	   randomised,	  placebo-­‐controlled,	  parallel-­‐group	   trial	  was	  conducted	  
by	  Dr	  Dinesh	  Shrikrishna.	  COPD	  patients	  were	  selected	  based	  on	  diagnosis	  using	  the	  Global	  
Initiative	  for	  Obstructive	  Lung	  Disease	  (GOLD)	  criteria	  and	  quadriceps	  weakness	  as	  defined	  
as	  a	  quadriceps	  maximum	  voluntary	  contraction	  (QMVC)	  in	  kilograms	  less	  than	  120%	  of	  the	  
patient’s	  body	  mass	  index	  (Swallow	  et	  al.,	  2007b).	  Patients	  were	  randomised	  into	  either	  the	  
ACE	  inhibitor	  (fosinopril	  10-­‐20mg)	  group	  or	  the	  placebo	  group	  (lactose)	  by	  the	  Clinical	  Trials	  
Department	   at	   the	   Royal	   Free	   Hampstead	   NHS	   Trust,	   UK.	   Biopsies	   were	   taken	   from	   the	  
vastus	  lateralis	  using	  a	  Bergstrom	  needle	  biopsy	  technique	  (Bergstrom,	  1975)	  as	  described	  
in	  (Shrikrishna	  et	  al.,	  2012)	  and	  the	  resulting	  sample	  was	  snap	  frozen	  in	  liquid	  nitrogen	  and	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2.2.14 	  	  Data	  Analysis	  
2.2.14.1 	  Autophagosome	  quantitation	  
	   The	   number	   of	   autophagosomes	   was	   counted	   using	   an	   automated	   algorithm	  
developed	   in	  Definiens®	   (Definiens,	  Germany)	   software	  with	   the	  assistance	  of	   the	   Imaging	  
Facility	  at	   Imperial	  College	  London,	  where	  all	  GFP	  punctae	  above	  the	  background	  intensity	  
were	  designated	  as	  autophagosomes	  (Figure	  4).	  The	  cell	  areas	  were	  defined	  manually	  and	  a	  
rolling	   GFP	   threshold	   (i.e.	   a	   threshold	   that	   increases	   with	   intensity)	   was	   subtracted	   to	  
account	  for	  the	  changes	  in	  background	  GFP	  intensity	  within	  a	  cell.	  For	  each	  treatment	  and	  
each	   time	   point,	   30-­‐40	   images	   were	   taken	   and	   number	   of	   GFP	   autophagosomes	   was	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Figure	   4	  Schematic	   of	   automated	   autophagy	   quantitation	  of	   LC3-­‐GFP	   transfected	   C2C12	  
cells	  
Images	   of	   cells	   were	   processed	   according	   to	   the	   schematic	   below	   to	   identify	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2.2.14.2 	  Fibre	  Analysis	   	  
Mouse	   muscle	   sections	   were	   stained	   with	   haematoxylin	   and	   eosin	   (H	   and	   E)	   by	  
Lorraine	  Lawrence	  as	  part	  of	  the	  histology	  service	  at	  Imperial	  College.	  The	  stained	  sections	  
imaged	   at	   20X	   magnification;	   fibre	   diameter	   measurements	   were	   performed	   in	   Image	   J,	  
where	  the	  shortest	  distance	  between	  2	  parallel	  lines	  of	  the	  fibre	  was	  measured.	  Three	  fields	  
of	  view	  from	  three	  ‘levels’	  of	  the	  TA	  per	  mouse	  were	  analysed,	  approximately	  80-­‐90	  fibres	  
measured	  per	  mouse.	  For	   fibre	   typing,	   images	  stained	  and	   imaged	  as	  described	   in	  section	  
2.2.2,	   three	   fields	   of	   view	   were	   taken	   from	   the	   two	   levels	   (selected	   based	   on	   gene	  
expression)	   and	   the	   number	   of	   fibres	   of	   each	   fibre	   type	  was	   counted	  manually	   using	   the	  
counting	  tool	  in	  Image	  J	  (Figure	  5).	  
	  
2.2.14.3 Statistical	  Analysis	  
Data	   are	   represented	   as	   mean	   ±	   SEM	   or	   median	   with	   inter-­‐quartile	   range	   (IQR).	  
Statistical	   analysis	   of	   qPCR	   data	   was	   performed	   using	   either	   Student’s	   T-­‐Test	   (normally	  
distributed	   data)	   or	   was	   by	   Mann-­‐Whitney	   U	   test	   (non-­‐normally	   disturbed	   data)	   where	  
appropriate	   using	   Graphpad®	   software	   (Prism,	   USA)	   where	   p<0.05	   was	   considered	  
statistically	  significant.	  For	  in	  vivo	  data	  where	  TAs	  from	  the	  same	  mouse	  were	  analysed	  and	  
for	   ACE	   trial	   where	   baseline	   measurements	   were	   compared	   to	   day	   90	   measurements,	  
paired	  t-­‐tests	  were	  performed.	  For	  comparisons	  between	  three	  groups,	  an	  ANOVA	  analysis	  
was	   used	   and	   to	   compare	   two	   independent	   variables,	   a	   two-­‐way	  ANOVA	  was	   used.	  Data	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Figure	  5	  Example	  of	  fibre	  type	  staining	  of	  electroporated	  TA	  cross-­‐section	  
Stitched	  image	  of	  whole	  TA	  cross-­‐section	  stained	  as	  described	  in	  section	  2.2.2.1,	  captured	  at	  
x10	  magnification	   (A).	   Single	   channel	   views	   of	   magnified	   image	   (B).	   The	   Green	   -­‐Type	   IIB	  
fibres,	  red=	  type	  IIA	  /	  laminin,	  none	  stained=	  type	  IIX,	  and	  blue	  =	  type	  I	  /	  nuclei.	  The	  dots	  on	  
the	  image	  are	  non-­‐specific	  staining.	  Large	  image	  scale	  bar	  represents	  500µm	  and	  magnified	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3.1 Introduction	  
Autophagy	   is	   a	   constitutively	   active	   cellular	   process,	   which	   degrades	   mis-­‐folded	  
proteins	   and	   abnormal	   organelles	   such	   as	   mitochondria	   in	   bulk.	   Autophagy	   is	   a	   house-­‐
keeping	   process,	   thought	   to	   be	   required	   for	   muscle	   homeostasis	   as	   these	   abnormal	  
organelles	   and	   protein	   aggregates	  may	   lead	   to	   cell	   dysfunction	   and	   even	   toxicity.	   During	  
autophagy,	   organelles	   and	   proteins	   are	   broken	   down	   into	   their	   constituent	   amino	   acid	  
components,	  which	  can	  then	  be	  recycled	  for	  use	  elsewhere	  in	  the	  cell,	  or	  to	  remove	  excess	  
proteins.	   There	   is	   evidence	   that	   autophagy	   and	   apoptosis	   are	   intrinsically	   linked	  with	   the	  
anti-­‐autophagy	   effect	   of	   the	   anti-­‐apoptotic	   Bcl-­‐2	   on	   Beclin	   (Pattingre	   et	   al.,	   2005).	   This	  
suggests	  a	  potential	  mechanism	  to	  regulate	  autophagy	  when	  cell	  survival	  signals	  are	  given	  
and	  prevent	  excessive	  autophagy.	  However,	   the	  extent	  to	  which	  autophagy	  and	  apoptosis	  
are	  linked	  is	  still	  unclear.	  
The	   dis-­‐regulation	   of	   autophagy	   is	   thought	   to	   have	   a	   significant	   role	   in	   several	  
diseases	   including	   cancer	   and	   Parkinson’s	   disease	   (Kundu	   and	   Thompson,	   2008).	  
Furthermore,	   autophagy	   is	   also	   thought	   to	  be	   important	   in	   a	  number	  of	  muscle	  diseases,	  
such	   as	   Pompe	   disease,	   where	   autophagosomes	   accumulate	   due	   to	   impaired	   lysosomal	  
degradation,	   and	   Danon’s	   disease	   in	   which	   lysosomes	   cannot	   form	   again	   leading	   to	  
autophagosome	  accumulation	  (Nishino,	  2003,	  Kundu	  and	  Thompson,	  2008).	  Recently	  there	  
has	   been	   a	   surge	   of	   interest	   in	   the	   role	   of	   autophagy	   in	   muscle	   wasting	   (Sandri,	   2010,	  
Mammucari	  et	  al.,	  2007a,	  Masiero	  et	  al.,	  2009)	  as	  lysosomal	  protein	  degradation	  may	  also	  
increase	   protein	   breakdown	   (Furuno	   et	   al.,	   1990).	   Recent	   studies	   have	   shown	   that	   the	  
autophagy-­‐lysosomal	   and	   ubiquitin-­‐proteasomal	   pathway	   may	   work	   in	   conjunction	   with	  
each	   other	   to	   contribute	   to	   muscle	   wasting.	   Although	   excessive	   autophagy	   can	   lead	   to	  
atrophy,	  the	  blockade	  of	  autophagy	  also	  has	  deleterious	  effects.	  Masiero	  et	  al.	  showed	  that	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knocking	  out	  a	  vital	  autophagy	  gene	  Atg7	  also	  caused	  muscle	  atrophy	  with	  an	  accumulation	  
of	  abnormal	  organelles	  such	  as	  mitochondria	  (Masiero	  et	  al.,	  2009).	  Similarly,	  Atg5	  knockout	  
mice	  showed	  muscle	  atrophy	  in	  mice	  (Raben	  et	  al.,	  2008).	  Thus	  the	  level	  of	  autophagy	  must	  
be	  maintained	  at	  a	  basal	  rate	  for	  muscle	  homeostasis.	  	  
TGF-­‐β	   has	   been	   shown	   to	   induce	   autophagy	   in	   bovine	   mammary	   epithelial	   and	  
murine	   glomerular	   mesangial	   cells	   as	   well	   as	   human	   hepatocellular	   carcinoma	   cells	  
(Gajewska	  et	  al.,	  2005,	  Ding	  et	  al.,	  2010,	  Kiyono	  et	  al.,	  2009).	  TGF-­‐β	  is	  a	  cytokine	  well-­‐known	  
for	  its	  role	  in	  inflammation	  (Wahl	  et	  al.,	  1989,	  Yoshimura	  et	  al.,	  2010).	  TGF-­‐β	  has	  also	  been	  
shown	   to	   be	   involved	   in	  muscle	   repair,	   fibrosis	   and	  myopathy	   (Li	   et	   al.,	   2004,	   Burks	   and	  
Cohn,	  2011).	   	  TGF-­‐β	  was	   first	   shown	  to	   increase	  autophagy	   in	  bovine	  mammary	  epithelial	  
cells	   (Gajewska	  et	   al.,	   2005).	  Gajewska	  et	  al.	   observed	  an	   increase	   in	  MAP1	  LC3,	   the	  only	  
known	   protein	   to	   be	   specific	   to	   and	   present	   throughout	   autophagy.	   As	   autophagy	   is	   a	  
dynamic	   process,	   it	   is	   problematic	   for	   researchers	   to	   measure;	   with	   LC3B	   the	   best	  
characterised	   protein.	   LC3	   is	   expressed	   as	   a	   pro-­‐peptide	   called	   pro-­‐LC3,	   which	   is	   then	  
proteolytically	  cleaved	  at	  its	  carboxyl	  terminal	  glycine	  residue	  by	  another	  autophagy	  protein	  
ATG4B,	   consequently	   forming	   LC3-­‐I	   (Mizushima,	   2007).	   Upon	   autophagy	   induction,	   a	  
phosphatidylethanolamine	   group	   is	   attached	   to	   LC3-­‐I,	   forming	   LC3-­‐II,	   which	   is	   then	  
integrated	   into	   the	   membrane.	   Due	   to	   the	   dynamic	   nature	   of	   the	   autophagy	   pathway,	  
measuring	  autophagy	  often	  requires	  the	  use	  of	  several	  different	  assays,	  of	  which	  one	  of	  the	  
most	  widely	  used	  methods,	  is	  measurement	  of	  LC3-­‐II	  turnover	  over	  time	  (Barth	  et	  al.,	  2010,	  
Mizushima	  et	  al.,	  2010).	  	  	  
The	  mechanisms	  behind	  muscle	  wasting	  are	  still	  unclear,	  but	  one	  potential	  candidate	  
of	   much	   interest	   is	   myostatin	   (also	   known	   as	   growth	   differentiation	   factor	   8,	   GDF-­‐8).	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Myostatin	  is	  also	  a	  member	  of	  the	  TGF-­‐β	  superfamily	  and	  a	  well-­‐known	  inhibitor	  of	  muscle	  
mass	  (McPherron	  et	  al.,	  1997).	  Myostatin	  has	  been	  shown	  to	  induce	  wasting	  in	  cell	  culture	  
and	  in	  mice	  by	  activating	  members	  of	  the	  UPS	  (McFarlane	  et	  al.,	  2006).	  
Growth	   differentiation	   factor	   15	   (GDF-­‐15)	   is	   another	   member	   of	   the	   TGF-­‐β	  
superfamily	  that	  has	  recently	  been	  shown	  to	  be	  associated	  with	  muscle	  mass	  regulation.	  In	  
an	   in	  vivo	  model	  of	  cardiac	  hypertrophy,	  mice	  were	  resistant	  to	  cardiac	  hypertrophy	  when	  
GDF-­‐15	   was	   over-­‐expressed	   transgenically	   (Xu	   et	   al.,	   2006).	   GDF-­‐15	   expression	   is	   up-­‐
regulated	   in	   stress	   and	   injury,	   due	   to	   oxidative	   stress,	   inflammation	   and	   tissue	   damage	  
(Mimeault	  and	  Batra,	  2010).	  GDF-­‐15	   is	   increasingly	  associated	  as	  an	   indicator	   for	  all	  cause	  
mortality,	   as	   it	   is	   associated	   with	   cardiovascular	   disease,	   cancer,	   and	   more	   importantly	  
cancer	   cachexia	   (Wiklund	   et	   al.,	   2010,	  Nickel	   et	   al.,	   2011,	   Johnen	   et	   al.,	   2007,	   Tsai	   et	   al.,	  
2012,	   Kempf	   et	   al.,	   2007).	   In	   addition,	   GDF-­‐15	   serum	   levels	   are	   highest	   in	   Chronic	   Heart	  
Failure	   (CHF)	   patients	   with	   the	   lowest	   BMI	   (Kempf	   et	   al.,	   2007).	   Indeed,	   data	   within	   the	  
group	  has	  also	  shown	  that	  patients	  admitted	  to	   intensive	  care	   following	  high	  risk	   thoracic	  
surgery	   with	   muscle	   wasting,	   also	   had	   increased	   GDF-­‐15	   levels	   (Bloch	   et	   al.,	   2013).	  
Interestingly,	   plasma	   myostatin	   levels	   decreased	   initially	   following	   surgery,	   but	   then	  
returned	  to	  baseline	  levels	  after	  7	  days.	  Thus,	  there	  is	  strong	  evidence	  GDF-­‐15	  has	  a	  role	  in	  
muscle	  wasting,	  potentially	  by	  activating	  autophagy.	  
Ang-­‐II	   is	   a	   vaso-­‐active	   peptide,	   which	   is	   part	   of	   the	   angiotensin-­‐renin	   system.	  
Although	  ang-­‐II	  is	  known	  to	  be	  involved	  in	  diabetes	  and	  cardiovascular	  disease	  (Dzau,	  1988,	  
Schernthaner	  et	  al.,	  1984),	  ang-­‐II	  also	  induces	  wasting	  in	  skeletal	  muscle	  in	  vivo	  (Brink	  et	  al.,	  
1996).	   Further	   to	   this,	   ang-­‐II	   also	   induces	  proteasome-­‐meditated	  protein	  degradation	  and	  
inhibits	  protein	  synthesis	  that	  is	  stimulated	  by	  TGF-­‐β	  signalling	  (Sanders	  et	  al.,	  2005,	  Russell	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et	   al.,	   2006).	   Ang-­‐II	   has	   been	   shown	   induce	   oxidative	   stress	   potently	   in	   smooth	   muscle,	  
endothelial	  cells	  and	  muscle	  (Griendling	  et	  al.,	  1994,	  Zhang	  et	  al.,	  1999a,	  Zhao	  et	  al.,	  2006b).	  
Ang-­‐II	   has	  been	   shown	   to	   induce	  autophagy	   in	  murine	  podocytes	   and	   cardiomyocytes	   via	  
oxidative	   stress	   (Yadav	   et	   al.,	   2010,	   Porrello	   et	   al.,	   2009,	   Dai	   and	   Rabinovitch,	   2011).	  
Oxidative	  stress	  has	  been	  shown	  to	   induce	  autophagy	   leading	  to	  the	  possibility	  that	  ang-­‐II	  
may	  activate	  autophagy	  in	  skeletal	  muscle	  (Dobrowolny	  et	  al.,	  2008).	  	  
	   The	   aim	   of	   this	   chapter	   was	   to	   firstly	   ascertain	   whether	   autophagy	   could	   be	  
measured	  in	  C2C12	  myoblasts	  and	  hence	  replicate	  the	  TGF-­‐β	  induced	  autophagic	  response	  
observed	  by	  other	  groups.	  Secondly,	   to	  determine	   the	  extent	   to	  which	  myostatin,	  GDF-­‐15	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3.2 Results	  
3.2.1 Induction	  of	  autophagy	  in	  C2C12	  murine	  skeletal	  muscle	  cells	  	  
Firstly,	   to	   prove	   that	   autophagy	   can	   be	   stimulated	   and	   detected	   in	   the	   C2C12	  
myoblast	   cell	   line,	   cells	  were	   treated	  with	   rapamycin,	   a	   known	   inducer	  of	   autophagy	  as	  a	  
positive	   control	   (Noda	   and	   Ohsumi,	   1998).	   In	   this	   instance,	   two	   methods	   of	   assaying	  
autophagy	  were	  used,	  measuring	  LC3-­‐II	  protein	  levels	  as	  discussed	  above	  and	  examining	  the	  
expression	  of	  a	  panel	  of	  autophagy	  related	  genes.	  	  
3.2.1.1 	  Rapamycin	  increases	  LC3-­‐II	  protein	  levels	  in	  C2C12	  cells	  
C2C12	  cells	  were	  treated	  with	  rapamycin	  and	  levels	  of	  LC3-­‐II	  protein	  were	  measured	  
by	   western	   blot.	   Rapamycin	   caused	   a	   sustained	   increase	   in	   LC3-­‐II	   protein	   from	   0.5-­‐3	   h	  
compared	   to	   vehicle	   control	   (Figure	   6).	   The	   DMSO	   vehicle	   control	   also	   showed	   a	   smaller	  
increase	  in	  LC3-­‐II	  levels.	  	  The	  blot	  was	  not	  quantified,	  as	  this	  is	  a	  single	  experiment.	  
C2C12	  cells	  were	  also	  subjected	  to	  amino	  acid	  starvation	  which	  is	  known	  to	   induce	  
autophagy	   by	   replacing	   the	   amino	   acid	   deficient	   media-­‐	   Earle’s	   Balanced	   Salt	   solution	  
(EBSS),	  before	  measuring	  gene	  expression	  by	  qPCR	  (Martinet	  et	  al.,	  2005).	  	  Consistent	  with	  
the	  effects	  of	  starvation	  on	  autophagy	  gene	  expression	  in	  vivo,	  amino	  acid	  starvation	  (EBSS)	  
caused	  a	  significant	  increase	  in	  expression	  of	  all	  autophagy	  markers	  after	  3	  h	  of	  treatment	  
(Figure	  6,	   fold	   increases:	  Lc3b:	  untreated	  1.00	  ±	  0.08,	   starved	  6.32	  ±	  2.12p=0.011,	  Atg4b:,	  
untreated	  1.00	  ±	  0.10,	   starved	  8.67	  ±	  2.35p<0.001,	  Atg12:	   untreated	  1.00	  ±	  0.09,	   starved	  
16.35	  ±	  6.10,	  p=0.0012,	  Unc	  51	  like	  protein	  (Ulk-­‐2):	  untreated	  1.00	  ±	  0.08,	  starved	  12.18	  ±	  
3.96,	  p<0.001,	  Beclin:	  untreated	  1.00	  ±	  0.13,	  starved	  48.30	  ±	  23.24,	  p<0.001,	  and	  Gamma-­‐
aminobutyric	   acid	   type	  A	   receptor-­‐associated	  protein	   (Gabarapl1):	  untreated	   1.00	   ±	   0.11,	  
starved	  20.40	  ±	  9.69,	  p<0.001).	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Figure	  6	  Autophagy	  induction	  in	  C2C12	  cells	  
C2C12	  cells	  were	  treated	  with	  1μM	  rapamycin	  over	  a	  time	  course	  from	  0,	  0.5,	  1.5,	  3,	  16	  h	  
and	  levels	  of	  LC3-­‐II	  were	  measured	  and	  compared	  to	  DMSO	  control.	  There	  was	  an	  increase	  
in	  LC3-­‐II	   levels	  with	  rapamycin	  at	  0.5,	  1.5	  and	  3	  h	  before	  returning	  back	  to	  basal	   levels	  by	  
16h.	   C2C12	   cells	   were	   serum	   starved	   using	   EBSS	   medium	   for	   3h	   and	   serum	   starvation	  
caused	  an	  increase	  in	  all	  autophagy	  related	  genes.	  Blot	  shown	  in	  (A)	  is	  representative	  of	  one	  
experiment.	   Data	   are	   shown	   in	   (B)	   represented	   as	   mean	  ±	  SEM	   from	   three	   independent	  
experiments	   normalised	   to	   GAPDH,	   and	   then	   untreated	   control.	   Significance	   tested	   by	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3.2.2 TGF-­‐β	  increases	  autophagy	  
TGF-­‐β	   has	   previously	   been	   shown	   to	   induce	   autophagy	   in	   a	   number	   of	   cell	   lines	  
(Gajewska	   et	   al.,	   2005,	   Ding	   et	   al.,	   2010).	   In	   order	   to	   confirm	   that	   TGF-­‐β	   also	   induced	  
autophagy	  in	  C2C12	  myoblasts,	  cells	  were	  treated	  with	  TGF-­‐β	  followed	  by	  measurement	  of	  
LC3-­‐II	   protein	   levels,	   autophagy	   related	   gene	   expression	   and	   LC3-­‐GFP	   positive	  
autophagosome	  numbers	  (Figure	  7).	  
3.2.2.1 TGF-­‐β	  increase	  LC3-­‐II	  expression	  
	  Treatment	  of	  C2C12	  cells	  with	  TGF-­‐β	   (Figure	  7)	  caused	  an	   increase	   in	  LC3-­‐II	   levels,	  
which	  peaked	  at	  1.5	  h,	  whereas	  in	  serum-­‐free	  DMEM	  control	  (untreated)	  cells,	  LC3-­‐II	  levels	  
decreased	  steadily	  over	  time.	  In	  this	  instance,	  there	  also	  appears	  to	  be	  some	  loss	  of	  cells	  as	  
the	  tubulin	  levels	  show,	  most	  likely	  due	  to	  serum	  starvation.	  
3.2.2.2 TGF-­‐β	  increases	  GABARAPL1	  expression	  	  
To	   determine	   whether	   TGF-­‐β	   affected	   the	   expression	   of	   components	   of	   the	  
autophagic	   pathway,	   the	   expression	   of	   the	   same	   panel	   of	   autophagy	   related	   genes	   was	  
quantified	   at	   3	   h.	   Autophagy	   gene	   expression	   tended	   to	   be	   higher	   in	   TGF-­‐β	   treated	   cells	  
consistent	  with	   an	   increase	   in	   autophagic	   gene	   expression	  with	   an	   increase	   in	  Gabarapl1	  
compared	   to	   control,	   however	   this	   increase	   was	   not	   significant	   (untreated	   1.00	   ±	   0.105,	  
TGF-­‐β	   1.49	   ±	   0.25,	   p=0.055).	   Furthermore,	   the	   increases	   in	   autophagy	   gene	   expression	  
caused	  by	  TGF-­‐β	  were	  smaller	  than	  those	  caused	  by	  myostatin	  and	  none	  reached	  statistical	  
significance	  on	  their	  own	  (Figure	  7).	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3.2.2.3 TGF-­‐β	  causes	  an	  apparent	  increase	  in	  autophagosome	  number	  	  
To	   examine	   if	   the	   increased	   LC3-­‐II	   protein	   expression	   associated	   with	   increased	  
autophagosome	  number,	  the	  effect	  of	  TGF-­‐β	  on	  autophagosome	  formation	  was	  determined	  
by	  fluorescence	  microscopy.	  Cells	  transiently	  transfected	  with	  a	  plasmid	  expressing	  LC3-­‐GFP	  
fusion	   protein,	   were	   treated	   with	   TGF-­‐β.	   Although	   this	   set	   of	   experiments	   was	   only	  
performed	   twice,	   TGF-­‐β	   caused	   an	   apparent	   increase	   in	   the	   average	   number	   of	  
autophagosomes	  at	  1	  h	  and	  1.5	  h	  compared	  to	  control	  (Figure	  8),	  although	  this	  increase	  was	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Figure	  7	  TGF-­‐β	  increases	  autophagy	  
TGF-­‐β	  treated	  C2C12	  cells	  showed	  an	  increase	  in	  LC3-­‐II	  levels	  after	  1.5	  and	  3	  h	  of	  exposure	  
to	  10ng/ml	  TGF-­‐β	  (A).	  	  At	  16	  h,	  levels	  of	  LC3-­‐II	  fell	  below	  basal	  levels.	  TGF-­‐β	  treatment	  for	  3h	  
caused	  an	  increase	  in	  the	  expression	  of	  Gabarapl1	  (p=0.055).	  The	  weak	  bands	  at	  16h	  may	  be	  
due	  to	  cell	  death	  caused	  by	  serum	  starvation.	  Blot	  shown	   in	   (A)	   is	   representative	  of	   three	  
independent	   experiments.	   Data	   are	   shown	   in	   (B)	   represented	   as	  mean	  ±	  SEM	   from	   three	  
independent	   experiments	   normalised	   to	  GAPDH,	   and	   then	   untreated	   control.	   Significance	  
tested	  by	  Mann-­‐Whitney	  U	  test.	  The	  variability	  between	  LC3-­‐II	  protein	  levels	  and	  autophagy	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Figure	  8	  TGF-­‐β	  causes	  an	  apparent	  increase	  in	  autophagosome	  number	  
Cells	  were	   transfected	  with	   LC3-­‐GFP,	   and	   treated	  10	  ng/ml	   TGF-­‐β	   for	   1	   and	  1.5	  h.	   Images	  
were	  captured	  and	  LC3-­‐GFP	  autophagosomes	  were	  quantified	  using	  an	  automated	  program.	  	  
Panel	   (A)	   show	   representative	   images	   of	   the	   blue	   and	   green	   channels	   split	   into	   separate	  
images,	  merged	  and	  quantified	  images	  taken	  at	  1	  and	  1.5	  h	  with	  (100×	  magnification,	  scale	  
bar	   represents	   8μm).	   Cells	   and	   autophagosome	   are	   circled	   in	   black.	   (B)	   shows	   the	  
quantification	  of	   the	  average	  number	  of	   autophagosomes	   for	  each	   time	  point.	   Treatment	  
with	   TGF-­‐β	   caused	   an	   increase	   in	   the	   number	   of	   autophagosomes	   at	   both	   1	   and	   1.5	  h	  
compared	   to	   DMEM	   untreated	   control,	   which	   was	   not	   significant.	   ∗Data	   shown	   in	   (B)	  
represented	  as	  mean	  ±	  SEM	  from	  two	  independent	  experiments	  (30-­‐40	  cells	  per	  group	  per	  
time	  point).	  	  	  
	  
	  



























































	   91	  
3.2.3 	  Myostatin	  increases	  autophagy	  	  
Given	   that	   myostatin	   causes	   atrophy	   by	   activating	   the	   ubiquitin-­‐proteasomal	  
pathway,	   it	   is	   likely	   that	   myostatin	   also	   activates	   autophagy.	   An	   analogous	   set	   of	  
experiments	   to	   those	   performed	   with	   TGF-­‐β	   was	   also	   repeated	   with	   myostatin;	   LC3-­‐II	  
protein	  levels,	  autophagy	  gene	  expression	  and	  autophagosome	  number	  were	  measured	  to	  
ascertain	  whether	  myostatin	  could	  induce	  autophagy.	  	  	  
3.2.3.1 Myostatin	  increases	  LC3-­‐II	  levels	  
Treatment	  of	  C2C12	  cells	  with	  myostatin	   caused	  a	  marked	   increase	   in	   LC3-­‐II	   levels	  
compared	   to	   controls.	   	   In	   the	   presence	   of	   myostatin,	   LC3-­‐II	   levels	   peaked	   at	   1.5	   h	   then	  
decreased	  over	  time	  to	  below	  basal	  levels	  (Figure	  9).	   
3.2.3.2 Myostatin	  increases	  expression	  of	  autophagy	  related	  genes	  	  
	  Therefore,	  to	  determine	  whether	  myostatin	  also	  increased	  the	  production	  of	  other	  
components	  of	  the	  autophagosome	  pathway,	  the	  expression	  of	  autophagy-­‐associated	  genes	  
was	  examined	  at	  3	  h.	  Myostatin	  caused	  a	  significant	  increase	  in	  the	  expression	  of	  autophagy	  
related	   genes	   compared	   to	  DMEM	  alone:	  Atg-­‐4b	   (untreated	  1.00	  ±0.10,	  myostatin	   3.17	  ±	  
0.99,	  p=0.019),	  Ulk-­‐2	  (untreated	  1.00	  ±	  0.13,	  myostatin	  2.5	  ±	  0.84,	  p=0.045),	  and	  a	  trend	  to	  
an	  increase	  in	  Gabarapl1	  expression	  (untreated	  1.00	  ±	  0.11,	  myostatin	  1.97	  ±	  0.51,	  p=0.068)	  
although	  this	  did	  not	  reach	  significance	  (Figure	  9).	  	  
3.2.3.3 Myostatin	  increases	  autophagosome	  number	  	  
Cells	   transiently	   transfected	  with	   LC3-­‐GFP	  were	   treated	  with	  myostatin.	  Myostatin	  
treatment	   resulted	   in	   an	   increased	   number	   of	   LC3-­‐GFP	   positive	   autophagic	   puncta	  
compared	   to	   untreated	   cells	   with	   a	   significant	   increase	   at	   1	   h	   (untreated	   1.00	   ±	   0.08,	  
myostatin	  1.76	  ±	  0.20,	  p<0.001,	  Figure	  10).	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Figure	  9	  Myostatin	  increases	  autophagy	  in	  skeletal	  muscle	  in	  vitro	  
Myostatin	   treated	   C2C12	   cells	   showed	   an	   increase	   in	   LC3-­‐II	   levels	   after	   0.5	   and	   1.5	   h	   of	  
exposure	   to	   20ng/ml	   myostatin	   (A).	   Subsequently,	   levels	   decreased	   back	   down	   to	   basal	  
levels	  (A).	  Similarly,	  myostatin	  caused	  an	  increase	  in	  a	  number	  of	  autophagy	  related	  genes	  
after	   3h	   of	   exposure,	   with	   a	   significant	   increase	   in	  Atg4b,	  Ulk-­‐2	   and	   a	   trend	   towards	   an	  
increase	   in	  Gabarapl1	   (B).	  Myostatin	  and	  control	  experiments	  were	  performed	   in	  parallel.	  
Blot	  shown	  in	  (A)	  representative	  of	  three	  independent	  experiments.	  Data	  are	  shown	  in	  (B)	  
represented	   as	  mean	  ±	  SEM	   from	   three	   independent	   experiments,	   normalised	   to	   GAPDH,	  
and	  then	  untreated	  control.	  Significance	  tested	  by	  Mann-­‐Whitney	  U	  test	  and	  is	  represented	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Figure	  10	  Myostatin	  increases	  in	  the	  number	  of	  autophagosomes	  
Cells	  were	  transfected	  with	  LC3-­‐GFP,	  and	  treated	  with	  and	  without	  20ng/ml	  myostatin	  for	  
0.5,	  1	  and	  1.5	  h.	  Images	  were	  captured	  and	  LC3-­‐GFP	  autophagosomes	  were	  quantified	  using	  
an	   automated	   program.	   Panel	   (A)	   show	   representative	   images	   of	   the	   blue	   and	   green	  
channels	  split	  into	  separate	  images,	  merged	  and	  quantified	  images	  taken	  at	  1	  and	  1.5	  h	  with	  
(100×	   magnification).	   (B)	   shows	   the	   quantification	   of	   the	   average	   number	   of	  
autophagosomes	  for	  each	  time	  point.	  Myostatin	  increased	  autophagosome	  number	  after	  1	  
and	   1.5	  h	   compared	   to	   DMEM	   untreated	   control.	   ∗Data	   are	   shown	   in	   (B)	   represented	   as	  
mean	  ±	  SEM	   from	   three	   independent	   experiments	   (30-­‐40	   cells	   per	   group	   per	   time	   point).	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3.2.4 GDF-­‐15	  and	  autophagy	  
GDF-­‐15	  expression	  is	  increasingly	  associated	  with	  cachexia,	  however,	  the	  mechanism	  
by	  which	  GDF-­‐15	  could	  cause	  muscle	  atrophy	  remains	  unclear	  (Tsai	  et	  al.,	  2012).	  C2C12	  cells	  
were	   treated	   with	   GDF-­‐15	   and	   levels	   of	   LC3-­‐II	   protein	   and	   the	   gene	   expression	   of	  
components	  of	  protein	  degradation	  pathways	  were	  measured	  to	  determine	  whether	  GDF-­‐
15	  induced	  autophagy	  in	  skeletal	  muscle.	  
3.2.4.1 	  GDF-­‐15	  causes	  a	  small	  increases	  LC3-­‐II	  
Treatment	  of	  C2C12	  cells	  with	  a	  range	  of	  doses	  of	  GDF-­‐15	  from	  1	  to	  50ng/ml	  showed	  
that	  GDF-­‐15	  caused	  an	  apparent	  small	   increase	   in	  LC3-­‐II	  between	  the	  ranges	  of	  1-­‐20ng/ml	  
compared	   to	  vehicle	   control	   (Figure	  11).	  However,	   the	  vehicle	   control	   also	   caused	  a	   large	  
increase	  in	  LC3-­‐II.	  Subsequently,	  C2C12	  cells	  were	  treated	  with	  10ng/ml	  GDF-­‐15	  over	  a	  time-­‐
course	  of	  0-­‐16	  h,	  which	  showed	  a	  marked	  increase	  in	  LC3-­‐II	  at	  0.5h,	  which	  rapidly	  decreased	  
whereas	   in	   vehicle	   treated	   cells,	   LC3-­‐II	   levels	   increased	   slightly	   between	   0.5-­‐3h	   and	   then	  
returned	   to	   basal	   levels.	   At	   20ng/ml,	   there	   was	   a	   mild	   increase	   in	   LC3-­‐II	   at	   0.5h,	   which	  
rapidly	  returned	  to	  the	  baseline	  (control)	  levels.	  As	  these	  experiments	  were	  only	  performed	  
once,	  the	  blots	  were	  not	  quantified.	  
3.3.5.2	   Effect	   of	   GDF-­‐15	   on	   autophagy,	   proteasomal	   degradation,	   and	   apoptosis	   gene	  
expression	  
No	   changes	   were	   observed	   in	   the	   expression	   of	   a	   panel	   of	   genes	   relating	   to	  
autophagy,	  proteasomal	  degradation,	  and	  apoptosis	  with	  50ng/ml	  GDF-­‐15,	  after	  3	  and	  16	  h	  
of	  exposure	  compared	  to	  control	  cells	  (Figure	  12).	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Figure	  11	  Effect	  of	  GDF-­‐15	  on	  autophagy	  
C2C12	   cells	  were	   treated	  with	   a	   range	   of	   concentrations	   of	  GDF-­‐15	   from	  0-­‐	   50ng/ml	   and	  
levels	  of	  LC3-­‐II	  were	  measured	  (A).	  There	  appeared	  to	  be	  a	  slight	  increase	  in	  LC3-­‐II	  at	  1,	  10,	  
20ng/ml.	  A	  time	  course	  was	  performed	  by	  treating	  cells	  with	  10	  and	  20ng/ml	   from	  0-­‐16h,	  
which	  resulted	  in	  both	  concentrations	  increasing	  LC3-­‐II	  at	  0.5	  h	  compared	  to	  control	  (B-­‐C).	  
Blot	   shown	   in	   (A),	   (B)	  and	   (C)	  are	   representative	  of	  one	  experiment.	  The	  variability	  of	   the	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Figure	  12	  GDF-­‐15	  does	  not	  induce	  autophagy	  gene	  expression	  
The	  effect	  of	  50ng/ml	  GDF-­‐15	  on	  a	  panel	  of	   autophagy	  genes	  was	  examined.	  No	   changes	  
were	   observed	   in	   genes	   involved	   in	   autophagy,	   proteasomal	   degradation	   or	   apoptosis	   at	  
either	  3	  or	  16	  h	   (A	  and	  B	   respectively).	  Data	  are	   shown	  represented	  as	  mean	  ±	  SEM	  from	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3.2.5 Ang-­‐II	  and	  autophagy	  
Ang-­‐II	   has	   been	   shown	   to	   stimulate	   autophagy	   in	   other	   cells	   including	  
cardiomyocytes	   (Dai	  and	  Rabinovitch,	  2011).	  Again,	   similar	  assays	  performed	  with	  GDF-­‐15	  
were	   replicated	  with	   ang-­‐II	   treatment	   to	   ascertain	   if	   ang-­‐II	   induces	   autophagy	   in	   skeletal	  
muscle	   in	   vitro.	   C2C12	   cells	  were	   treated	  with	   ang-­‐II	   and	   levels	   of	   LC3-­‐II	   protein	   and	   the	  
gene	  expression	  of	  components	  of	  protein	  degradation	  pathways	  were	  measured.	  
3.2.5.1 Ang-­‐II	  causes	  a	  modest	  increase	  in	  LC3-­‐II	  
	  	   A	   concentration	   response	   of	   ang-­‐II	   treatment	   showed	   that	   overall,	   between	   the	  
doses	  of	  0.1,	  1,	  10,	  50μM;	  there	  was	  only	  a	  modest	   induction	  of	  autophagy	  (Figure	  13).	  A	  
small	   increase	   in	  LC3-­‐II	  at	  1μM	  compared	   to	  DMSO	  vehicle	  after	  1.5	  h	  was	  observed.	  The	  
concentration	   response	   was	   performed	   to	   indicate	   which	   concentration	   of	   ang-­‐II	   is	   the	  
optimum	  stimulator	  of	  autophagy.	  Treatment	  with	  1μM	  ang-­‐II	  over	  a	  time	  course	  from	  0-­‐	  16	  
h	  showed	  that	   there	  was	  a	  marked	   increase	   in	  LC3-­‐II	   from	  0.5-­‐3	  h,	  which	  peaked	  at	  1.5	  h	  
compared	   to	   vehicle,	   before	   decreasing	   to	   levels	   similar	   to	   control.	   There	   was	   a	   smaller	  
increase	   in	   LC3-­‐II	   with	   DMSO	   control,	   which	   remained	   the	   same	   between	   0.5-­‐3	   h,	   then	  
returned	  to	  similar	  levels	  observed	  at	  0	  h	  time	  point.	  
3.3.4.2	   Effect	   of	   ang-­‐II	   on	   autophagy,	   proteasomal	   degradation,	   and	   apoptosis	   gene	  
expression	  
A	  panel	  of	  genes	  were	  selected	  to	  examine	  the	  effect	  of	  ang-­‐II	  on	  autophagy	  (Lc3b	  
and	  Atg4b),	   proteasomal	   degradation	   (Atrogin1	   and	  Murf1)	   and	   apoptosis	   (Bax	   and	  Bad)	  
(Figure	   13).	   Treatment	   of	   C2C12	   cells	  with	   ang-­‐II	   did	   not	   cause	   an	   increase	   in	   the	  mRNA	  
expression	  of	  Lc3b	  and	  Atg4b	  either	  after	  3	  h	  and	  16	  h.	  However,	  ang-­‐II	  caused	  a	  significant	  
increase	  in	  Murf-­‐1	  (control	  1.00	  ±	  0.06,	  ang-­‐II	  2.55	  ±	  0.71,	  p=0.021)	  expression	  at	  3	  h	  and	  a	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trend	  to	  an	  increase	  in	  Atrogin	  (control	  1.00	  ±	  0.09,	  ang-­‐II	  2.22	  ±	  0.51),	  Bad	  (control	  1.00	  ±	  
0.10,	  ang-­‐II	  2.36	  ±	  0.63)	  and	  Bax	  	  (control	  1.00	  ±	  0.11,	  ang-­‐II	  2.32	  ±	  0.70),	  expression	  at	  3	  h,	  
although	  none	  reached	  significance.	  No	  changes	  were	  observed	  after	  16	  h	  of	  treatment	  with	  
ang-­‐II.	  
3.2.6 Techniques	  used	  to	  measure	  autophagy	  
The	   data	   in	   this	   chapter	   show	   the	   techniques	   used	   are	   robust,	   as	   an	   increase	   in	  
autophagy	  was	  detected	  with	  myostatin	  and	  TGF-­‐β	  in	  all	  three	  techniques.	  The	  techniques	  
used	  are	  sensitive,	  as	  smaller	  responses	  in	  autophagy	  were	  detectable,	  i.e.	  increases	  in	  LC3-­‐
II	  with	  ang-­‐II	  and	  GDF-­‐15.	  TGF-­‐β	  family	  members	  did	  not	  necessarily	  cause	  the	  same	  degree	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Figure	  13	  Effect	  of	  Ang-­‐II	  on	  autophagy	  	  
C2C12	  cells	  were	  treated	  with	  a	  range	  of	  concentrations	  from	  0,	  0.1,	  1,	  10,	  50μM	  ang-­‐II,	  and	  
levels	  of	  LC3-­‐II	  were	  measured	  after	  1.5	  h	   (A).	  No	  significant	  changes	   in	  LC3-­‐II	   levels	  were	  
observed.	  C2C12	  cells	  were	  then	  treated	  with	  1μM	  ang-­‐II,	  and	  exposed	  for	  0.5,	  1.5,	  3	  and	  
16h	  (B).	  Ang-­‐II	  caused	  a	  small	  increase	  in	  LC3-­‐II	  at	  0.5-­‐1.5	  h,	  before	  returning	  to	  basal	  levels.	  	  
C2C12	  cells	  were	  treated	  with	  1μM	  ang-­‐II	  for	  3	  and	  16h	  and	  the	  gene	  expression	  of	  a	  panel	  
of	  genes	  was	  measured.	  At	  3h,	  ang-­‐II	   caused	  a	   significant	   increase	   in	  Murf1	   (C).	  No	  other	  
changes	  in	  gene	  expression	  at	  16h	  (D).	  Blot	  shown	  in	  (A)	  representative	  of	  one	  independent	  
experiment.	   Data	   are	   shown	   in	   (B)	   represented	   as	   mean	  ±	  SEM	   from	   three	   independent	  
experiments	  normalised	  to	  RPLPO,	  and	  then	  untreated	  control.	  Significance	  tested	  by	  Mann-­‐
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3.3 Discussion	  
The	   data	   above	   demonstrates	   that	   myostatin	   is	   a	   novel	   inducer	   of	   autophagy	   in	  
skeletal	   muscle	   (Lee	   et	   al.,	   2011).	   The	   induction	   of	   autophagy	   by	   myostatin	   may	   be	   the	  
mechanism	  by	  which	  myostatin	  causes	   loss	  of	  protein	  and	  thus	   leads	  to	  muscle	  mass	   loss.	  
The	   role	   of	   myostatin	   as	   an	   autophagy	   inducer	   would	   be	   concurrent	   with	   the	   increased	  
levels	   of	   myostatin	   observed	   a	   number	   of	   muscle	   wasting	   diseases.	   This	   observation	   is	  
consistent	   with	   previous	   studies	   showing	   TGF-­‐β	   induces	   autophagy.	   Myostatin	   caused	   a	  
transient	  increase	  in	  LC3-­‐II,	  suggesting	  that	  autophagic	  flux	  was	  still	  occurring.	  By	  measuring	  
LC3-­‐II	   levels	   over	   a	   period	   of	   16	   h,	   LC3-­‐II	   processing	   and	   degradation	   was	   shown	   to	   still	  
occur,	   this	   is	   a	   significant	   caveat	   in	   measuring	   autophagy	   as	   it	   is	   a	   dynamic	   process.	  
Increases	   in	   LC3-­‐II	   at	   a	   single	   time	   point	   may	   actually	   be	   due	   to	   a	   blockade	   in	   LC3-­‐II	  
processing	   (Mizushima	   et	   al.,	   2010).	   Further	   to	   the	   increase	   in	   LC3-­‐II,	   there	   was	   also	   a	  
concurrent	  increase	  in	  the	  generation	  of	  autophagosomes,	  quantified	  by	  the	  number	  of	  LC3-­‐
GFP	   positive	   punctae	   generated	   in	   C2C12	   cells	   treated	   with	   myostatin.	   Lastly,	   myostatin	  
caused	  changes	  in	  the	  expression	  of	  several	  genes	  involved	  in	  the	  autophagy	  pathway,	  again	  
reconfirming	  the	  induction	  of	  autophagy.	  	  
Another	   group	   studying	   the	   effect	   of	   myostatin	   in	   cancer	   cachexia	   recently	  
corroborated	   the	   data	   presented	   here.	   Lorikeddy	   et	   al.	   observed	   that	   myostatin	   derived	  
from	  murine	  colorectal	  carcinoma	  cells	  also	  caused	  an	  increase	  in	  LC3-­‐II	  in	  C2C12	  myotubes	  
(Lokireddy	  et	  al.,	  2011,	  Lokireddy	  et	  al.,	  2012a).	  Studies	  have	  shown	  that	  autophagy	  may	  be	  
up-­‐regulated	   during	   atrophy	   conditions	   suggesting	   that	   degradation	   by	   the	   autophagy-­‐
lysosomal	  pathway	  may	  play	  a	  part	  in	  muscle	  mass	  loss.	  LC3	  and	  GABARAPL1	  expression	  are	  
increased	  in	  cancer	  and	  starvation,	  furthermore;	  myostatin	  is	  also	  associated	  with	  the	  same	  
in	  these	  same	  conditions	  (Mizushima	  et	  al.,	  2004,	  Yoshioka	  et	  al.,	  2008,	  Miao	  et	  al.,	  2010,	  
	   103	  
Lokireddy	  et	  al.,	  2012a,	  Reardon	  et	  al.,	  2001).	  Thus,	   increased	  myostatin	   in	  these	  diseases	  
may	   contribute	   to	   increased	   autophagy.	   Mizushima	   et	   al.	   showed	   that	   when	   LC3-­‐GFP	  
transgenic	  mice	  were	  starved	  to	   induce	  autophagy,	  they	  exhibited	  a	  significant	   increase	   in	  
autophagy	  in	  the	  extensor	  digitorum	  longus	  (EDL)	  which	  has	  predominantly	  fast	  twitch	  fibres	  
(Mizushima	   et	   al.,	   2004).	   The	   evidence	   presented	   by	   Mizushima	   et	   al.	   may	   support	   the	  
observation	  that	  myostatin	  has	  a	  greater	  wasting	  effect	  on	   fast	   twitch	   fibres	  compared	  to	  
slow	   twitch	   fibres,	   as	   myostatin	   may	   be	   inducing	   autophagy	   specifically	   in	   fast	   fibres	  
(Amthor	  et	   al.,	   2007,	  Hennebry	  et	   al.,	   2009).	   The	  data	   above	   suggests	   the	  possibility	   that	  
myostatin	   increases	  both	  autophagy	  and	  proteasomal	  degradation	  perhaps	   synergistically,	  
to	  contribute	  loss	  of	  muscle	  mass.	  	  
The	  above	  data	  also	  shows	  that	  TGF-­‐β	  induces	  autophagy	  in	  murine	  myoblasts.	  The	  
induction	  of	  autophagy	  by	  TGF-­‐β	  is	  consistent	  with	  other	  studies	  (Ding	  et	  al.,	  2010,	  Kiyono	  et	  
al.,	  2009,	  Gajewska	  et	  al.,	  2005).	  The	  activation	  of	  autophagy	  by	  TGF-­‐β	  is	  unclear	  but	  Kiyono	  
et	   al	   have	   shown	   that	   SMAD	   proteins	   and	   the	   c-­‐Jun	   N-­‐terminal	   kinase (JNK)	   pathway	  
mediate	   TGF-­‐β	   induced	   autophagy	   in	   hepatocellular	   carcinoma	   cells	   (Kiyono	   et	   al.,	   2009,	  
Suzuki	   et	   al.,	   2010).	   The	   data	   presented	   in	   this	   chapter	   indicate	   that	   both	  myostatin	   and	  
TGF-­‐β	  stimulation	  of	  C2C12	  cells	  results	  in	  the	  increased	  formation	  of	  autophagosomes	  and	  
therefore,	  are	   inducers	  of	  the	  autophagy	  pathway	  in	  these	  cells.	   	  Evidently,	  myostatin	  and	  
TGF-­‐β	   mediated	   stimulation	   of	   autophagy	   may	   be	   part	   of	   the	   mechanism	   by	   which	  
myostatin	   and	   TGF-­‐β	   contribute	   to	   skeletal	   muscle	   remodelling	   and	   cause	   their	  
pathophysiological	  effects	  on	  muscle	  mass.	  	  
Ang-­‐II	  appears	  to	  only	  cause	  a	  slight	  effect	  on	  autophagy	  suggesting	  that	  it	  does	  not	  
exert	   its	  effects	  on	  skeletal	  muscle	  mass	   through	  autophagy.	  However,	  other	  groups	  have	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also	  demonstrated	  that	  ang-­‐II	   increases	  the	  E3	  ligase	  MuRF-­‐1	  and	  the	  pro-­‐apoptotic	  factor	  
BAX	  (Fabris	  et	  al.,	  2007),	  showing	  that	  ang-­‐II	  signals	  in	  a	  similar	  way	  in	  C2C12	  cells,	  but	  again	  
does	  not	  stimulate	  autophagy	  strongly.	  	  
GDF-­‐15	   is	   a	   promising	   candidate	   for	   atrophy.	   Recently,	   there	   have	   been	   an	  
increasing	  number	  of	  studies	  examining	  GDF-­‐15	  levels	  from	  patients	  with	  chronic	  diseases.	  
GDF-­‐15	   is	   currently	   being	   touted	   an	   indicator	   for	   survival.	   Although	   its	   effects	   were	  
originally	  thought	  to	  be	  due	  to	  loss	  of	  appetite,	  the	  clinical	  data	  in	  cancer	  patients	  suggests	  
that	  GDF-­‐15	  may	  directly	  affect	  muscle	  mass	  (Macia	  et	  al.,	  2012,	  Breit	  et	  al.,	  2011,	  Johnen	  et	  
al.,	  2007,	  Tsai	  et	  al.,	  2012,	  Kempf	  et	  al.,	  2007,	  Nickel	  et	  al.,	  2011).	  However,	  the	  data	  shown	  
above	  suggests	  that	  GDF-­‐15	  has	  an	  alternative	  mode	  of	  action	  to	  exert	   its	  muscle	  wasting	  
effects	   other	   than	   autophagy.	   The	   signalling	   pathway	   used	   by	   GDF-­‐15	   has	   yet	   to	   be	  
elucidated.	  GDF-­‐15,	  compared	  the	  other	  TGF-­‐β	  superfamily	  members	  studied	  here,	  does	  not	  
appear	  to	  induce	  autophagy	  	  
There	  are	  a	  number	  of	  limitations	  present	  in	  the	  data	  above.	  There	  are	  a	  number	  of	  
experiments	  discussed	  in	  this	  chapter	  which	  have	  a	  small	  ‘n’	  number,	  in	  particular	  the	  effect	  
of	  TGF-­‐β	  on	  LC3-­‐GFP	  autophagosomes,	   the	  effect	  of	  GDF-­‐15	  and	  ang-­‐II	  on	  LC3-­‐II	   levels.	   In	  
the	  GDF-­‐15	  LC3-­‐II	  protein	  experiments,	  there	  appears	  to	  be	  some	  variability	  in	  basal	  LC3-­‐II	  
levels,	  perhaps	  due	  to	  cell	  variability,	   thus	  suggesting	   the	  need	  to	  repeat	   the	  experiments	  
and	  to	  use	  other	  techniques.	  Although	  myostatin	  and	  TGF-­‐β	  appeared	  not	  to	  cause	  a	  change	  
in	   LC3B	  gene	  expression,	  both	  did	   cause	  an	   increase	   in	   LC3-­‐II	   and	   LC3-­‐GFP	  protein	   levels.	  
This	   data	   may	   indicate	   that	   autophagy	   is	   not	   transcriptionally	   regulated,	   but	   post-­‐
transcriptionally.	   Evidently	   these	   experiments	   cannot	   be	   entirely	   relied	   upon	   to	   draw	  
conclusions	   alone,	   however,	   given	   that	   there	   are	   several	   methods	   used	   to	   quantify	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autophagy,	   overall	   the	   data	   as	   a	  whole	   is	   consistent	   hence	   the	   interpretation	   from	   these	  
sets	  of	  data	  as	  a	  whole	   is	   reliable.	   	   The	  data	  above	   focussed	  on	  myoblasts;	   the	  effects	  of	  
these	  cytokines	  maybe	  greater	  if	  observed	  in	  myotubes.	  
For	   the	   effect	   of	  GDF-­‐15	  on	   autophagy	   gene	   expression	   –	  myoblasts	  were	   treated	  
with	  a	  50ng/ml	  dose	  of	  GDF-­‐15	  gene	  expression;	  10	  or	  20ng/ml	  of	  GDF-­‐15	  would	  perhaps	  be	  
more	  appropriate	  doses	   to	  use	  given	   that	  a	   larger	  effect	  on	  LC3-­‐II	  protein	  expression	  was	  
seen	  at	  these	  concentrations.	  
In	   addition,	   there	   are	  no	   experiments	   examining	   LC3-­‐GFP	  positive	   autophagosome	  
number	   using	   the	   automated	   quantification	   software	   with	   either	   ang-­‐II	   or	   with	   GDF-­‐15.	  
These	  experiments	  would	  be	  useful	  to	  examine	  in	  detail	  the	  degree	  of	  autophagy	  activation	  
in	  C2C12.	  However,	  given	   that	   the	   level	  of	  activation	  was	  so	   low,	  any	  changes	   in	  LC3-­‐GFP	  
levels	  may	  not	  be	  detectable.	  
Although,	  GDF-­‐15,	  TGF-­‐β	  and	  myostatin	  are	  within	  the	  same	  superfamily,	  there	  are	  
indeed	  subtle	  differences	  in	  the	  how	  they	  exert	  their	  effects,	  perhaps	  due	  to	  differences	  in	  
signalling	   pathways.	   Whether	   GDF-­‐15	   can	   directly	   cause	   wasting	   in	   vitro	   will	   be	   further	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4.1 Introduction	  
Muscle	   atrophy	   is	   also	   a	   significant	   co-­‐morbidity	   in	   COPD	   patients	   (Chapter	   1.1),	  
furthermore,	   in	   these	   patients,	   a	   fibre	   type	   shift	   with	   an	   increase	   in	   the	   proportion	   of	  
glycolytic	  type	  II	  fibres	  is	  observed	  in	  the	  quadriceps	  (Gosker	  et	  al.,	  2002b,	  Jobin	  et	  al.,	  1998,	  
Whittom	  et	  al.,	  1998).	  Additional	  to	  the	  fibre	  shift,	  the	  preferential	  atrophy	  of	  type	  II	  fibres	  
over	   type	   I	   fibres	   also	   occurs	   in	   COPD.	   This	   type	   II	   specific	   fibre	   atrophy	   has	   also	   been	  
observed	  in	  other	  diseases	  such	  as	  AIDS,	  cancer	  related	  atrophy,	  disuse	  related	  atrophy	  and	  
sarcopenia	   (Gosker	   et	   al.,	   2002a,	   Degens	   and	   Alway,	   2006,	   Gosker	   et	   al.,	   2003),	   thus	  
suggesting	   that	   the	   susceptibility	   of	   type	   II	   fibres	   to	   atrophy	   may	   be	   an	   important	  
contributor	  to	  muscle	  dysfunction.	  The	  type	  II	  fibre	  shift	  and	  atrophy	  not	  only	  contribute	  to	  
loss	  of	  muscle	  mass,	  but	  also	  to	  dysfunction	  as	  type	  II	   fibres	  are	   less	  endurant	  and	  have	  a	  
decreased	  oxidative	  capacity	  compared	  to	  type	  I	  fibres	  (Jakobsson	  et	  al.,	  1990).	  
The	   specific	   atrophy	   of	   type	   II	   fibres	  may	   be	   due	   to	   increased	   protein	   breakdown	  
within	  these	  fibres,	  suggesting	  that	  there	  may	  be	  increased	  atrophy	  signalling.	  Myostatin	  is	  a	  
well-­‐known	   inhibitor	   of	  muscle	  mass,	   and	   exerts	   its	   effects	   in	   a	   fibre	   specific	   manner	   as	  
myostatin	  knockout	  mice	  showed	  an	   increase	   in	   the	  proportion	  of	   the	   fast	   twitch	  type	   IIB	  
fibres	  (Hennebry	  et	  al.,	  2009,	  McPherron	  et	  al.,	  1997).	  Myostatin	  is	  preferentially	  and	  most	  
abundantly	  expressed	  in	  type	  IIB	  fibres	  (Kirk	  et	  al.,	  2000).	  	  Myostatin	  levels	  are	  increased	  in	  
COPD	   (Plant	   et	   al.,	   2010)	   as	   well	   as	   in	   type	   II	   fibre	   atrophy	   diseases	   thus	   implicating	  
myostatin	  in	  fibre-­‐specific	  atrophy	  in	  COPD	  (Gustafsson	  et	  al.,	  2010,	  Gonzalez-­‐Cadavid	  et	  al.,	  
1998).	  Together,	  these	  data	  strongly	  suggest	  that	  myostatin	  exerts	  its	  effects	  mainly	  in	  type	  
II	   fibres.	  One	  mechanism	  by	  which	   the	  effects	  of	  myostatin	  could	  be	  modulated	   in	  a	   fibre	  
dependent	  manner,	  would	  be	  through	  interaction	  with	  a	  fibre	  specific	  adaptor	  protein.	  One	  
such	  protein	  adaptor	  is	  FHL1.	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FHL1	   is	   involved	   in	  the	  regulation	  of	  muscle	  phenotype,	  and	  has	  a	  diverse	  range	  of	  
roles	  that	  appear	  contradictory.	  FHL1	  over	  expression	  in	  vitro	  causes	  myotube	  hypertrophy	  
and	   in	   transgenic	   mice	   FHL1	   causes	   myofibre	   hypertrophy	   as	   well	   as	   an	   increase	   in	   the	  
proportion	   of	   type	   IIA	   fibres	   (Cowling	   et	   al.,	   2008).	   Furthermore,	   mutations	   in	   FHL1	   in	  
humans	   cause	   atrophy	  of	   the	  postural	  muscles	   and	  pseudo-­‐hypertrophy	   in	   other	  muscles	  
(Windpassinger	  et	  al.,	   2008).	   Together	   these	  data	   suggest	   that	   FHL1	   is	   involved	   in	  muscle	  
hypertrophy.	  	  
However,	   an	   opposing	   role	   for	   FHL1	   has	   also	   been	   suggested.	   FHL1	   expression	   is	  
increased	  after	  3	  days	  of	  denervation	  in	  mice	  (Raffaello	  et	  al.,	  2006)	  and	  FHL1	  expression	  is	  
also	  suppressed	  in	  healthy	  people	  undergoing	  long-­‐term	  strength	  training	  (Roth	  et	  al.,	  2002)	  
suggesting	  that	  FHL1	  is	  more	  associated	  with	  skeletal	  atrophy.	  In	  a	  cohort	  of	  COPD	  patients	  
studied	  within	  the	  group,	  FHL1	  protein	  and	  mRNA	  expression	  correlated	  with	  myosin	  heavy	  
chain	  type	  IIA	  mRNA	  expression	  (Lewis	  et	  al.,	  2010).	  In	  addition	  to	  this,	  FHL1	  correlated	  with	  
inactivity	  and	  weakness	   in	   the	  same	  patients	   (Lewis	  et	  al.,	  2010,	  Riddoch	  Contreras	  et	  al.,	  
2008).	   	   Together,	   these	   lines	   of	   evidence	   suggest	   that	   the	   role	   of	   FHL1	   may	   be	   more	  
complex	   than	   first	   thought	   and	   that	   its	   role	   in	   skeletal	  muscle	  may	  be	  dependent	   on	   the	  
signalling	  pathway	  context	  in	  the	  muscle.	  Nevertheless,	  it	  is	  clear	  that	  FHL1	  is	  important	  in	  
the	  regulation	  of	  muscle	  mass.	  
	   Recent	  data	   showed	   that	  FHL	  proteins	   interact	  with	  SMAD	   (Small	  Mothers	  Against	  
Decapentaplegic)	   proteins	   leading	   to	   their	   phosphorylation	   and	   activation	   in	   hepatic	  
carcinoma	  cells	  (Ding	  et	  al.,	  2009).	  	  One	  effect	  of	  this	  interaction	  is	  likely	  to	  be	  an	  increase	  in	  
the	  activity	  and	  a	  reduction	  in	  the	  threshold	  of	  activity	  of	  factors	  that	  activate	  signalling	  via	  
the	  SMAD	  pathway.	   	   SMAD	  proteins	  are	  key	  signalling	  molecules	   involved	   in	  TGF-­‐β	   family	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signalling.	   Given	   that	   FHL	   proteins	   have	   been	   shown	   to	   interact	   both	   functionally	   and	  
physically	   with	   TGF-­‐β	   in	   tumour	   cell	   lines,	   FHL	   proteins	   could	   enhance	   TGF-­‐β/myostatin	  
signalling	   in	   type	   II	   fibres	   in	   skeletal	   muscle,	   thus	   sensitising	   these	   fibres	   to	   the	   atrophy	  
signal	   and	   leading	   to	   wasting.	   	   Such	   a	   mechanism	   would	   help	   to	   explain	   the	   apparently	  
diverse	  effects	  of	  FHL1	  in	  cells.	  
In	  addition,	  the	  signalling	  of	  other	  members	  of	  the	  TGF-­‐β	  super	  family,	  such	  as	  GDF-­‐
15,	  may	  also	  be	  affected	  by	  FHL1,	  given	  that	  GDF-­‐15	  was	  previously	  shown	  to	  cause	  a	  mild	  
induction	  of	  autophagy	  in	  section	  3.2.4.	  Ang-­‐II	  is	  a	  non-­‐TGF-­‐β	  superfamily	  protein	  that	  may	  
also	  be	  involved	  in	  muscle	  wasting.	  Angiotensin	  signalling	  has	  been	  shown	  to	  be	  detrimental	  
to	  muscle	  (Sanders	  et	  al.,	  2005,	  Russell	  et	  al.,	  2006)	  concurrently;	  recent	  studies	  interfering	  
with	  ang-­‐II	  signalling	  have	  been	  shown	  to	  benefit	  the	  muscle	  (Sumukadas	  et	  al.,	  2007,	  Carter	  
et	  al.,	  2005).	  This	  raises	  the	  possibility	  that	  GDF-­‐15	  and	  ang-­‐II	  signalling	  in	  muscle	  may	  also	  
be	  sensitive	  to	  signalling	  modulation	  by	  FHL1.	  
The	  aim	  of	   this	   chapter	  was	   to	  ascertain	  whether	  FHL1	  augmented	  TGF-­‐β	   in	  muscle	  
cells	   in	  vitro	  and	  to	  examine	  whether	  myostatin	  signalling	  was	  also	  potentiated.	  The	  effect	  
of	   FHL1	  over-­‐expression	  on	  myostatin	   induced	  wasting	  was	   also	   examined	   in	   cell	   culture,	  
and	  the	  effect	  of	  the	  combined	  myostatin	  and	  FHL1	  over-­‐expression	  in	  vivo	  was	  examined	  in	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4.2 Results	  
4.2.1 Does	  FHL1	  modify	  TGF-­‐β	  family	  activity	  in	  muscle	  in	  vitro?	  
In	   this	   study	   the	  effect	  of	  FHL1	  on	  myostatin	  dependent	  signalling	  was	  analysed	   in	  
vitro	   using	   luciferase	   assays	   and	   by	   determining	   myotube	   diameter	   and	   in	   vivo	   using	  
electroporation.	   The	   effect	   of	   FHL1	   on	   another	   TGF-­‐β	   superfamily	   member	   (Growth	  
Differentiation	   Factor-­‐15,	   GDF-­‐15)	   was	   also	   examined	   in	   vitro	   to	   determine	   whether	   any	  
effect	  was	  present	  on	  signalling	  by	  other	  members	  of	  the	  TGF-­‐β	  family.	  Finally,	  the	  effects	  of	  
FHL1	  on	  ang-­‐II	  dependent	  wasting	  were	  studied	  to	  determine	  whether	  the	  effects	  of	  FHL1	  
occurred	  irrespective	  of	  the	  signalling	  system.	  	   
4.2.1.1 FHL1	  potentiates	  TGF-­‐β	  family	  ligand	  signalling	  	  
4.2.1.1.1 FHL1	  potentiates	  TGF-­‐β	  signalling	  
FHL1	  has	   been	   shown	   to	   interact	  with	   SMAD	  proteins	   in	   hepatocellular	   carcinoma	  
cells	  (Ding	  et	  al.,	  2009).	  	  To	  examine	  the	  effect	  of	  FHL1	  on	  TGF-­‐β	  induced	  SMAD	  signalling	  in	  
myoblasts,	  C2C12	  cells	  were	  transiently	  co-­‐transfected	  with	  a	  reporter	  plasmid	  containing	  a	  
SMAD	   binding	   element	   fused	   to	   a	   firefly	   luciferase	   reporter	   gene	   p(CAGA)12,	   along	   with	  
either	  pC-­‐FHL1	  or	  pCDNA	  (empty	  vector	  control)	  and	  then	  treated	  with	  10ng/ml	  TGF-­‐β	  for	  
16	   h.	   In	   the	   absence	   of	   any	   FHL1	   protein,	   TGF-­‐β	   caused	   an	   increase	   in	   luciferase	   activity	  
(Figure	   14),	   however	   in	   the	   presence	   of	   FHL1,	   TGF-­‐β	   induced	   luciferase	   activity	   was	  
potentiated	   further	   (pCDNA	  3.88	  ±	  0.24,	  pC-­‐FHL1	  6.87	  ±	  0.26	   fold	   increase,	  p<0.001).	  This	  
data	  confirmed	  that	  in	  this	  experimental	  setup,	  FHL1	  behaved	  similarly	  in	  C2C12	  cells	  as	  in	  
hepatocellular	  carcinoma	  cells.	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Figure	  14	  FHL1	  potentiates	  TGF-­‐β 	  induced	  SMAD	  signalling.	  
Interaction	  between	  FHL1	  and	  TGF-­‐β	   induced	   luciferase	  activity	  was	  assessed	  by	  using	  the	  
SMAD	   luciferase	  reporter	  p(CAGA)12.	  C2C12	  cells	  were	  treated	  with	  10ng/ml	  TGF-­‐β.	  TGF-­‐β	  
induced	  a	  4-­‐fold	  increase	  in	  luciferase	  activity.	  In	  the	  presence	  of	  pC-­‐FHL1,	  this	  was	  further	  
potentiated	  ~1.8	  fold.	  Data	  pooled	  from	  4	  independent	  experiments	  represented	  as	  mean	  ±	  
SEM,	   normalised	   to	   pCDNA	   non-­‐treated	   control.	   Significance	   tested	   by	  Mann-­‐Whitney	   U	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4.2.1.1.2 FHL1	  potentiates	  myostatin	  signalling	  
	  	   To	  investigate	  the	  effect	  of	  FHL	  proteins	  on	  myostatin	  signalling,	  similar	  experiments	  
were	  performed	  as	  above,	  using	  myostatin	  at	  a	  range	  of	  concentrations	  from	  0-­‐100ng/ml	  to	  
identify	   a	   threshold	   concentration.	   There	   was	   no	   apparent	   change	   in	   luciferase	   reporter	  
activity	  at	  50ng/ml	  myostatin	  or	  below;	  however,	   there	  was	  an	   increase	  with	  100ng/ml	  of	  
myostatin	   (100ng/ml	   myostatin	   1.43	   ±	   0.16	   fold,	   0ng/ml	   1.00	   ±	   0.06)	   (Figure	   15).	   In	   the	  
presence	  of	  FHL1,	  however,	   the	  activity	  of	   the	  p(CAGA)12	  promoter	  was	  potentiated	  at	  all	  
concentrations,	  with	  an	  increase	  at	  	  20ng/ml	  myostatin	  (pCDNA	  1.13	  ±	  0.10,	  pC-­‐FHL1	  1.43	  ±	  
0.11	   fold	   increase,	   p=0.035).	   FHL1	   caused	   a	   maximal	   increase	   in	   luciferase	   activity	   at	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Figure	  15	  FHL1	  potentiates	  myostatin	  induced	  SMAD	  signalling.	  
Interaction	  between	  FHL1	  and	  myostatin	   induced	   luciferase	  activity	  was	  assessed	  by	  using	  
the	   SMAD	   luciferase	   reporter	   p(CAGA)12.	   C2C12	   cells	   were	   treated	   with	   a	   range	   of	  
myostatin	   concentrations.	   FHL1	   expression	   enhanced	   the	   concentration-­‐dependent	  
induction	   of	   myostatin	   induced	   luciferase	   activity.	   Data	   represented	   as	   mean	   ±	   SEM,	  
normalised	  to	  pCDNA	  non-­‐treated	  control.	  Significance	  tested	  by	  Mann-­‐Whitney	  U	  test	  and	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4.2.1.2 Myostatin	  induces	  wasting	  in	  vitro	  in	  the	  presence	  of	  FHL1	  
The	   above	   data	   suggested	   that	   FHL1	   would	   potentiate	   myostatin	   signalling,	   thus	  
FHL1	  would	  enhance	  myostatin	  dependent	  wasting,	  and	  therefore	  reduce	  myotube	  width.	  
To	  determine	  the	  effect	  of	  FHL1	  on	  myotube	  width,	  cells	  were	  co-­‐transfected	  with	  the	  FHL1	  
expression	   vector	   (pC-­‐FHL1)	   together	   with	   an	   EGFP	   expression	   vector	   (pCAGGS-­‐GFP)	   to	  
identify	  transfected	  cells.	  	  The	  cells	  were	  then	  differentiated	  for	  10	  days	  so	  that	  the	  effects	  
of	  FHL1	  on	   the	  cells	  were	  not	  due	   to	  changes	   in	  myotube	   formation	  before	   the	   threshold	  
concentration	  of	  myostatin	   (20ng/ml)	  was	  added.	  The	  cells	  were	  then	  monitored	  over	  the	  
subsequent	  4	  days	  as	  described	  in	  section	  2.2.1.4.	  	  
The	  FHL1	  transfected	  myotubes	  were	  larger	  in	  median	  diameter	  compared	  to	  control	  
transfected	  cells	   in	  the	  absence	  of	  myostatin	  (median	  values	  and	  interquartile	  range,	  FHL1	  
31.1µm	  (25.5,	  39.8)	  compared	  to	  Control	  30.1μm	  (22.8,	  36.2)	  p<0.05)	  (Figure	  16,	  Figure	  17).	  
Myostatin	   had	   no	   effect	   on	   myotube	   diameter	   on	   control	   transfected	   cells	   after	   48h	   of	  
treatment	   (myostatin	   29.6μm	   (24.1,	   33.4),	   Control	   30.1μm	   (22.8,	   36.2)).	   However,	   this	  
concentration	   was	   sufficient	   to	   reduce	   the	   size	   of	   FHL1	   over-­‐expressing	  myotubes	   (FHL1	  
31.1μm	  (25.5,	  39.8),	  FHL1	  +	  myostatin	  (27.1μm,	  23.9,	  31.6)	  p<0.001).	  
	   After	  a	  further	  48h,	  similar	  results	  were	  observed	  	  (Figure	  16,	  Figure	  17);	  there	  was	  
no	  effect	  of	  myostatin	  alone	  (myostatin	  29.3μm,	  (24.9,	  37.4)	  Control	  30.4μm,	  (25.3,	  36.0)).	  
Again,	  the	  concentration	  of	  myostatin	  was	  able	  to	  reduce	  myotube	  diameter	  in	  FHL1	  over-­‐
expressing	  cells	  (FHL1	  31.5μm,	  (27.5,	  36.2),	  FHL1	  +	  myostatin	  28.5μm,	  (23.9,	  31.1)	  p<0.001).	  
However,	  after	  a	  total	  of	  96h	  of	  treatment,	  FHL1	  failed	  to	  increase	  the	  diameter	  of	  the	  over-­‐
expressing	  myotubes	  (FHL1	  31.5μm,	  (27.5,	  36.2)	  Control	  (30.4μm,	  (25.3,	  36.0)).	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At	  both	  48	  and	  96h	  time	  points,	  the	  median	  widths	  of	  the	  myotubes	  over-­‐expressing	  
FHL1	  and	  treated	  with	  myostatin	  were	  smaller	  compared	  to	  control	   transfected	  myotubes	  
treated	   with	   myostatin,	   in	   neither	   instance	   did	   this	   observation	   reach	   significance	  
(myostatin	  29.6μm	  (24.1,	  33.4)	  compared	  to	  FHL1	  +	  myostatin	  (27.1μm,	  23.9,	  31.6)	  p=0.078)	  
and	  at	  96h	  (myostatin	  29.3μm,	  (24.9,	  37.4)	  compared	  to	  FHL1	  +	  myostatin	  (28.5μm,	  (23.9,	  
31.1)	   p=0.062)	   (Figure	   16).	   However,	   when	   the	   data	   for	   48	   and	   96h	   is	   combined	   by	  
normalizing	  to	  the	  median	  width	  of	  the	  myostatin	  treated	  myotubes	  at	  the	  same	  time	  point,	  
FHL1	   over-­‐expressing	   myotubes	   treated	   with	   myostatin	   were	   reduced	   to	   93%	   (81,	   101,	  
p>0.001)	  of	  the	  myostatin	  treated	  myotubes.	  	  
The	   above	   data	   showed	   that	   FHL1	   enhances	  myostatin	   signalling	   functionally	   and	  
can	   lead	   to	  a	  physiological	   response	   in	  vitro	  providing	   strong	  evidence	   that	   the	  FHL1	  may	  
have	   a	   biological	   role	   in	   modifying	   myostatin	   signalling.	   Thus	   leading	   to	   the	   question	   of	  
whether	  FHL1	  affects	  myostatin	  signalling	  in	  a	  similar	  fashion	  in	  vivo,	  this	  data	  also	  presents	  
a	  potential	  mechanism	  by	  which	  type	  II	  fibres	  atrophy	  more	  than	  other	  fibre	  types	  in	  COPD	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Figure	  16	  FHL1	  enhanced	  myostatin	  induced	  myotube	  wasting.	  
C2C12	  myotubes	  either	  expressing	  pC-­‐FHL1	  or	  pCDNA	  were	  observed	   in	   the	  presence	  and	  
absence	   of	   myostatin.	   There	   was	   no	   effect	   of	   either	   pCDNA	   untreated	   or	   pCDNA	   with	  
20ng/ml	  myostatin.	   FHL1	   over-­‐expression	   caused	  myotube	   hypertrophy.	   However,	   in	   the	  
presence	  of	  myostatin	  +	  FHL1,	  myotube	  diameter	  was	  reduced.	  Graphs	  show	  medians	  with	  
interquartile	  range	  (IQR)	  of	  myotube	  diameter	  after	  48	  (A)	  and	  96	  h	  (B)	  of	  treatment,	  with	  
each	  data	  point	   representing	   the	  mean	  diameter	  of	   each	  myotube	  measured	  within	  each	  
different	   group.	   From	   each	   treatment,	   70-­‐100	   myotubes	   measured	   from	   20-­‐25	   fields	   of	  
view.	  Data	  represent	  pooled	  data	   from	  3	   independent	  experiments.	  Significance	  tested	  by	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Figure	  17	  Effect	  of	  FHL1	  and	  myostatin	  on	  myotubes	  
C2C12	  myotubes	  either	  expressing	  pC-­‐FHL1	  or	  pCDNA	  were	  observed	   in	   the	  presence	  and	  
absence	   of	   myostatin.	   The	   panel	   shows	   representative	   images	   of	   myotubes	   from	   each	  
treatment	   group	   at	   48h.	   There	  was	   no	   effect	   of	   either	   pCDNA	   untreated	   or	   pCDNA	  with	  
20ng/ml	  myostatin.	   FHL1	   over-­‐expression	   caused	  myotube	   hypertrophy.	   However,	   in	   the	  
presence	  of	  myostatin	  +	   FHL1,	  myotube	  diameter	  was	   reduced.	  Representative	   images	  of	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4.2.2 	  Does	  FHL1	  modify	  TGF-­‐β	  family	  activity	  in	  muscle	  in	  vivo?	  
To	  determine	  the	  effect	  of	  FHL1	  on	  myostatin	  signalling	  in	  vivo,	  FHL1	  and	  myostatin	  
were	   over-­‐expressed	   together	   in	   the	   tibialis	   anterior	   (TA)	   of	   adult	   female	   mice	   by	  
electroporation.	  Electroporation	  has	  been	  shown	  to	  be	  an	  effective	  method	  of	  gene	  transfer	  
in	  mature	   adult	  muscle.	   Compared	   to	   viral	   gene	   transfer,	   electroporation	   offers	   reduced	  
cytotoxicity,	   immunogenicity	   and	   insertional	   mutagenesis	   as	   well	   as	   being	   a	   faster	   and	  
cheaper	  method	   of	   gene	   delivery.	   Plasmid	   injection	   followed	   by	   electroporation	   has	   also	  
proven	  to	  be	  an	  improvement	  from	  plasmid	  injection	  alone,	  decreasing	  variability	  within	  the	  
individual	   and	   increasing	   transgene	   expression	   (Schertzer	   and	   Lynch,	   2008,	   Davis	   et	   al.,	  
1993).	  Durieux	  et	  al.	  have	  over	  expressed	  myostatin	  using	  electroporation	  and	  observed	  a	  
significant	  loss	  of	  muscle	  mass	  and	  a	  reduction	  in	  fibre	  cross	  sectional	  area	  (Durieux	  et	  al.,	  
2007).	  	  
As	   there	   was	   no	   precedence	   of	   examining	   the	   effect	   of	   FHL1	   and	   myostatin	  
interaction	   in	   vivo;	   a	   small	   study	   was	   conducted	   in	   collaboration	   with	   Professor	   Dominic	  
Wells	  at	  the	  Royal	  Veterinary	  College,	  London.	  Professor	  Wells	  performed	  all	   in	  vivo	  work.	  
Three	  groups	  of	  animals	  were	  generated	  in	  which	  a	  different	  combinations	  of	  pCAGGS-­‐FHL1,	  
pCAGGS-­‐Myostatin	   and	   pCAGGS	   (empty	   vector)	   were	   over-­‐expressed:	   group	   1	   over-­‐
expressed	  myostatin	  in	  one	  TA	  with	  the	  empty	  vector	  control	  in	  the	  other	  TA,	  group	  2	  over-­‐
expressed	  FHL1	  in	  one	  TA	  with	  the	  empty	  vector	  control	  in	  the	  other	  TA,	  and	  group	  3	  over	  
expressed	  FHL1	  +	  myostatin	   in	  one	  TA	  whilst	   the	  other	  TA	  only	  over-­‐expressed	  myostatin.	  
The	  mice	  were	  electroporated	  as	  described	  in	  section	  2.2.11.	  After	  2	  weeks,	  the	  mice	  were	  
sacrificed	   and	  both	   TA	  muscles	  were	   excised	   and	   analysed.	   For	   clarity,	   pCAGGS-­‐FHL1	   and	  
pCAGGS-­‐myostatin	  will	  be	  hereafter	  referred	  to	  as	  FHL1	  and	  myostatin	  or	  Mstn	  respectively.	  
For	  further	  clarity,	  the	  myosin	  isoform	  genes	  will	  be	  referred	  to	  by	  the	  fibre	  type	  that	  there	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are	  expressed,	  with	  Myh7-­‐as	  Myosin	  Heavy	  Chain	  (MyHC)	  I,	  Myh2-­‐	  MyHC	  IIA,	  Myh1-­‐	  MyHC	  
IIX,	  and	  Myh4-­‐	  MyHC	  IIB.	  
	  
4.2.2.1 Changes	  in	  TA	  weight	  	  
TA	  muscles	  were	  excised	  and	  weighed.	  Consistent	  with	  other	  studies	  that	  have	  over-­‐
expressed	  myostatin	   ectopically	   (Durieux	   et	   al.,	   2007)	  myostatin	   over-­‐expression	   reduced	  
(25.7%	   ±	   4.1)	   the	   mean	   wet	   weight	   of	   the	   TA	   when	   normalised	   to	   whole	   body	   weight	  
(myostatin	  0.141%	  ±	  0.010,	  pCAGGS	  0.190%	  ±	  0.010,	  p=0.005)	  (Figure	  18).	  	  However,	  there	  
was	  no	  effect	  of	  FHL1	  over-­‐expression	  on	  TA	  weight	  (FHL1	  0.200%	  ±	  0.009,	  pCAGGS	  0.204%	  
±	  0.007)	  and	  no	  change	  between	  the	  myostatin	  +	  FHL1	  group	  compared	  to	   the	  myostatin	  
control	   TA	   weights	   (FHL1	   +	   myostatin	   0.151%	   ±	   0.006,	   myostatin	   0.154%	   ±	   0.004).	   The	  
average	  of	  all	   the	  myostatin	  expressing	  TAs	   (i.e.	   the	  myostatin	  group	  and	  the	  myostatin	  +	  
FHL1	   group)	   (0.159%	  ±0.006)	  was	   significantly	   reduced	   compared	   to	   the	   average	   of	   non-­‐
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Figure	  18	  Changes	  in	  TA	  wet	  weight	  in	  electroporated	  mice.	  	  	  
Myostatin	  over-­‐expression	  caused	  a	  reduction	  in	  TA	  wet	  weight	  compared	  to	  empty	  vector	  
control	  (pCAGGS).	  No	  changes	  were	  observed	  in	  the	  FHL1	  over	  expression	  group	  or	  the	  FHL1	  
+	  myostatin	  group	  compared	  to	  their	  control	  TA	  (within	  the	  same	  animal).	   	  Each	  animal	   is	  
represented	  as	  a	  data	  point	  with	  line	  drawn	  to	  its	  corresponding	  leg.	  Each	  group	  consisted	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Figure	  19	  Effect	  of	  myostatin	  over-­‐expression	  on	  TA	  muscle	  weight.	  	  
Myostatin	  over-­‐expression	  caused	  a	  reduction	  in	  TA	  weight	  compared	  to	  non-­‐myostatin	  
over-­‐expressing	  TAs	  (i.e.	  the	  FHL1	  group).	  Bars	  represent	  mean	  ±SEM,	  and	  each	  data	  point	  
represents	  a	  single	  TA	  muscle	  normalised	  to	  body	  weight.	  Each	  of	  the	  three	  experimental	  
sets	  consisted	  of	  4	  animals.	  The	  myostatin	  and	  myostatin	  +	  FHL1	  groups	  have	  been	  
compared	  to	  the	  FHL1	  group	  (i.e.	  each	  TA	  was	  assigned	  to	  either	  the	  myostatin	  expressing	  
or	  the	  non	  myostatin	  expressing	  group	  shown	  below;	  16	  TAs	  ‘expressed’	  myostatin	  whilst	  8	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4.2.2.2 Changes	  in	  fibre	  diameter	  	  
TA	   muscles	   were	   processed	   and	   fibre	   diameters	   were	   measured	   from	   H	   and	   E	  
stained	   TA	   sections,	   as	   described	   in	   section	   2.2.11.2.	   Measurements	   of	   fibre	   diameter	  
showed	   an	   approximate	   10%	   reduction	   in	   mean	   fibre	   diameter	   in	   the	   myostatin	   over-­‐
expressing	  group,	  compared	  to	  the	  empty	  vector	  control	  within	  the	  same	  animal,	  (myostatin	  
32.9µm	  ±	  0.443,	  pCAGGS	  36.6µm	  ±	  1.51,	  p=0.034)	  (Figure	  20,	  Figure	  21).	  In	  the	  FHL1	  over-­‐
expression	  group,	  consistent	  with	  the	  FHL1	  transgenic	  mice,	  there	  was	  an	  increase	  (~9%)	  in	  
fibre	   diameter	   compared	   to	   the	   empty	   vector	   control	   (FHL1	   42.7µm	   ±	   0.467,	   pCAGGS	  
39.0µm	   ±	   0.485,	   p=0.002).	   Moreover,	   the	   myostatin	   +	   FHL1	   group	   showed	   a	   further	  
reduction	   (~11%)	   in	   fibre	   diameter	   compared	   to	   the	   myostatin	   only	   TA	   (myostatin	   +	  
pCAGGS-­‐FHL1	   30.4µm	   ±	   1.25,	  myostatin	   33.4µm	   ±	   1.01,	   p=0.032).	   Equally,	   the	   reduction	  
caused	   by	   myostatin	   alone	   in	   both	   groups	   (myostatin	   +	   FHL1	   and	   myostatin)	   was	  
approximately	  the	  same	  (33.4µm	  ±	  1.01,	  32.9µm	  ±	  0.443	  respectively)	  thus	  demonstrating	  
that	  the	  wasting	  caused	  by	  myostatin	  was	  repeatable.	  	  
	  The	  groups	  were	  examined	  as	  individual	  TA	  muscles	  therefore	  allowing	  the	  TAs	  for	  
each	  transfection	  group	  to	  be	  pooled	  (Figure	  21D).	  Again,	  there	  was	  a	  significant	  decrease	  
(~10%)	   in	   the	  myostatin	   group	   compared	   to	  pCAGGS	   control	   (33.1µm	  ±	   0.5	   n=8,	   pCAGGS	  
37.8µm	   ±	   0.9,	   n=8,	   p=0.0002),	   whereas	   FHL1	   caused	   a	   13%	   increase	   in	   fibre	   diameter	  
compared	   to	   control	   (FHL1	   42.7µm	   ±	   0.5,	   n=4,	   p=0.0034).	   Co-­‐expression	   of	   FHL1	   with	  
myostatin	   in	   the	   same	   TA	   caused	   a	   larger	   decrease	   in	   fibre	   diameter	   than	   expression	   of	  
myostatin	   alone	   (a	   20%	   further	   reduction,	   to	   30.4µm	   ±	   1.2,	   n=4,	   p=0.033,	   Figure	   21).	  	  
Comparing	  the	  diameter	  of	  myofibres	  over-­‐expressing	  FHL1	   in	  the	  presence	  or	  absence	  of	  
myostatin	  showed	  that	  myostatin	  decreased	  fibre	  diameter	  in	  this	  situation	  from	  42.7µm	  ±	  
0.5	  to	  30.4µm	  ±	  1.2,	  a	  reduction	  of	  approximately	  25%	  (p<0.0001).	  	  
	   123	  
Figure	  20	  Changes	  in	  fibre	  diameter	  in	  the	  myostatin	  and	  FHL1,	  myostatin	  alone	  and	  FHL1	  
alone	  groups.	  
Representative	  images	  of	  TA	  sections	  from	  the	  3	  different	  groups.	  The	  contralateral	  control	  
TA	  is	  on	  the	  left	  and	  the	  ‘treated’	  TA	  on	  the	  right.	  Cross	  sections	  were	  stained	  with	  H	  and	  E.	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Figure	  21	  Changes	  in	  fibre	  diameter	  of	  electroporated	  mice.	  	  
Myostatin	  over-­‐expression	  caused	  a	  trend	  reduced	  fibre	  diameter	  (A).	  FHL1	  over-­‐expression	  
significantly	   increase	   fibre	  diameter	   (B)	   and	  myostatin	  +	   FHL1	   caused	  a	   further	  decreased	  
fibre	  diameter	  (C).	  Pooled	  analyses	  shown	  in	  (D).	  Each	  animal	  is	  represented	  as	  a	  data	  point	  
with	   line	   drawn	   to	   its	   corresponding	   TA.	   Each	   group	   consisted	   of	   4	   animals.	   Significance	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4.2.2.3 Fibre	  size	  distribution	  
The	  effects	  of	  co-­‐expression	  of	  FHL1	  and	  myostatin	  on	  fibre	  size	  were	  also	  examined	  
by	  comparing	  the	  effect	  of	  expression	  on	  fibre	  size	  distribution.	  	  Myostatin	  caused	  a	  shift	  in	  
the	   fibre	   size	  profile	   towards	   smaller	   fibres	   compared	   to	  electroporation	  with	   the	   control	  
vector	  alone	  (Figure	  22A),	  whereas	  expression	  with	  FHL1	  caused	  a	  small	  shift	  towards	  larger	  
fibres	  (Figure	  22B).	  	  However,	  transfection	  with	  both	  FHL1	  and	  myostatin	  into	  the	  same	  TA	  
caused	  a	  greater	  shift	  towards	  smaller	  fibres	  than	  transfection	  with	  myostatin	  alone	  (Figure	  
22C).	  There	  was	  no	  difference	  in	  the	  fibre-­‐size	  profile	  of	  the	  TA	  expressing	  myostatin	  alone	  
in	  mice	  electroporated	  with	  pCAGGS	  control	  in	  the	  other	  TA,	  compared	  to	  those	  expressing	  
both	   myostatin	   and	   FHL1	   (Figure	   22D).	   Thus,	   the	   effects	   of	   myostatin	   alone	   were	   not	  
affected	  by	  the	  electroporation	  into	  the	  contralateral	  TA.	  Similarly,	  there	  was	  no	  difference	  
in	   the	   fibre	   size	   profile	   of	   TAs	   electroporated	   with	   the	   control	   vector	   (pCAGGS)	   in	   mice	  
electroporated	   with	   myostatin	   or	   FHL1	   in	   the	   other	   TA	   (Figure	   22E).	   The	   fibre	   diameter	  
profiles	   in	   the	   FHL1	   expressing	  muscles	  were	   then	   compared	  with	   those	   expressing	   both	  
FHL1	   and	   myostatin	   (Figure	   22F).	   This	   comparison	   showed	   that	   in	   the	   presence	   of	   FHL1	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Figure	  22	  Changes	  in	  fibre	  distribution	  caused	  by	  FHL1	  and	  myostatin	  over-­‐expression	  
Myostatin	  expression	   increased	   the	  proportion	  of	   small	   diameter	   fibres	   in	   the	  TA	  of	  mice	  
(myostatin	  compared	  to	  pCAGGS	  1	  control	  electroporated	  TAs	  from	  the	  same	  animals	  (n=4),	  
A).	   Electroporation	   of	   FHL1	   increased	   the	   proportion	   of	   larger	   diameter	   fibres	   (B),	   FHL1	  
expression	  compared	  to	  pCAGGS-­‐2	  control	  from	  the	  same	  animals	  (n=4).	  Electroporation	  of	  
FHL1	  and	  myostatin	  together	  caused	  a	  greater	  reduction	  in	  fibre	  diameter	  than	  expression	  
of	   myostatin	   alone	   (myostatin	   +	   FHL1	   compared	   to	   myostatin	   2,	   expression	   in	   the	  
contralateral	  TA	  of	  the	  same	  animals	  (n=4),	  C).	  There	  was	  no	  difference	  in	  the	  distribution	  of	  
fibre	  diameters	   in	  the	  myostatin	  expressing	  TAs,	  caused	  by	  the	  factors	  electroporated	  into	  
the	   contralateral	   leg	   (myostatin	   1	   from	   the	   controls	   group	   and	   myostatin	   2	   from	   the	  
combined	   group	   (n=4),	   E)	   or	   in	   the	   TAs	   electroporated	   with	   control	   vector	   (pCAGGS	   1	  
control	   from	   the	   myostatin	   group,	   pCAGGS	   2	   control	   from	   the	   FHL1	   group	   (n=4),	   D).	  	  
Myostatin	  caused	  a	   larger	  decrease	  in	  fibre	  diameter	   in	  TAs	  expressing	  FHL1	  than	  in	  those	  
not	  expressing	  FHL1	  (compare	  F	  and	  A).	  In	  each	  group,	  80-­‐90	  randomly	  selected	  fibres	  were	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4.2.2.4 Changes	  in	  fibre	  type	  proportion	  
TA	   sections	   were	   stained	   with	   fluorochrome-­‐linked	   antibodies	   for	   each	   fibre	   type	  
and	   analysed	   as	   described	   in	   section	   2.2.14.2.	   Analysis	   of	   fibre	   proportion	   showed	   that	  
myostatin	   over-­‐expression	   caused	   a	   significant	   increase	   in	   the	   proportion	   of	   slower	  more	  
oxidative	   fibre	   types	   (type	   IIA	   and	   IIX)	   and	   a	   concomitant	   decrease	   in	   the	   fast	   more	  
glycolytic	  fibre	  types	  (IIB	  and	  the	  hybrid	  IIX/B,	  Table	  8).	  This	  observation	  is	  consistent	  with	  
the	  effects	  of	  reduced	  myostatin	  levels,	  which	  increase	  the	  proportion	  of	  faster	  fibre	  types.	  
Over-­‐expression	  of	  FHL1	  caused	  a	  significant	  decrease	  in	  type	  IIX	  fibres;	  this	  would	  appear	  
to	  be	   converse	   to	  previous	   studies	   (Cowling	   et	   al.,	   2008).	   In	   the	  myostatin	   +	   FHL1	   group,	  
there	  was	  an	  increase	  in	  the	  oxidative	  fibre	  types	  (IIA/IIX)	  and	  a	  decrease	  in	  the	  hybrid	  type	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Table	  8	  Fibre	  type	  changes	  in	  the	  myostatin,	  FHL1	  and	  myostatin	  +	  FHL1	  groups	  
Over	  expression	  of	  myostatin	  caused	  an	  increase	  in	  the	  proportion	  of	  more	  oxidative	  fibres	  
and	   a	   decrease	   in	   the	   glycolytic	   fibres	   type	   IIB	   and	   IIB/X.	   FHL1	   over-­‐expression	   caused	   a	  
decrease	   in	  the	  proportion	  of	   type	   IIX	   fibres.	  Over	  expression	  of	  both	  myostatin	  and	  FHL1	  
caused	  a	  decrease	  in	  oxidative	  type	  IIA,	  IIX	  fibres	  and	  type	  IIX/B	  hybrid	  fibres,	  although	  this	  
was	   not	   significant.	   Fibre	   proportion	   represented	   as	   mean	   %	   ±	   SEM	   of	   4	   animals.	  
Significance	  tested	  by	  paired	  t-­‐tests.	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4.2.2.5 Changes	  in	  Gene	  expression	  
4.2.2.5.1 Changes	  in	  the	  Myostatin	  –pCAGGs	  group	  
Myostatin	   over-­‐expression	   was	   confirmed	   by	   qPCR	   with	   a	   large	   increase	   in	   the	  
myostatin	   over	   expressing	   TA	   compared	   to	   the	   contralateral	   control	   (4.86	   fold,	   p<0.01)	  
(Table	   9,	   Figure	   23).	   Changes	   in	   myostatin	   signalling	   were	   determined	   by	   examining	   the	  
expression	   of	   Plasminogen	   Activator	   Inhibitor-­‐1	   (Pai-­‐1),	   a	   downstream	   target	   of	   TGF-­‐β	  
family	  signalling,	  which	  increased	  (1.49	  fold,	  p<0.05),	  suggesting	  the	  induction	  of	  myostatin	  
signalling.	  Atrophy	  pathways	  regulated	  by	  myostatin	  were	  also	  examined.	  Surprisingly,	  there	  
was	   a	   trend	   to	   a	   down-­‐regulation	   of	   autophagy	   by	   myostatin	   over	   expression,	   with	   a	  
decrease	  Atg4b	   (0.73	  fold,	  p=0.059)	  and	  Atb12l	   (0.58	  fold,	  p=0.076),	  but	  these	  differences	  
did	  not	  reach	  statistical	  significance.	  No	  other	  changes	  were	  observed	  in	  the	  expression	  of	  
either	   proteasomal	   degradation	   related	   genes	   or	   apoptosis	   related	   genes.	   Instead,	   there	  
was	  an	  up-­‐regulation	  of	  the	  myogenic	  transcription	  factor	  Myogenin	  (1.82	  fold,	  p<0.05).	  In	  
the	  myostatin	   over	   expression	   group,	   there	  was	   a	   large	   and	   significant	   increase	   in	  MyHC	  
type	  I	  expression	  Myhc	  I	  (13.11	  fold,	  p<0.01).	  Concomitantly,	  there	  was	  a	  decrease	  in	  Myhc	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Table	  9	  Gene	  expression	  changes	  in	  the	  myostatin	  group	  compared	  to	  pCAGGS	  control	  	  
Gene	   expression	   data	   of	   myostatin	   over-­‐expression	   group	   normalised	   to	   contra-­‐lateral	  
pCAGGS	   control	   TA,	   post	   normalisation	   to	   geomean	   of	   β2-­‐microglobulin	   and	   RPLPO.	  
Statistical	  significance	  represented	  by	  *	  p<0.05,	  **	  p<0.01	  from	  paired	  t-­‐tests.	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Figure	  23	  Significant	  gene	  expression	  changes	  in	  the	  myostatin	  compared	  to	  the	  pCAGGS	  
control.	  	  
Gene	  expression	  data	  for	  the	  myostatin	  over-­‐expression	  group	  normalised	  to	  contra-­‐lateral	  
pCAGGS	  control	   TA.	   Each	  animal	   is	   represented	  as	  a	   log	  data	  point	  with	   line	  drawn	   to	   its	  
corresponding	  TA.	  Each	  group	  consisted	  of	  4	  animals.	  Significance	  tested	  using	  paired	  t-­‐tests	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4.2.2.5.2 Changes	  in	  the	  FHL1	  –pCAGGs	  group	  
Over-­‐expression	   of	   Fhl1	   was	   analysed	   by	  QPCR,	  which	   showed	   a	   small	   increase	   in	  
Fhl1	  in	  the	  FHL1	  over-­‐expression	  group	  (1.8	  fold,	  p=0.083)	  (Table	  10,	  Figure	  24).	  There	  was	  a	  
trend	  to	  an	  increase	  in	  Vegf-­‐C,	  a	  TGF-­‐β	  signalling	  related	  gene	  (1.2	  fold	  p=0.085)	  and	  a	  trend	  
to	  a	  decrease	  in	  Bax	  expression,	  a	  gene	  involved	  in	  apoptosis	  (0.85	  fold,	  p=0.075).	  However,	  
none	  of	  these	  changes	  reached	  statistical	  significance.	  	  In	  part,	  the	  lack	  of	  changes	  observed	  
in	   the	   group	   may	   have	   arisen	   from	   one	   control	   TA	   with	   very	   high	   endogenous	   FHL1	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Table	  10	  Gene	  expression	  changes	  in	  the	  FHL1	  group	  compared	  to	  pCAGGS	  control.	  
Gene	  expression	  data	  for	  FHL1	  over-­‐expression	  group	  normalised	  to	  contra-­‐lateral	  pCAGGS	  
control	   TA,	   post	   normalisation	   to	   geomean	   of	   β2-­‐microglobulin	   and	   RPLPO.	   Fhl1	   was	  
measured	   700-­‐800bp	   exon	   to	   intron	   boundary.	   Statistical	   significance	   represented	   by	   *	  
p<0.05,	  **	  p<0.01	  from	  paired	  t-­‐tests.	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Figure	   24	   Significant	   gene	   expression	   changes	   in	   the	   FHL1	   compared	   to	   the	   pCAGGS	  
control.	  	  
Each	  animal	  is	  represented	  as	  a	  log	  data	  point	  with	  line	  drawn	  to	  its	  corresponding	  TA.	  Each	  
group	   consisted	   of	   4	   animals.	   Significance	   analysed	   by	   paired	   t-­‐tests	   and	   represented	   as	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4.2.2.5.3 Changes	  in	  the	  Myostatin	  –Myostatin	  +	  FHL1	  group	  
In	   myostatin	   +	   FHL1	   double	   over-­‐expression	   group,	   over-­‐expression	   of	   FHL1	   was	  
confirmed	  by	  Q-­‐PCR	   (1.66	   fold,	   p<0.05,	   Table	  11,	   Figure	  25).	   Examination	  of	   TGF-­‐β	   family	  
signalling	  revealed	  no	  changes	   in	  the	  signalling	  pathway	  compared	  to	  the	  myostatin	  alone	  
expression	  group.	  There	  was	  an	  up-­‐regulation	  of	  autophagy,	  with	  a	  trend	  to	  an	  increase	  in	  
Atg4b	  (1.41	  fold,	  p=0.052)	  and	  a	  significant	  increase	  in	  Atg12l	  (1.46,	  p<0.05)	  expression.	  In	  
the	   myostatin	   +	   FHL1	   group,	   there	   was	   also	   a	   trend	   to	   an	   increase	   in	  Murf1	   (1.27	   fold,	  
p=0.056).	   In	   addition,	   there	   was	   also	   an	   increase	   in	   pro-­‐apoptotic	   related	   genes,	   with	   a	  
significant	  increase	  in	  Bax	  (1.29	  fold,	  p<0.01)	  and	  Bad	  (1.36	  fold,	  p<0.05).	  When	  expression	  
of	  the	  myosin	  heavy	  chains	  were	  examined,	  there	  was	  a	  trend	  to	  an	  increase	  in	  Myhc	  I	  in	  the	  
FHL1	   +	  myostatin	   group	   compared	   to	  myostatin	   (2.99	   fold,	   p=0.075),	   and	   an	   increase	   in	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Table	  11	  Gene	  expression	  changes	  in	  the	  myostatin	  +	  FHL1	  group	  compared	  to	  myostatin	  
control	  	  
Gene	  expression	  data	  for	  the	  myostatin	  +	  FHL1	  over-­‐expression	  group	  normalised	  to	  contra-­‐
lateral	  myostatin	  control	  TA,	  post	  normalisation	  to	  geomean	  of	  β2	  microglobulin	  and	  RPLPO.	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Figure	  25	  Significant	   gene	  expression	   changes	   in	   the	  FHL1	  +	  myostatin	   compared	   to	   the	  
myostatin	  group.	  	  
Each	  animal	  is	  represented	  as	  a	  log	  data	  point	  with	  line	  drawn	  to	  its	  corresponding	  leg.	  Each	  
group	   consisted	   of	   4	   animals.	   Significance	   analysed	   by	   paired	   t-­‐tests	   and	   represented	   as	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4.2.2.6 FHL1	  protein	  expression	  analysis	  	  
TA	  muscles	  were	  processed	  as	  described	  in	  section	  2.2.11.2,	  with	  the	  entire	  length	  of	  
the	  TA	  sectioned	  into	  levels.	  Alternate	  levels	  of	  the	  TA	  extracted	  for	  RNA	  and	  protein.	  The	  
highest	   levels	   of	   electroporation	   were	   supposedly	   between	   halfway	   to	   two	   thirds	   of	   the	  
length	  of	  the	  TA.	  Three	  alternate	  levels	  (level	  5,	  7	  and	  9)	  were	  processed	  for	  RNA	  and	  levels	  
of	   FHL1	  measured.	   The	   level	  with	   the	   greatest	   FHL1	   expression	  was	   used	   for	   subsequent	  
gene	  expression,	  and	  protein	  analysis.	  
	  
4.2.2.6.1 FHL1	  immuno-­‐fluorescent	  staining	  
Confirmation	   of	   FHL1	   expression	   through	   analysis	   of	   immuno-­‐staining	   was	  
inconclusive.	   The	   localisation	   of	   the	   staining	   appeared	   to	   be	   in	   accordance	   with	   FHL1	  
expression	   in	  normal	  humans	  where	   in	  most	  cases,	  FHL1	   immuno-­‐staining	  appeared	  to	  be	  
mainly	  sarcoplasmic	  (Schessl	  et	  al.,	  2008).	  However,	  the	  staining	  was	  not	  particularly	  strong	  
in	  all	  groups	  despite	  the	  fact	  that	  the	  FHL1	  antibody	  has	  previously	  been	  verified	  by	  western	  
blot	   in	   cell	   culture	   and	   in	   another	   FHL1	   over	   expression	   animal	   model.	   There	   was	  
considerable	  variance	  in	  FHL1	  protein	  expression	  within	  the	  over-­‐expression	  groups	  as	  well	  
as	   between	   the	   groups,	   even	  between	   the	   FHL1	   and	   empty	   vector	   control	   TA	   (Figure	   26,	  
Figure	  27	  and	  Figure	  28).	  Although	  there	  were	  a	  number	  of	  centralised	  nuclei,	  there	  was	  no	  
difference	   in	   the	   number	   of	   centralised	   and	   non-­‐centralised	   nuclei	   across	   groups.	  
Optimisation	   for	   SMAD2/3	   and	   phosphorylated	   SMAD2/3	   was	   not	   successful	   for	   either	  
immuno-­‐fluorescent	  staining	  or	  western	  blotting.	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Figure	  26	  FHL1	  immuno-­‐staining	  in	  the	  myostatin	  over	  expression	  group.	  
There	   was	   little	   to	   no	   FHL1	   expression	   in	   the	   myostatin	   over	   expression	   group.	  
Representative	  images	  of	  the	  whole	  TA	  of	  4	  mice,	  with	  nuclei	  stained	  with	  DAPI,	  and	  FHL1	  
immuno-­‐fluorescence	   viewed	   in	   the	   green	   channel.	   Scale	   bar	   represents	   100µm,	   images	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Figure	  27	  FHL1	  immuno	  staining	  in	  the	  FHL1	  over	  expression	  group	  
There	  was	  a	  degree	  of	  FHL1	  expression	   in	   the	  FHL1	  over	  expression	  group	  and	  the	  empty	  
vector	   control,	   but	   the	   difference	   between	   the	   two	   groups	   was	   not	   appreciably	   strong.	  
Representative	  images	  of	  the	  whole	  TA	  of	  4	  mice,	  with	  nuclei	  stained	  with	  DAPI,	  and	  FHL1	  
immuno-­‐fluorescence	   viewed	   in	   the	   green	   channel.	   Scale	   bar	   represents	   100µm,	   images	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Figure	  28	  FHL1	  immuno-­‐staining	  in	  the	  myostatin	  +	  FHL1	  over	  expression	  group	  
There	  was	  little	  to	  no	  FHL1	  expression	  in	  the	  myostatin	  over	  expression	  group,	  and	  a	  slight	  
increase	   in	   FHL1	   expression	   in	   one	   of	   the	   mice	   in	   the	   group,	   however,	   this	   was	   not	  
significantly	  so.	  Representative	  images	  of	  the	  whole	  TA	  of	  4	  mice,	  with	  nuclei	  stained	  with	  
DAPI,	   and	   FHL1	   immuno-­‐fluorescence	   viewed	   in	   the	   green	   channel.	   Scale	   bar	   represents	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4.2.2.6.2 FHL1	  expression	  by	  western	  blotting	  
Protein	  lysates	  from	  TA	  levels	  adjacent	  to	  those	  analysed	  for	  gene	  expression	  were	  
analysed	  for	  FHL1	  expression	  by	  western	  blotting.	  Western	  analysis	  showed	  the	  detection	  of	  
all	  3	  FHL1	  isoforms:	  1-­‐36kDa,	  2-­‐	  33kDa,	  and	  3-­‐	  31kDa	  in	  the	  mice.	  However,	  FHL1	  isoform	  3,	  
the	   smallest	   isoform,	   is	   the	   isoform	   that	  was	  over-­‐expressed	  and	   indeed	   it	   appears	   to	  be	  
more	  consistently	  expressed	  throughout	  the	  different	  groups	  of	  mice	   in	   the	  western	  blots	  
(Figure	   29).	   Quantitation	   by	   densitometry	   showed	   that	   there	   was	   no	   increase	   in	   FHL1	  
protein	   expression	   in	   the	   FHL1	   over-­‐expression	   group	   compared	   to	   the	   pCAGGS	   empty	  
vector	  control	  or	  in	  the	  FHL1	  +	  myostatin	  TA	  compared	  to	  the	  myostatin	  only	  TA.	  Levels	  of	  
FHL1	   were	   also	   detected	   in	   the	   non-­‐electroporated	   control.	   In	   the	   myostatin	   over-­‐
expression	   group,	   FHL1	  was	   lowly	   expressed	   in	   general,	  whilst	   the	  pCAGGS	   control	   group	  
showed	  higher	  expression	  levels	  than	  the	  myostatin	  TA.	  In	  addition,	  the	  non-­‐electroporated	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Figure	   29	   FHL1	   protein	   expression	   in	   FHL1,	   myostatin,	   and	   FHL1	   +	   myostatin	  
electroporation	  groups	  
FHL1	   protein	   levels	   were	   measured	   by	   western	   analysis	   (A).	   There	   were	   no	   consistent	  
changes	  in	  any	  groups.	  Levels	  of	  FHL1	  a,	  b	  and	  c	  were	  detected	  and	  normalised	  to	  α-­‐tubulin.	  
Graph	  of	  quantification	  of	  densitometry	  shown	  below.	  Groups	  shown	  in	  corresponding	  pairs	  
with	   contralateral	   TA	   adjacent	   (B,	   red-­‐	   myostatin	   group,	   blue-­‐	   FHL1	   group	   and	   orange-­‐	  
myostatin	  +	  FHL1	  group).	  A	  single	  non-­‐electroporated	  mouse	  muscle	  lysate	  was	  loaded	  onto	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4.2.3 Does	  FHL1	  modify	  atrophy	  response	  in	  other	  stimuli	  in	  vitro?	  
The	   data	   above	   has	   shown	   that	   FHL1	   can	   modify	   myostatin	   signalling	   in	   skeletal	  
muscle.	   In	  order	   to	  ascertain	  whether	  other	  atrophy	  signalling	  pathways	  were	  affected	  by	  
FHL1,	   similar	   in	   vitro	   experiments	   were	   performed	   with	   other	   atrophy	   stimuli	   that	   were	  
examined	  in	  Chapter	  2-­‐	  GDF-­‐15	  and	  ang-­‐II.	  	  	  
4.2.3.1 GDF-­‐15	  does	  not	  appear	  to	  signal	  through	  SMAD	  proteins	  
To	  determine	  whether	  FHL1	  could	  affect	  GDF-­‐15	  induced	  SMAD	  signalling,	  FHL1	  was	  
transiently	  transfected	  into	  C2C12	  cells	  either	  in	  the	  presence	  or	  absence	  of	  GDF-­‐15.	  Based	  
on	  the	  results	  from	  section	  3.2.4,	  cells	  were	  treated	  with	  a	  range	  of	  GDF-­‐15	  concentrations	  
from	   0,	   1,	   10,	   20	   and	   50ng/ml.	   Using	   the	   p(CAGA)12	   promoter,	   no	   increase	   in	   luciferase	  
activity	   was	   observed	   at	   any	   dose	   of	   GDF-­‐15	   and	   no	   consistent	   concentration	   response	  
could	   be	   obtained	   (Figure	   30).	   However,	   at	   50ng/ml	   there	  was	   a	   trend	   to	   an	   increase	   in	  
luciferase	  activity	  but	  only	  in	  the	  presence	  of	  FHL1,	  but	  this	  did	  not	  reach	  significance	  (pC-­‐
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Figure	  30	  FHL1	  does	  not	  potentiate	  GDF-­‐15	  induced	  SMAD	  signalling.	  
Interaction	  between	  FHL	  proteins	  and	  GDF-­‐15	  induced	  SMAD	  signalling	  was	  also	  assessed	  by	  
using	  the	  SMAD	  luciferase	  reporter	  p(CAGA)12.	  	  GDF-­‐15	  treatment	  did	  not	  cause	  a	  consistent	  
induction	  of	  SMAD	  signalling,	  nor	  was	  there	  a	  great	  effect	  with	  FHL1	  over-­‐expression.	  There	  
was	  an	  increase	  at	  50ng/ml,	  which	  was	  not	  significant.	  Data	  represented	  as	  mean	  ±	  SEM,	  of	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4.2.3.2 GDF-­‐15	  induces	  myotube	  wasting	  	  
	   To	   examine	   the	   effect	   of	   GDF-­‐15	   and	   FHL1	   on	   myotube	   width,	   FHL1	   was	   over-­‐
expressed	  in	  the	  presence	  and	  absence	  of	  GDF-­‐15	  and	  myotube	  width	  was	  measured.	  GDF-­‐
15	  caused	  a	  reduction	  in	  myotube	  diameter,	  compared	  to	  vehicle	  control	  both	  at	  48	  h	  (GDF-­‐
15	   17.8μm	   (14.9,	   21.8),	   Control	   21.3μm,	   (17.4,	   29.9)	   p<0.001)	   and	   96	   h	   (GDF-­‐15	   20.0μm	  
(17.0,	  24.3),	  Control	  (22.6um	  (17.9,	  29.4)	  p<0.001)	  (Figure	  31,	  Figure	  32).	  In	  the	  presence	  of	  
FHL1,	  GDF-­‐15	  caused	  a	  reduction	  in	  myotube	  width	  compared	  to	  FHL1	  alone	  at	  48	  h	  (FHL1	  +	  
GDF-­‐15	   18.7μm,	   (15.6,	   22.3),	   FHL1	   23.3μm	   (19.5,	   27.3)	   p<0.001).	   At	   96	   h,	   GDF-­‐15	   also	  
caused	  a	  decrease	  in	  myotube	  diameter	  in	  FHL1	  expressing	  cells,	  however	  the	  reduction	  was	  
milder	   compared	   to	   48h	   (FHL1+	   GDF-­‐15	   19.8μm	   (16.6,	   22.6),	   FHL1	   23.7μm	   (20.0,	   30.6),	  
p<0.01).	  In	  these	  sets	  of	  experiments,	  FHL1	  did	  not	  cause	  hypertrophy	  of	  myotube	  diameter	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Figure	  31	  GDF-­‐15	  induces	  myotube	  wasting	  
C2C12	  myotubes	  either	  expressing	  FHL1	  or	  pCDNA	  were	  treated	  with	  GDF-­‐15	  or	  untreated.	  
There	  was	  no	  effect	  of	  pCDNA	  vehicle.	  However,	  wasting	  was	  induced	  when	  myotubes	  were	  
treated	  with	  50ng/ml	  GDF-­‐15.	  In	  this	  instance,	  FHL1	  over-­‐expression	  did	  not	  cause	  myotube	  
hypertrophy.	   In	  the	  presence	  of	  GDF-­‐15	  +	  FHL1,	  myotube	  diameter	  was	  reduced,	  however	  
not	  to	  a	  greater	  extent	  than	  with	  GDF-­‐15	  alone.	  Graphs	  show	  medians	  with	  IQR	  of	  myotube	  
diameter	  after	  48	  (A)	  and	  96	  h	  (B)	  of	  treatment,	  with	  each	  data	  point	  representing	  the	  mean	  
diameter	  of	  each	  myotube	  measured	  within	  each	  different	  group.	  From	  each	  treatment,	  70-­‐
110	   myotubes	   measured	   from	   20-­‐25	   fields	   of	   view.	   Data	   represent	   pooled	   data	   from	   3	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Figure	  32	  Effect	  of	  GDF-­‐15	  and	  FHL1	  on	  myotubes	  
C2C12	  myotubes	  either	  expressing	  FHL1	  or	  pCDNA	  were	  treated	  with	  GDF-­‐15	  or	  untreated.	  
Panel	  A	  shows	  representative	   images	  of	  myotubes	   from	  each	  treatment	  group.	  There	  was	  
no	  effect	  of	  pCDNA	  vehicle.	  However,	  wasting	  was	   induced	  when	  myotubes	  were	   treated	  
with	   50ng/ml	   GDF-­‐15.	   In	   this	   instance,	   FHL1	   over-­‐expression	   did	   not	   cause	   myotube	  
hypertrophy.	   In	  the	  presence	  of	  GDF-­‐15	  +	  FHL1,	  myotube	  diameter	  was	  reduced,	  however	  
not	  to	  a	  greater	  extent	  than	  with	  GDF-­‐15	  alone.	  Images	  captured	  at	  10x	  magnification.	  Scale	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4.2.3.3 Ang-­‐II	  in	  myotube	  wasting	  
A	   similar	   set	   of	   experiments	  was	   repeated	   in	   the	   presence	   and	   absence	   of	   ang-­‐II.	  
Ang-­‐II	   caused	   a	   reduction	   in	   myotube	   diameter	   compared	   to	   DMSO	   control,	   both	   at	   48	  
(pCDNA	   +	   Ang-­‐II	   35.9μm,	   27.0,	   40.8,	   pCDNA	  DMSO	   40.8μm,	   32.1,	   50.1	   p<0.001)	   and	   96h	  
(pCDNA	  +	  Ang-­‐II	  32.4μm,	  28.4,	  43.1,	  pCDNA	  DMSO	  43.8μm,	  34.4,	  54.2,	  p<0.001)	  (Figure	  33,	  
Figure	   34).	   There	  was	   also	   a	   decrease	   in	   FHL1	   +	   ang-­‐II	   compared	   to	   FHL1	   DMSO	   treated	  
myotubes	  at	  96	  h	  (FHL1	  ANG-­‐II	  35.7μm,	  29.2,	  45.5,	  FHL1	  DMSO	  39.4μm,	  31.3,	  49.8	  p=0.068),	  
although	  this	  did	  not	  reach	  significance.	  Although	  FHL1	  still	  caused	  an	  increase	  in	  myotube	  
width	   in	   the	   absence	   of	   DMSO	   vehicle,	   seen	   at	   48h	   (FHL1-­‐	   40.7μm,	   33.1,	   48.1,	   pCDNA	  
35.7μm,	   28.9,	   46.2	   p<0.05),	   this	   effect	   was	   not	   observed	   in	   the	   presence	   of	   the	   vehicle.	  
Furthermore,	   prolonged	   exposure	   to	   DMSO	   appeared	   to	   cause	   an	   increase	   in	   myotube	  
diameter,	   as	   there	  was	  a	   trend	   to	  an	   increase	   in	  diameter	  with	  DMSO	  compared	   to	  FHL1	  
DMSO	  (DMSO	  43.8μm,	  34.4,	  54.2,	  FHL1+	  DMSO	  39.4μm,	  31.3,	  45.5,	  p=0.051)	  at	  96	  h,	  again	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Figure	  33	  FHL1	  did	  not	  enhance	  ang-­‐II	  induced	  myotube	  wasting	  
C2C12	   myotubes	   either	   expressing	   FHL1	   or	   pCDNA	   were	   treated	   with	   ang-­‐II	   or	   vehicle	  
control.	   There	  was	  no	  effect	   of	   pCDNA	  vehicle	  or	   pCDNA	  horse	   serum.	  However,	  wasting	  
was	  induced	  when	  myotubes	  were	  treated	  with	  1μM	  ang-­‐II,	  both	  at	  48	  and	  96h.	  There	  was	  a	  
trend	  to	  a	  decrease	  with	  ang-­‐II	  and	  FHL1	  compared	  to	  FHL1	  vehicle.	  Again,	  in	  this	  instance,	  
there	   was	   no	   significant	   myotube	   hypertrophy	   compared	   to	   FHL1	   vehicle	   compared	   to	  
vehicle.	  However,	  FHL1	  did	  cause	  hypertrophy	  in	  horse	  serum	  alone.	  Graphs	  show	  medians	  
with	  IQR	  of	  myotube	  diameter	  after	  48	  (A)	  and	  96	  h	  (B)	  of	  treatment,	  with	  each	  data	  point	  
representing	   the	  mean	  diameter	  of	   each	  myotube	  measured	  within	   each	  different	   group.	  
From	  each	  treatment,	  70-­‐80	  myotubes	  measured	  from	  20-­‐25	  fields	  of	  view.	  Data	  represent	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Figure	  34	  Effect	  of	  ang-­‐II	  and	  FHL1	  myotubes	  
C2C12	   myotubes	   either	   expressing	   FHL1	   or	   pCDNA	   were	   treated	   with	   ang-­‐II	   or	   vehicle	  
control.	   Representative	   images	   of	   myotubes	   from	   each	   treatment	   group	   shown	   below.	  
There	   was	   no	   effect	   of	   pCDNA	   vehicle	   or	   pCDNA	   horse	   serum.	   However,	   wasting	   was	  
induced	   when	   myotubes	   were	   treated	   with	   1μM	   ang-­‐II,	   both	   at	   48	   and	   96h.	   Images	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4.3 Discussion	  
Overall,	   the	   data	   presented	   in	   the	   chapter	   provides	   a	   strong	   argument	   for	   a	  
biological	  interaction	  between	  FHL1	  and	  myostatin.	  FHL1	  enhanced	  myostatin	  signalling	  at	  a	  
sub-­‐threshold	   concentration	   and	   this	   enhancement	   could	   be	   visualised	   in	   the	   wasting	   of	  
myotubes	   in	   culture.	   This	   in	   vitro	   data	   in	   both	   myoblasts	   and	   myotubes	   has	   evidently	  
translated	   in	   a	  mouse	  model,	   in	  which	   all	   of	   the	   protein	   degradation	   pathways	  were	   up-­‐
regulated	   in	   the	  myostatin	   +	   FHL1	   expression	   group.	   Together,	   this	   data	   provides	   strong	  
evidence	   that	   the	   modulation	   of	   myostatin	   signalling	   and	   indeed	   TGF-­‐β	   superfamily	  
signalling	  by	  FHL1,	  could	  be	  the	  mechanism	  by	  which	  selective	  wasting	  of	  type	  II	  fibres	  occur	  
in	  diseases	  such	  as	  COPD.	  
In	  the	  luciferase	  assays,	  myostatin	  was	  a	  weaker	  inducer	  of	  the	  p(CAGA)12	  promoter	  
than	  TGF-­‐β	  (approximately	  10	   fold),	  such	  that	  concentrations	  of	  myostatin	  below	  50ng/ml	  
did	  not	   illicit	  an	  detectable	  p(CAGA)12	  response,	  suggesting	  different	  receptor	  affinities	   for	  
myostatin	   and	  TGF-­‐β.	   The	   ligand	   specificity	   is	   determined	  by	   the	   type	   II	   receptor	   (i.e.	   the	  
TGF-­‐β	  receptor	  type	  II	  (TβRII)	  for	  TGF-­‐β	  and	  activin	  receptor	  type	  II	  (ActRII)	  for	  myostatin).	  
TβRII	  and	  TβRI	  are	  thought	  to	  be	  specific	  for	  TGF-­‐β,	  whilst	  other	  serine	  threonine	  receptor	  
kinases	  including	  ActRII,	  are	  thought	  to	  bind	  more	  promiscuously	  (Massagué,	  1998,	  Attisano	  
and	   Wrana,	   2002),	   suggesting	   a	   less	   specific	   affinity	   for	   myostatin.	   Myostatin	   has	   been	  
shown	   to	   induce	   TGF-­‐β	   production	   and	   can	   instigate	   different	   signalling	   cascades	   such	   as	  
the	   JNK	  TAK1	  pathway	   (Huang	  et	  al.,	  2007,	  Huang	  et	  al.,	  2011).	   	  C2C12	  myoblasts	   treated	  
with	   TGF-­‐β	   responded	   very	   similarly	   to	   levels	   observed	   previously	   in	   human	   glioblastoma	  
cells	  (Piek	  et	  al.,	  1999).	  
	   154	  
FHL	   proteins	   have	   been	   shown	   to	   interact	   physically	   and	   functionally	   with	   SMAD	  
proteins,	  even	  in	  the	  absence	  of	  TGF-­‐β	  (Ding	  et	  al.,	  2009).	  The	  above	  data	  shows	  that	  FHL1	  
can	   indeed	   both	   activate	   and	   potentiate	   TGF-­‐β	   induced	   SMAD	   signalling	   in	   muscle	   cells.	  
Furthermore,	   the	   data	   above	   is	   additionally	   supported	   by	   data	   from	   Dr	   Susy	   Bloch,	   who	  
obtained	  similar	  results	  in	  differentiating	  myoblasts	  (data	  unpublished).	  	  
The	   observations	   presented	   here	   on	   the	   effect	   of	   FHL1	   on	   myostatin	   dependent	  
luciferase	  activity	  were	  corroborated	  by	   in	  vitro	  studies	  on	  myotube	  diameter	  where	  FHL1	  
facilitated	  myostatin	  dependent	  wasting	  at	   low	  myostatin	  concentrations.	  Previous	  studies	  
by	  Lokireddy	  et	  al.,	  have	  shown	  that	  at	  3-­‐5μg/ml,	  myostatin	  can	   induce	  wasting	   in	  human	  
skeletal	   muscle	   myotubes	   (Lokireddy	   et	   al.,	   2011).	   Here,	   a	   much	   lower	   concentration	   of	  
20ng/ml	   was	   used	   and	   as	   anticipated,	   no	   effect	   on	   myotube	   diameter	   was	   observed.	  
However,	  when	  FHL1	  was	  over	  expressed	  with	  myostatin,	  there	  was	  a	  significant	  reduction	  
in	   myotube	   diameter.	   The	   over-­‐expression	   of	   FHL1	   in	   these	   myotubes	   resulted	   in	  
hypertrophy,	  which	  was	  consistent	  with	  the	  study	  performed	  by	  Cowling	  et	  al.	  (Cowling	  et	  
al.,	   2008).	   However,	   given	   the	   length	   of	   the	   experiment	   (approximately	   2	   weeks	   from	  
transfection	   to	   imaging),	   the	   over-­‐expression	   of	   FHL1	  may	   have	   declined	   after	   96h	   from	  
treatment	   (14	   days	   from	   transfection)	   as	   the	   hypertrophic	   effect	   was	   diminished	   or	   the	  
recruitment	  of	   satellite	  cells	  during	  differentiation	  may	  have	  diluted	  FHL1	  expression.	   It	   is	  
possible	  that	  a	  greater	  effect	  of	  myostatin	  and	  FHL1	  would	  be	  observed	  at	  an	  earlier	  time	  
point;	   equally	   however,	   the	   cells	   may	   not	   be	   fully	   differentiated.	   Regardless	   of	   the	  
limitations	   of	   the	   length	   of	   FHL1	   expression,	   the	   functional	   interaction	   observed	   in	  
myoblasts	  was	  demonstrated	  in	  vitro.	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The	   interaction	  between	  FHL1	  and	  myostatin	  was	   then	  observed	   in	  a	   small	   in	   vivo	  
study,	   by	   over-­‐expressing	   FHL1	   and	   myostatin	   in	   the	   TA	   of	   adult	   mice.	   The	   data	   above	  
proves,	   to	   an	   extent,	   the	   biological	   existence	   of	   the	   interaction	   of	   FHL1	   on	   myostatin	  
signalling	   in	  vivo.	  FHL1	  enhances	  myostatin	  signalling,	  and	   increases	  the	  atrophy	  signalling	  
pathways:	  proteasomal	  degradation,	  apoptosis	  and	  autophagy,	  thus	  implicating	  FHL1	  in	  the	  
loss	  of	  muscle	  mass.	  
Although	  the	  effect	  of	  myostatin	  over-­‐expression	  on	  gene	  expression	  did	  appear	  to	  
be	   similar	   to	   other	   studies,	   i.e.	   the	   increase	   in	   oxidative	   myosin	   heavy	   chain	   gene	  
expression,	   the	   increase	   in	  autophagy	  observed	   in	  vitro	  was	  not	  mirrored	   in	  vivo;	   rather	  a	  
compensatory	  increase	  in	  myogenesis	  was	  observed.	  However,	  measurement	  of	  autophagy	  
at	   a	   single	   time	   point	   may	   be	   misleading	   as	   autophagy	   may	   have	   been	   increased	   at	   an	  
earlier	  time	  point	  then	  fallen	  to	  basal	  levels	  as	  shown	  in	  cell	  culture	  in	  section	  3.2.3.	  Equally,	  
the	   fibre	   atrophy	   in	   the	   myostatin	   over-­‐expression	   may	   have	   been	   caused	   by	   another	  
pathway.	  Whilst	   few	   changes	  were	   observed	   in	   the	   individual	   over-­‐expression	   groups	   for	  
myostatin	   or	   FHL1	   alone,	   there	   were	   significant	   changes	   the	   signalling	   pathways	   in	   the	  
myostatin	  +	  FHL1	  group.	  In	  the	  co-­‐over-­‐expression	  group,	  there	  was	  an	  up-­‐regulation	  of	  all	  
atrophy	  related	  pathways:	  autophagy,	  proteasomal	  degradation	  and	  apoptosis.	  The	  in	  vitro	  
data	   suggested	   that	   FHL1	   enhanced	   downstream	   myostatin	   signalling.	   This	   data	   would	  
support	   the	   notion	   that	   FHL1	   augments	   downstream	   myostatin	   signalling	   and	   has	   an	  
additive	  effect	  on	  the	  signalling	  pathways	  that	  myostatin	  regulates.	  Given	  the	  association	  of	  
both	   FHL1	   and	   myostatin	   with	   type	   II	   fibres,	   this	   data	   would	   suggest	   that	   FHL1	   enables	  
myostatin	   to	   selectively	   cause	   wasting	   in	   certain	   fibre	   types.	   One	   caveat	   to	   this	  
interpretation	   is	   the	   low	   levels	  of	   FHL1	  gene	  expression,	   	   given	   that	   FHL1	  expression	  was	  
measured	  at	  an	  exon-­‐intron	  boundary,	  however,	  this	  may	  again	  to	  due	  to	  the	  time	  the	  TAs	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were	   harvested	   and	   expression	   levels	   after	   14	   days.	   Another	   limitation	   is	   the	   inability	   to	  
observe	  increased	  FHL1	  protein	  in	  the	  electroporated	  muscles	  as	  discussed	  below.	  	  	  
In	   comparison	   to	   Durieux’s	   work,	   the	  myostatin	   over-­‐expression	  work	   is	   strikingly	  
similar;	   they	   observed	   a	   reduction	   in	   fibre	   cross	   sectional	   area	   as	   well	   as	   a	   reduction	   in	  
muscle	  mass	  (Durieux	  et	  al.,	  2007).	  Indeed,	  Durieux	  et	  al.	  also	  observed	  no	  changes	  in	  fibre	  
proportion	   even	   though	   20	   times	   as	   much	   plasmid	   DNA	   was	   used	   in	   their	   model.	   The	  
increase	   in	   fibre	   diameter	   observed	   in	   FHL1	   over-­‐expression	   is	   consistent	   with	   the	  
observations	   of	   Cowling	  et	   al.	  who	  observed	   a	   20%	   increase	   in	   gastrocnemius	   fibre	   cross	  
sectional	   area	   and	   a	   fibre	   shift	   with	   an	   increase	   in	   the	   proportion	   of	   type	   IIA	   fibres	   in	  
transgenic	  mice	  where	  the	  increase	  in	  FHL1	  expression	  occurred	  at	  6	  and	  12	  weeks	  of	  age	  
(Cowling	  et	  al.,	  2008).	  	  
The	   changes	   in	   the	   fibre	   diameter	   observed	   in	   the	  mice	  were	   consistent	  with	   the	  
changes	  observed	   in	   vitro.	   There	  was	   a	   reduction	   in	   fibre	  diameter	   in	   the	  myostatin	  over	  
expression	  group	  and	  a	   converse	   increase	   in	   the	  FHL1	  over	  expression	  group,	   in	   line	  with	  
other	  over	  expression	  studies	   (Reisz-­‐Porszasz	  et	  al.,	  2003,	  Cowling	  et	  al.,	  2008,	  Durieux	  et	  
al.,	  2007).	  Most	  importantly,	  the	  myostatin	  +	  FHL1	  group	  showed	  that	  there	  was	  an	  additive	  
effect	  of	  myostatin	  with	  FHL1	  and	  a	  greater	  decrease	   in	   fibre	  diameter	   in	   line	  with	   the	   in	  
vitro	   data	   and	   that	   consistent	   with	   these	   changes,	   FHL1	   enhanced	   the	   expression	   of	  
UPS/autophagy/apoptosis	  associated	  genes.	  	  
In	   the	   myostatin	   over	   expression	   group,	   there	   was	   a	   significant	   change	   in	   the	  
proportion	  of	  the	  fibre	  types	  to	  the	  more	  oxidative	  slow	  twitch	  type	  II	  fibres,	  indicating	  that	  
myostatin	  does	   indeed	  exert	   its	  effects	  on	  the	  fast	  twitch	  fibres	  and	  perhaps	  causes	  these	  
fibres	  to	  waste	  more	  than	  the	  slower	  twitch	  type	  II	  fibres.	  There	  was	  a	  significant	  decrease	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in	  the	  proportion	  of	  type	  IIX	  fibres	  in	  the	  FHL1	  over	  expression	  group,	  however,	  Cowling	  et	  
al.	   observed	   a	   significant	   increase	   in	   type	   IIA	   fibres	   (Schessl	   et	   al.,	   2008,	   Cowling	   et	   al.,	  
2008).	   Durieux	   et	   al.	   observed	   a	   decrease	   in	   type	   IIB	   and	   IIX	   mRNA	   expression,	   and	  
conversely	   in	  myostatin	  null	  mice,	   there	   is	  an	   increase	   in	  the	  percentage	  of	  type	   IIB	   fibres	  
accompanied	  by	  a	  decrease	  in	  type	  IIA	  fibres	  (Hennebry	  et	  al.,	  2009,	  Durieux	  et	  al.,	  2007).	  In	  
line	  with	   these	   studies,	   there	  was	   an	   increase	   in	   the	  proportion	  of	   type	   IIA	   and	  decrease	  
type	  IIB	  observed	  in	  the	  myostatin	  over-­‐expressing	  mice.	  However,	  in	  the	  myostatin	  +	  FHL1	  
group,	  there	  were	  no	  consistent	  or	  significant	  changes	  in	  fibre	  type	  proportion.	  	  
FHL1	  over-­‐expression	  was	  analysed	  by	  measuring	  FHL1	  protein	  expression	  using	  both	  
western	   blotting	   and	   immunofluorescence.	   However,	   both	   techniques	   failed	   to	   detect	   an	  
increase	   in	   FHL1	   expression	   14	   days	   after	   electroporation.	   The	   presence	   of	   a	   significant	  
amount	   of	   basal	   FHL1	   expression	   in	   the	   TA	   before	   electroporation,	   may	   account	   for	   the	  
difficulty	   in	   detecting	   an	   increase	   in	   expression	   after	   electroporation	   (i.e.	   above	   a	   higher	  
background	  level).	  The	  FHL1	  antibody	  has	  been	  verified	  in	  cell	  culture	  and	  in	  another	  FHL1	  
over-­‐expression	   animal	   model	   within	   the	   group	   (data	   unpublished).	   Additionally,	   the	  
marked	   decrease	   in	  myostatin	   expression	   14	   days	   after	   electroporation	   is	   similar	   to	   that	  
observed	  by	  Durieux	  et	  al.	  The	   lack	  of	  FHL1	  expression	  may	  also	  be	  a	  consequence	  of	   the	  
decreased	  expression	  after	  14	  days;	  perhaps	  examining	  expression	  earlier	  would	  result	  in	  an	  
increase	  in	  FHL1	  over-­‐expression,	  and	  thus	  a	  larger	  increase	  compared	  to	  baseline	  to	  detect.	  
Furthermore,	  the	  length	  of	  time	  the	  plasmids	  were	  expressing	  in	  the	  muscle	  may	  affect	  the	  
levels	   of	   FHL1	  over-­‐expression	   in	   this	  model	   compared	   to	  others.	   The	   levels	   of	   FHL1	  may	  
have	   rapidly	   decreased	   after	   the	   initial	   electroporation	   or	   the	   pCAGGS	   promoter	   may	  
express	  differently	  in	  female	  and	  male	  mice-­‐	  these	  factors	  may	  also	  affect	  gene	  expression	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in	   this	  model	   compared	   to	   others.	   Due	   to	   time	   constraints,	   analysis	   of	  myostatin	   protein	  
expression	  could	  not	  be	  optimised.	  	  
GDF-­‐15	   is	   a	   member	   of	   the	   TGF-­‐β	   super	   family	   and	   has	   been	   associated	   with	  
cachexia	   in	   other	   diseases	   (Johnen	   et	   al.,	   2007,	   Tsai	   et	   al.,	   2012).	   Firstly,	   the	   interaction	  
between	   FHL1	   and	   GDF-­‐15	   induced	   p(CAGA)12	   signalling	   was	   examined;	   at	   the	   range	   of	  
concentrations	   used,	   no	   robust	   luciferase	   response	   was	   observed,	   and	   FHL1	   weakly	  
augmented	  this	  response	  at	  the	  highest	  concentration	  used.	  This	  data	  suggests	  that	  GDF-­‐15	  
may	   not	   signal	   via	   the	   same	   intermediary	   as	   myostatin	   (i.e.	   SMAD	   proteins)	   or	   perhaps	  
different	   concentrations	   of	   GDF-­‐15	  would	   generate	   a	   detectable	   luciferase	   response.	   The	  
data	  above	  has	  also	  demonstrated	  that	  GDF-­‐15	   induces	  myotube	  wasting;	  however,	   there	  
was	  no	  further	  reduction	  of	  myotube	  diameter	   in	  the	  presence	  of	  FHL1,	  thus	  the	  effect	  of	  
FHL1	  could	  not	  be	  delineated	  from	  that	  of	  GDF-­‐15.	  In	  addition,	  in	  these	  sets	  of	  experiments,	  
FHL1	  untreated	  myotubes	  were	  not	  larger	  than	  pCDNA	  untreated	  myotubes.	  This	  difference	  
in	   the	   interaction	   of	   GDF-­‐15	   with	   FHL1	   compared	   to	   myostatin	   may	   be	   due	   to	   the	  
concentration	  of	  GDF-­‐15	  used,	   i.e.	  a	  maximal	   concentration	  of	  GDF-­‐15	  may	  not	  allow	  any	  
further	  myotube	  wasting.	  Furthermore,	  there	  may	  be	  reduced	  FHL1	  expression	  due	  to	  poor	  
FHL1	   transfection	   efficiency.	   One	   possibility	  would	   be	   to	   examine	   gene	   expression	   in	   the	  
presence	   of	   FHL1	   in	  myotubes.	   Lastly,	   the	  myotube	   data	  may	   simply	   reflect	   that	   GDF-­‐15	  
does	   not	   signal	   through	   SMAD	   proteins,	   which	  may	   be	   the	   interacting	   intermediary	  with	  
FHL1.	  	  
There	  are	  also	  other	  lines	  of	  evidence	  suggesting	  that	  GDF-­‐15	  signals	  via	  a	  different	  
signalling	   mechanism	   to	   other	   TGF-­‐β	   superfamily	   members.	   GDF-­‐15	   has	   been	   shown	   to	  
signal	   via	  MAP	   kinases	   (Johnen	   et	   al.,	   2007,	   Subramaniam	  et	   al.,	   2003).	   Although	  GDF-­‐15	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appears	   to	   use	   a	   slightly	   different	   pathway	   to	   TGF-­‐β	   and	   myostatin,	   the	   exact	   signalling	  
pathways	  used	  to	  induce	  atrophy	  have	  yet	  to	  be	  elucidated.	  The	  data	  presented	  above	  does	  
however,	   provide	   evidence	   to	   support	   the	   role	   of	   GDF-­‐15	   in	   muscle	   wasting,	   which	   is	  
additional	  to	  data	  observed	  within	  the	  group	  showing	  that	  patients	  recovering	  from	  cardio-­‐
thoracic	   surgery	   with	   muscle	   wasting	   had	   higher	   levels	   of	   serum	   GDF-­‐15	   compared	   to	  
patients	  that	  did	  not	  waste	  (Bloch	  et	  al.,	  2013,	  Johnen	  et	  al.,	  2007).	  
Although	   ang-­‐II	   is	   not	   a	   member	   of	   the	   TGF-­‐β	   superfamily;	   ang-­‐II	   signalling	   does	  
induce	  TGF-­‐β	  signalling	  through	  oxidative	  stress	  (Wei	  et	  al.,	  2008).	  Ang-­‐II	  has	  been	  shown	  to	  
induce	   wasting	   in	   myotubes	   by	   other	   groups	   (Brink	   et	   al.,	   1999,	   Russell	   et	   al.,	   2006).	  
Similarly	   in	   the	   data	   above,	   ang-­‐II	   induced	   wasting	   in	   myotubes,	   but	   this	   effect	   was	   not	  
augmented	   by	   FHL1	   expression.	   This	   suggests	   that	   ang-­‐II	   and	   FHL1	   do	   not	   interact	  
functionally;	   however,	   it	   is	   also	   possible	   that	   a	   demonstration	   of	   the	   augmentation	   of	  
atrophic	  effects	  of	  ang-­‐II	  would	  only	  be	  observed	  at	  lower	  concentrations	  of	  ang-­‐II.	  	  
	   Overall,	   the	   above	  data	  has	   shown	   that	   the	  presence	  of	   FHL1	  enhances	  myostatin	  
signalling	   in	   skeletal	   muscle.	   Furthermore,	   as	   FHL1	   expression	   is	   associated	   with	   type	   II	  
fibres	   (Cowling	   et	   al.,	   2008),	   this	   interaction	   may	   contribute	   to	   the	   type	   II	   fibre	   specific	  
effects	   of	   myostatin.	   This	   is	   particularly	   of	   interest	   in	   COPD	   associated	   muscle	   atrophy,	  
where	  there	  is	  a	  preferential	  atrophy	  of	  type	  II	  fibres	  compared	  with	  type	  I	  fibres	  (Gosker	  et	  
al.,	   2002a,	   Gosker	   et	   al.,	   2003).	   Furthermore,	   myostatin	   levels	   have	   been	   shown	   to	   be	  
increased	  in	  COPD	  patients	  (Plant	  et	  al.,	  2010),	  and	  myostatin	  is	  also	  associated	  with	  type	  II	  
fibres	  (Kirk	  et	  al.,	  2000).	  FHL1	  expression	  is	  also	  associated	  with	  type	  II	  fibres,	  inactivity	  and	  
weakness	   in	   COPD	   muscle	   (Lewis	   et	   al.,	   2010).	   The	   data	   presented	   here	   showing	   FHL1	  
augmented	   myostatin	   signalling	   in	   vitro	   and	   potentiated	   myostatin-­‐induced	   atrophy	   and	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atrophy	   signalling	   in	   vivo,	   provide	   compelling	   evidence	   that	   FHL1	   can	   be	   associated	  with	  
atrophy	  as	  well	  as	  hypertrophy,	  and	  that	  the	  interaction	  between	  FHL1	  and	  myostatin	  may	  
be	   involved	   in	   muscle	   wasting.	   It	   is	   highly	   likely	   that	   the	   role	   of	   FHL1	  may	   be	   signalling	  
context	  dependent.	  In	  the	  presence	  of	  hypertrophy	  signalling,	  FHL1	  aids	  hypertrophy,	  and	  in	  
the	  presence	  of	  atrophic	   factors	  such	  as	  myostatin,	  FHL1	  augments	  atrophy.	  Furthermore,	  
as	  FHL1	  is	  predominantly	  expressed	  in	  type	  II	  fibres,	  this	  interaction	  may	  contribute	  to	  the	  
type	   II	   specificity	   of	  myostatin	   dependent	   atrophy.	   However,	   there	  may	   also	   be	   roles	   for	  
other	   atrophy	   related	   molecules	   not	   limited	   to	   myostatin,	   such	   as	   GDF-­‐15	   and	   ang-­‐II	   in	  
muscle	  wasting.	   Although	  GDF-­‐15	   and	   ang-­‐II	  may	   not	   appear	   to	   be	   potentiated	   by	   FHL1,	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5.1 Introduction	  
	   Muscle	  mass	  loss	  is	  a	  significant	  co-­‐morbidity	  in	  patients	  with	  COPD	  (Debigaré	  et	  al.,	  
2001,	  Schols	  et	  al.,	  1993a,	  Barnes	  and	  Celli,	  2009).	  Cigarette	  smoke,	  which	  is	  thought	  to	  be	  
the	  primary	  cause	  of	  COPD	  in	  the	  developed	  world	  (Løkke	  et	  al.,	  2006),	  may	  directly	  cause	  
loss	  of	  muscle	  mass.	  Although	  most	  studies	  have	  examined	  the	  effect	  of	  cigarette	  smoke	  in	  
the	  lungs,	  the	  exposure	  of	  the	  skeletal	  muscles	  to	  smoke	  is	  thought	  to	  be	  systemic	  via	  the	  
circulation	  either	  as	  a	  ‘spill	  over’	  of	  chemicals	  or	  oxidative	  stress	  from	  the	  lung	  or	  as	  a	  direct	  
effect	   of	   the	   chemicals	   in	   smoke	   (Barnes	   and	   Celli,	   2009).	   Given	   that	   smoking	   itself	   is	  
associated	   with	   decreased	   body	   weight	   (Stavropoulos-­‐Kalinoglou	   et	   al.,	   2008),	   skeletal	  
muscle	   will	   also	   be	   affected	   by	   cigarette	   smoke	   leading	   to	   atrophy.	   Cigarette	   smoke	   has	  
been	   shown	   to	   directly	   increase	   myostatin	   and	   atrogin-­‐1,	   factors	   involved	   in	   protein	  
degradation,	  with	  a	  concomitant	  decrease	   in	  the	  rate	  of	  protein	  synthesis	  (Petersen	  et	  al.,	  
2007).	  Cigarette	   smoke	  has	  also	  been	   shown	   to	   cause	  wasting	   in	   vitro	   (Rom	  et	  al.,	   2013).	  
Cigarette	   smoke	   is	   thought	   to	   affect	   the	  pathways	   involved	   in	   loss	  of	   protein	   such	  as	   the	  
UPS	  and	  apoptosis	  (Agustí	  et	  al.,	  2002,	  Doucet	  et	  al.,	  2007,	  Plant	  et	  al.,	  2010).	  However,	  one	  
pathway	  that	  has	  been	  relatively	  under	  characterised	  is	  the	  autophagy-­‐lysosome	  pathway.	  	  
	   Autophagy	  is	  a	  likely	  mechanism	  for	  muscle	  wasting	  in	  COPD	  as	  elevated	  levels	  of	  the	  
autophagy	   related	   proteins	   have	   been	   observed	   in	   the	   lung.	   Smoke	   exposure	   has	   been	  
shown	   to	   increase	   autophagy	   in	   lung	   cells	   in	   vitro	   (Chen	   et	   al.,	   2008).	   Chen	   et	   al.	   also	  
recorded	  an	  increase	  in	  protein	  levels	  of	  LC3-­‐II,	  BECLIN,	  ATG7	  and	  ATG5	  as	  well	  as	  increased	  
autophagosome	   number	   in	   lung	   sections	   from	   COPD	   patients.	   Chen	   et	   al.	   also	   observed	  
increased	   levels	   of	   LC3-­‐II	   and	   ATG4B	   in	   lung	   tissue	   homogenates	   from	   mice	   exposed	   to	  
cigarette	  smoke	  for	  6	  months.	  The	  effect	  of	  smoke	  on	  autophagy	  has	  also	  been	  examined	  in	  
vitro	   where	   lung	   epithelial	   cells	   exposed	   to	   aqueous	   cigarette	   smoke	   extract	   showed	   an	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increase	   in	  autophagy	  (Kim	  et	  al.,	  2008b).	   In	  addition,	  cigarette	  smoke	  has	  been	  shown	  to	  
promote	  the	  breakdown	  of	  AKT,	  a	  key	  regulator	  of	  autophagy	  (Kim	  et	  al.,	  2011).	  This	  leads	  
to	   the	   possibility	   that	   smoke	   may	   induce	   increased	   autophagy	   in	   skeletal	   muscle,	   thus	  
resulting	  in	  muscle	  mass	  loss	  as	  observed	  in	  COPD.	  Few	  studies	  have	  investigated	  the	  role	  of	  
autophagy	  in	  skeletal	  muscle,	  aside	  from	  Plant	  et	  al.	  who	  reported	  an	  increase	  in	  ATROGIN1,	  
but	  observed	  no	  change	   in	  mRNA	  levels	  of	  LC3B	  and	  BECLIN	   (Plant	  et	  al.,	  2010).	  However,	  
the	  changes	  were	  observed	  in	  a	  small	  study	  group,	  thus	   it	  would	  be	  premature	  to	  assume	  
that	  autophagy	  is	  not	  involved	  in	  muscle	  wasting	  in	  COPD	  at	  all.	  	  
Autophagy	   is	   a	   likely	   contributor	   to	   muscle	   wasting	   in	   COPD	   as	   smoke	   has	   been	  
shown	  to	  induce	  oxidative	  stress	  in	  skeletal	  muscles	  in	  vivo	  and	  in	  COPD	  patients.	  Barriero	  et	  
al.	  showed	  that	  protein	  modification	  levels	  were	  increased	  in	  guinea	  pigs	  exposed	  to	  smoke,	  
healthy	  smokers,	  as	  well	  as	  COPD	  patients	  (Barreiro	  et	  al.,	  2010b).	  Cigarette	  smoke	  induced	  
oxidative	   stress	   leads	   to	   damage	   within	   cells	   such	   as	   protein	   carbonylation	   and	   tyrosine	  
nitration,	  which	  may	   cause	  damaged	   cells	   to	  be	  more	   susceptible	   to	  protein	  degradation,	  
and	  subsequently	  contribute	   to	  muscle	   loss	   (Barreiro	  et	  al.,	  2010b).	   Induction	  of	  oxidative	  
stress	  both	  in	  vitro	  and	  in	  vivo	  has	  been	  shown	  to	  induce	  autophagy	  as	  well	  as	  proteasomal	  
degradation	  in	  muscle	  (McClung	  et	  al.,	  2010).	  
	  	   As	  discussed	  in	  the	  previous	  Chapters	  (3	  and	  4),	  myostatin	  is	  an	  important	  cytokine	  
involved	  in	  muscle	  wasting	  (McPherron	  et	  al.,	  1997,	  Amthor	  et	  al.,	  2007).	  Increased	  levels	  of	  
myostatin	   mRNA	   in	   quadriceps	   have	   been	   shown	   to	   inversely	   correlate	   with	   strength,	  
endurance	   and	   physical	   activity	   in	   COPD	   (Man	   et	   al.,	   2010).	   Recently,	   increased	   levels	   of	  
serum	  myostatin	  have	  shown	  to	  be	  associated	  with	  muscle	  wasting	  in	  COPD	  patients	  (Ju	  and	  
Chen,	   2012).	   As	  myostatin	  was	   shown	   to	   induce	   autophagy,	   this	  would	   also	   suggest	   that	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myostatin	   may	   be	   inducing	   wasting	   through	   autophagy	   (Lee	   et	   al.,	   2011).	   In	   addition,	  
hypoxia	  has	  been	  shown	  to	  increase	  myostatin	  levels	  in	  skeletal	  muscles	  in	  vitro	  and	  in	  vivo	  
(Hayot	   et	   al.,	   2011)	   which	   given	   that	   hypoxemia	   in	   COPD	   patients	  may	   lead	   to	   oxidative	  
stress	  (Koechlin	  et	  al.,	  2005b),	  this	  would	  again	  contribute	  to	  increased	  autophagy	  in	  COPD	  
patients.	  	  
	   The	   increase	   in	  oxidative	  stress	  exertion	  on	  skeletal	  muscle	  could	   therefore	   induce	  
myostatin	  and	  autophagy	  directly	  or	  indirectly,	  leading	  to	  increased	  protein	  break	  down	  and	  
therefore	  loss	  of	  protein.	  In	  this	  chapter,	  the	  effect	  of	  cigarette	  smoke	  on	  autophagy	  in	  an	  
animal	   model	   of	   chronic	   smoke	   exposure	   and	   the	   effect	   of	   COPD	   disease	   on	   autophagy	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5.2 Results	  
5.2.1 Effect	  of	  chronic	  smoke	  exposure	  on	  skeletal	  muscle	  in	  vivo	  
The	  primary	  cause	  of	  COPD	  in	  the	  developed	  world	  is	  tobacco	  smoke.	  Accordingly,	  a	  
chronic	  smoke	  exposure	  model	   in	  mice	  was	  used	  as	  a	  simplified	   in	  vivo	  model	  to	  examine	  
whether	  tobacco	  smoke	  induces	  muscle	  atrophy	  and	  changes	   in	  autophagy.	  Body	  weights,	  
gastrocnemius	   weights	   and	   gastrocnemius	   samples	   from	   19-­‐month	  mice	   from	   the	   smoke	  
exposure	  model	   (as	   described	   in	   section	   2.2.12),	  were	   donated	   by	  GSK,	  USA.	   	   The	  model	  
consisted	   of	   three	   groups:	   mice	   exposed	   to	   smoke	   in	   the	   smoking	   apparatus	   (smoke	   air	  
n=20),	  mice	  exposed	  to	  air	   in	  the	  device	  (forced	  air/sham	  treated	  n=18,	  hereafter	  referred	  
to	  as	  forced	  air)	  and	  mice	   left	   in	  normal	  room	  air	  (i.e.	  not	  exposed	  to	  the	  smoking	  device,	  
room	  air	  n=8,	  hereafter	  referred	  as	  room	  air).	  Gastrocnemius	  muscles	  were	  excised	  from	  the	  
mice	  after	  19	  months	  of	  exposure	  and	  gifted	  to	  the	  group	  for	  analysis.	  
5.2.1.1 Exposure	  to	  smoke	  causes	  a	  loss	  of	  muscle	  mass	  in	  vivo	  
Whole	   body	   weight	   measurements	   at	   19	   months	   showed	   that	   there	   was	   loss	   in	  
weight	   in	   both	   the	   forced	   air	   (forced	   air	   24.4g	   ±	   0.5,	   p<0.0001)	   and	   the	   smoke	   air	   group	  
(23.6g	  ±	  0.6,	  compared	  to	  room	  air	  p<0.0001)	  compared	  to	  room	  air	  group	  (room	  air	  31.0g	  ±	  
1.0,	   Figure	   35).	   The	   loss	   in	  weight	   in	   only	   the	   groups	   that	  were	   placed	   into	   the	   smoking	  
device	  suggests	  that	  the	  model	  itself	  caused	  weight	  loss.	  However,	  examination	  of	  the	  wet	  
gastrocnemius	  weights	  revealed	  that	  in	  fact	  only	  the	  smoke	  air	  group	  lost	  locomotor	  muscle	  
mass	   compared	   to	   either	   the	   forced	   air	   or	   the	   room	   air	   controls	   (room	   air	   0.13g	   ±	   0.01	  
compared	  to	  smoke	  air	  0.11g	  ±	  0.01	  p=0.005,	  forced	  air	  0.13g	  ±	  0.01,	  compared	  to	  smoke	  
air,	  p=0.004,	  Figure	  35).	  There	  was	  a	  21%	  reduction	  in	  gastrocnemius	  weight	   in	  the	  smoke	  
air	  group	  compared	  to	  the	  forced	  air	  and	  room	  air	  groups.	  
	   166	  
Figure	   35	   Changes	   in	  mouse	   body	  weight	   and	   gastrocnemius	   wet	   weight	   in	   the	   smoke	  
model	  
Body	  weights	  of	  the	  mice	  at	  19	  months	  showed	  that	  both	  the	  forced	  and	  smoke	  air	  group	  
had	   a	   significant	   reduction	   in	   body	   weight	   compared	   to	   the	   room	   air	   control	   (A).	   Body	  
weight	  data	  analysed	  by	  ANOVA	  p<0.0001;	  t-­‐tests	  between	  the	  groups	  represented	  below,	  
where	  ***	  represents	  p<0.0001.	  Wet	  gastrocnemius	  weights	  of	  mice	  at	  19	  months	  showed	  
that	   only	   the	   smoke	   air	   group	  had	   a	   reduction	   in	  gastrocnemius	  weight	   compared	   to	   the	  
room	  and	  forced	  air	  groups	  (B).	  ANOVA	  analysis	  of	  gastrocnemius	  weights	  **p<0.01,	  t-­‐tests	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5.2.1.2 Changes	  in	  the	  myostatin	  expression	  and	  TGF-­‐β 	  family	  signalling	  due	  to	  chronic	  
smoke	  exposure	  
Analysis	   of	   myostatin	   levels	   showed	   that	   there	   was	   a	   significant	   increase	   in	  
myostatin	   levels	   in	   the	   forced	   air	   group	   (23.6	   ±	   5.4	   fold	   compared	   to	   room	  air	   1.0	   ±	   0.1,	  
p<0.0001,	   Figure	   36).	   Myostatin	   levels	   were	   also	   significantly	   increased	   in	   the	   smoke	   air	  
group	   compared	   to	   room	   air	   controls	   (8.4	   ±	   2.4,	   p<0.0001);	   but	   levels	   were	   decreased	  
compared	  to	  forced	  air	  group	  (p=0.0167).	  	  
As	   myostatin	   levels	   were	   down-­‐regulated	   compared	   to	   the	   forced	   air	   controls	  
(forced	   air	   1.00	   ±0.21,	   smoke	   air	   0.44	   ±0.11,	   p=0.039),	   other	   TGF-­‐β	   related	   genes	   were	  
examined;	  Vegfc,	   Smad7,	   Pai-­‐1,	   Tgf-­‐β	   and	  Cyr61.	  Overall,	   there	  was	   a	   down	   regulation	   in	  
most	   genes,	  with	   a	   significant	   decrease	   in	  Vegf-­‐C	   (forced	   air	   1.00	   ±	   0.11,	   smoke	   air	   0.71	  
±0.13,	   p=0.041),	   Pai-­‐1	   (forced	   air	   1.00	   ±0.07,	   smoke	   air	   0.68	   ±0.07,	   p=0.0068,	   Table	   12,	  
Figure	  37).	  There	  was	  a	  decrease	  in	  Tgf-­‐β	  expression	  (forced	  air	  1.00	  ±0.13,	  smoke	  air	  0.75	  
±0.10,	  p=0.073).	  Also,	  there	  was	  a	  significant	  increase	  in	  the	  inhibitory	  Smad7	  expression	  in	  
the	  smoke	  air	  group	  compared	  to	  the	  forced	  air	  group	  (forced	  air	  1.00	  ±0.07,	  smoke	  air	  1.32	  
±0.12,	   p=0.02).	   Correlations	   between	  myostatin	   and	   components	   of	   TGF-­‐β	   related	   genes	  
were	   examined	   for	   Pai-­‐1,	   Vegfc	   and	   Atg4b.	   There	   was	   a	   significant	   correlation	   between	  
myostatin	   expression	   and	  Pai-­‐1	   (r2=0.628)	  Vegfc	   (r2=0.804)	   and	  Atg4b	   (r2=0.415,	   p<0.001)	  
(Figure	  38).	  
To	   examine	   the	   effects	   of	   smoke	   alone	   in	   this	   model,	   subsequent	   analyses	   were	  
simplified	  to	  only	  the	  forced	  and	  smoke	  air	  groups,	  whilst	  the	  room	  air	  group	  was	  omitted.	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Figure	  36	  Myostatin	  mRNA	  levels	  in	  the	  room,	  forced	  and	  smoke	  air	  group	  normalised	  to	  
room	  air	  
Analysis	  of	  the	  myostatin	  mRNA	  levels	  showed	  that	  although	  there	  was	  an	   increase	   in	  the	  
smoke	   air	   group,	   forced	   air	   group	   had	   a	   greater	   increase	   compared	   to	   room	   air	   control.	  
ANOVA	  analysis	   showed	   that	   there	  was	  a	   significant	  difference	  between	   the	   three	  groups	  
(p<0.001).	  Each	  animal	  is	  represented	  as	  a	  log	  data	  point,	  where	  the	  bars	  represent	  mean	  ±	  
SEM.	  Data	  normalised	  to	  room	  air	  group.	  Room	  air	  n=8,	  forced	  air	  n=18	  and	  smoke	  air	  n=20.	  
Significance	   within	   the	   groups	   was	   analysed	   by	   t-­‐test,	   which	   are	   shown	   on	   bars	   below.	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Figure	  37	  Decrease	  in	  TGF-­‐β 	  signalling	  in	  Smoke	  air	  mice	  
Mstn,	  Pai-­‐1	   and	  Vegfc	  mRNA	  expression	  were	  all	   significantly	  decreased	  compared	   to	   the	  
forced	   air	   control	   mice.	   However,	   there	   was	   a	   significant	   increase	   in	   Smad7	   mRNA	  
expression	  compared	  to	  Forced	  air	  control.	  Each	  animal	  is	  represented	  as	  a	  log	  data	  point,	  
where	  the	  bars	  represent	  mean	  ±	  SEM.	  Forced	  air	  group	  n=18,	  and	  smoke	  air	  group	  n=20.	  
Significance	  tested	  by	  t-­‐test	  and	  represented	  as	  *	  p<0.05,	  **	  p<0.01.	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Figure	   38	   Correlations	   between	   myostatin	   mRNA	   and	   TGF-­‐β 	   signalling	   targets	   and	  
autophagy	  
Myostatin	  mRNA	  levels	  correlated	  positively	  with	  the	  mRNA	  expression	  of	  TGF-­‐β	  signalling	  
targets	   Vegf-­‐C	   and	   Pai-­‐1	   as	   well	   as	   the	   autophagy	   gene	   Atg4b	   in	   the	   room,	   forced	   and	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5.2.1.3 Changes	  in	  cytoskeletal	  proteins	  and	  myosin	  heavy	  chain	  expression	  	  
Expression	   of	   the	   myosin	   heavy	   chain	   isoforms	   was	   measured	   in	   the	   forced	   and	  
smoke	   air	   group.	   Expression	   of	   the	  myosin	   heavy	   chains	   was	   increased	   in	   the	   smoke	   air	  
group	  compared	   to	   the	   forced	  air	   group,	  Myhc	   I	   (forced	  air	  1.00	  ±	  0.18,	   smoke	  air	  1.77	  ±	  
0.34,	  p=0.041),	  Myhc	  IIx	  (forced	  air	  1.00	  ±	  0.17,	  smoke	  air	  1.57	  ±	  0.21,	  p=0.028)	  and	  Myhc	  IIb	  	  
(forced	  air	  1.00	  ±	  0.20,	  smoke	  air	  2.16	  ±	  0.26,	  p=0.0006)	  were	  all	  significantly	   increased	  in	  
the	   smoke	  air	   group	   compared	   to	   the	   forced	  air	   group	   (Table	  12,	   Figure	  39).	   The	  median	  
Myhc	  IIa	  gene	  expression	  was	  higher	  in	  the	  smoke	  air	  mice	  compared	  to	  the	  forced	  air	  mice,	  
however	   this	   did	   not	   reach	   significance	   (forced	   air	   1.00	   ±	   0.16,	   smoke	   air	   1.48	   ±	   0.25,	  
p=0.081).	  
As	   discussed	  previously,	   FHL	   proteins	   play	   an	   important	   part	   in	   the	  modulation	   of	  
muscle	  mass	  (Cowling	  et	  al.,	  2008).	  Given	  that	  myostatin	  has	  been	  reported	  to	  be	  involved	  
in	  the	  loss	  of	  muscle	  mass	  in	  COPD	  and	  myostatin	  has	  been	  shown	  to	  interact	  with	  FHL1	  as	  
observed	  in	  Chapter	  4,	  Fhl1	  and	  Fhl3	  mRNA	  expression	  were	  also	  examined.	  However,	  there	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Table	  12	  Gene	  expression	  changes	  in	  the	  forced	  and	  smoke	  air	  groups	  
Gene	  expression	  analysis	  of	   the	  Smoke	  air	  group	  compared	  to	   the	  Forced	  air	  group.	  qPCR	  
data	  normalised	  to	  the	  forced	  air	  group	  post	  normalisation	  to	  geomean	  of	  HPRT	  and	  RPLPO.	  















Myhc	  I	   1.00	  ±0.18	   1.77	  ±0.34	   0.041	  
Myhc	  IIa	   1.00	  ±0.16	   1.48	  ±0.25	   ns	  
Myhc	  IIx	   1.00	  ±0.17	   1.57	  ±0.21	   0.028	  
Myhc	  IIb	   1.00	  ±0.20	   2.16	  ±0.26	   0.0006	  
TGF-­‐β	  
signalling	  
Vegf-­‐c	   1.00	  ±0.11	   0.71	  ±0.13	   0.041	  
Smad-­‐7	   1.00	  ±0.07	   1.32	  ±0.12	   0.020	  
Myostatin	  	   1.00	  ±0.21	   0.44	  ±0.11	   0.039	  
Pai-­‐1	   1.00	  ±0.07	   0.68	  ±0.07	   0.007	  
Tgf-­‐beta	   1.00	  ±0.13	   0.75	  ±0.10	   0.073	  
Cyr	  61	   1.00	  ±0.14	   1.16	  ±0.15	   ns	  
Autophagy	  
Atg-­‐4b	   1.00	  ±0.07	   0.71	  ±0.06	   0.0041	  
Lc3b	   1.00	  ±0.12	   1.10	  ±0.10	   ns	  
Ulk-­‐2	   1.00	  ±0.14	   1.27	  ±0.11	   0.068	  
Gabarapl1	   1.00	  ±0.09	   1.07	  ±0.09	   ns	  
Atg-­‐12	   1.00	  ±0.08	   1.24	  ±0.08	   0.038	  
Beclin	   1.00	  ±0.07	   1.20-­‐	  ±0.08	   ns	  
Proteasomal	  
Degradation	  
Atrogin1	   1.00	  ±0.20	   1.15	  ±0.19	   ns	  
Murf1	   1.00	  ±0.14	   1.27	  ±0.24	   ns	  
Apoptosis	   Bax	   1.00	  ±0.08	   0.90	  ±0.05	   ns	  
FHL	  	   Fhl1	   1.00	  ±0.14	   1.25	  ±0.14	   ns	  
Fhl3	   1.00	  ±0.12	   1.03	  ±0.09	   ns	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Figure	  39	  Increase	  in	  expression	  in	  MHC	  expression	  in	  the	  Smoke	  Air	  mice	  
Myhc	  I,	  IIx	  and	  IIb	  mRNA	  expression	  were	  all	  significantly	  increased	  in	  the	  Smoke	  air	  group	  
compared	  to	  Forced	  air	  control.	  There	  was	  a	  trend	  to	  an	  increase	  in	  Myhc	  IIa,	  which	  did	  not	  
reach	  significance.	  Each	  animal	  is	  represented	  as	  a	  log	  data	  point,	  where	  the	  bars	  represent	  
mean	  ±	  SEM.	  Forced	  air	  group	  n=18,	  and	  smoke	  air	  group	  n=20.	  Significance	  tested	  by	  t-­‐test	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5.2.1.4 Changes	  in	  protein	  degradation	  pathways	  expression	  due	  to	  chronic	  smoke	  
exposure	  	  	  
Targets	   involved	   in	   proteolysis	   were	   also	   measured.	   There	   was	   no	   change	   in	   the	  
expression	  of	  proteins	  involved	  in	  protein	  degradation:	  Atrogin1	  and	  Murf1,	  which	  encode	  
proteins,	  involved	  in	  proteasomal	  degradation	  and	  Bax	  (which	  encodes	  a	  protein	  involved	  in	  
apoptosis	  (Table	  12).	  	  To	  assess	  the	  effect	  of	  smoke	  on	  autophagy	  the	  expression	  of	  a	  panel	  
of	  autophagy	  related	  genes	  -­‐	  Atg4b,	  Lc3b,	  Ulk2,	  Atg12l,	  Gabarapl1	  and	  Beclin	  was	  examined.	  
Atg4b	  was	   significantly	   reduced	   in	   the	   smoke	  air	   group	   (forced	  air	  1.00	  ±	  0.07,	   smoke	  air	  
0.71	  ±	  0.06,	  p=0.0041,	  Table	  12,	  Figure	  40).	  Conversely,	  Atg12l	  was	  significantly	   increased	  
(forced	  air	  1.00	  ±	  0.08,	  smoke	  air	  1.24	  ±0.08,	  p=0.038)	  with	  a	  trend	  to	  an	   increase	   in	  Ulk2	  
(forced	  air	  1.00	  ±	  0.14,	   smoke	  air	  1.27	  ±0.11,	  p=0.068)	  and	  Beclin	   (forced	  air	  1.00	  ±	  0.07,	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Figure	  40	  Changes	  in	  autophagy	  gene	  expression	  in	  the	  Smoke	  Air	  group	  
There	   was	   a	   significant	   decrease	   in	   Atg4b	   mRNA	   expression	   in	   the	   smoke	   air	   group	  
compared	   to	   the	   forced	   air	   group.	   However,	   there	   was	   a	   significant	   increase	   in	   Atg12l	  
expression	  in	  the	  smoke	  air	  group.	  Each	  animal	  is	  represented	  as	  a	  log	  data	  point,	  where	  the	  
bars	  represent	  mean	  ±	  SEM.	  Forced	  air	  group	  n=18,	  and	  smoke	  air	  group	  n=20.	  Significance	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5.2.1.5 Histological	  analysis	  of	  the	  gastrocnemius	  cross	  sections	  
Unfortunately,	  no	  histological	  analysis	  could	  be	  performed	  due	  to	  poor	  quality	  of	  the	  
sections	  (Figure	  41).	  There	  was	  a	  substantial	  loss	  of	  fibre	  integrity	  cross	  all	  muscle	  samples,	  
possibly	  as	  a	  result	  of	  incorrect	  freezing	  of	  the	  muscles	  in	  OCT.	  	  
	  
Figure	  41	  Histological	  analysis	  of	  gastrocnemius	  sections	  
Representative	  images	  of	  H	  and	  E	  stained	  sections	  of	  the	  gastrocnemius	  of	  each	  mouse	  from	  
each	   group-­‐	   regular	   air,	   forced	   air	   (17	   and	   48)	   and	   smoke	   air	   (24	   and	   53)	   mouse.	   In	   all	  
groups,	   no	   histological	   analysis	   could	   be	   performed	   due	   to	   the	   poor	   condition	   of	   the	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5.2.2 	  Effect	  of	  COPD	  disease	  on	  autophagy	  in	  humans	  
The	  effect	  of	  COPD	  on	  autophagy	   in	  muscle	  was	  examined.	  Vastus	   lateralis	  muscle	  
biopsies	  were	  obtained	  from	  COPD	  patients	  and	  healthy	  controls	  by	  Dr	  Dinesh	  Shrikrishna	  to	  
analyse.	  Samples	  were	  processed	  and	  RNA	  extracted	  in	  collaboration	  with	  Dr	  Shrikrishna	  as	  
described	  in	  2.2.7.1.	  
	  
5.2.2.1 Effect	  of	  COPD	  on	  autophagy	  in	  skeletal	  muscle	  	  
The	  effect	  of	  COPD	  on	  autophagy	  was	  examined	   in	  the	  baseline	  samples	  (Day	  0)	   in	  
patients	   and	   from	   healthy	   controls.	   Analysis	   of	   the	   expression	   of	   the	   autophagy	   related	  
genes	  ATG4B,	  ATG12L,	  BECLIN	  and	  LC3B	  revealed	  that	  there	  was	  no	  difference	  in	  expression	  
in	   COPD	   patients	   compared	   to	   healthy	   controls	   (Table	   13).	   The	   expression	   of	   two	   TGF-­‐β	  
related	  genes	  were	  also	  analysed-­‐	  MSTN	  and	  PAI-­‐1,	  and	  there	  was	  no	  significant	  change	  in	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Table	  13	  Comparison	  gene	  expression	   in	  healthy	  controls	  compared	  to	  COPD	  patients	  at	  
baseline	  
Relative	  gene	  expression	  values	  for	  autophagy	  related	  and	  TGF-­‐β	  signalling	  genes	  of	  COPD	  



















ATG4B	   1.00	  ±	  0.18	   0.72	  ±	  0.098	   ns	  
ATG12L	   1.00	  ±	  0.20	  	   1.18	  ±	  0.299	   ns	  
BECLIN	   1.00	  ±	  0.16	   0.65	  ±	  0.08	   ns	  
LC3B	   1.00	  ±	  0.25	   0.66	  ±	  0.12	   ns	  
TGF-­‐β 	  
signalling	  
MYOSTATIN	   1.00	  ±	  0.19	   2.07	  ±	  0.84	   ns	  
PAI-­‐1	   1.00	  ±	  0.18	   1.53	  ±	  1.11	  	   ns	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5.2.3 Effect	  of	  ACE	  inhibition	  on	  autophagy	  in	  COPD	  patients	  
The	  COPD	  patients	  studied	  above	  were	  part	  of	  a	  randomised	  double-­‐blinded	  placebo	  
controlled	  study	  conducted	  by	  Dr	  Dinesh	  Shrikrishna,	  examining	  the	  longitudinal	  effect	  (i.e.	  
across	   time)	   of	   the	   ACE	   inhibitor	   fosinopril	   in	   COPD	   patients	   compared	   to	   placebo.	   The	  
biopsies	   were	   also	   used	   to	   analyse	   the	   effect	   of	   ACE	   inhibition	   on	   autophagy.	   Muscle	  
biopsies	  were	  taken	  from	  patients	  at	  baseline	  (day	  0,	  the	  same	  samples	  used	  to	  study	  the	  
effect	   of	   autophagy	   on	   COPD)	   and	   3	   months	   after	   being	   given	   placebo	   or	   fosinopril.	   As	  
discussed	   previously,	   ang-­‐II	  may	   play	   an	   important	   role	   in	  muscle	  wasting.	   Thus	   blocking	  
ang-­‐II	  signalling	  by	  blocking	  the	  conversion	  of	  ang-­‐I	  to	  ang-­‐II	  may	  prevent	  loss	  of	  muscle.	  The	  
details	  of	  the	  study	  are	  outlined	  in	  section	  2.2.13.	  
	  
5.2.3.1 Trial	  Outcomes	  
Dr	  Shrikrishna	  observed	  that	  after	  3	  months	  of	  fosinopril	  or	  placebo	  treatment,	  there	  
was	   no	   change	   in	   muscle	   function	   measurements	   including	   quadriceps	   endurance	   and	  
exercise	   capacity,	   aside	   from	  an	   improvement	   in	   quadriceps	  maximal	   voluntary	   contraction	  
(QVMC)	   in	   both	   groups.	   There	   was	   also	   no	   difference	   in	   mid-­‐thigh	   cross-­‐sectional	   area	  
(MTCSA)	  at	  3	  months.	  There	  were	  no	  significant	  differences	  in	  mRNA	  expression	  of	  hypertrophy	  
or	   atrophy	   signalling	   proteins	   including:	   IGF-­‐1,	   MyoD,	   atrogin-­‐1,	   TGF-­‐β	   and	   MHC	   isoform	  
between	  the	  fosinopril	  and	  placebo	  group	  at	  3	  months.	  There	  was	  also	  no	  significant	  difference	  
in	   serum	   inflammatory	   cytokines	   between	   the	   groups	   at	   3	  months.	   Dr	   Shrikrishna	   concluded	  
that	   the	   data	   did	   not	   support	   the	   role	   of	   ACE	   inhibitors	   to	   augment	   muscle	   dysfunction	   in	  
patients	  with	  COPD.	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5.2.3.2 Baseline	  muscle	  biopsy	  measurements	  of	  autophagy	  	  
There	   were	   no	   significant	   differences	   in	   autophagy,	   myostatin	   and	   PAI-­‐1	   gene	  





Table	  14	  Baseline	  gene	  expression	  of	  COPD	  patient	  cohort	  in	  the	  fosinopril	  trial	  
Relative	   gene	   expression	   values	   of	   COPD	   patients	   in	   the	   fosinopril	   trial	   at	   baseline	   for	  
autophagy	   related	   and	   TGF-­‐β	   signalling	   genes.	   The	   expression	   of	   the	   fosinopril	   group	   is	  













ATG4B	   1.00	  ±	  0.177	   0.854	  ±	  0.177	   ns	  
ATG12L	   1.00	  ±	  0.202	  	   1.25	  ±	  0.370	   ns	  
BECLIN	   1.00	  ±	  0.156	   0.927	  ±	  0.175	   ns	  
LC3B	   1.00	  ±	  0.246	   0.737	  ±	  0.191	   ns	  
TGF-­‐β 	  
signalling	  
MYOSTATIN	   1.00	  ±	  0.191	   1.09	  ±	  0.285	   ns	  
PAI-­‐1	   1.00	  ±	  0.175	   0.687	  ±	  0.194	  	   ns	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5.2.3.3 Effect	  of	  fosinopril	  treatment	  compared	  to	  placebo	  on	  gene	  expression	  	  
To	  determine	  the	  effect	  of	  ACE	   inhibition	  compared	  to	  placebo,	   the	  same	  panel	  of	  
genes	   was	   analysed	   at	   3	   months.	   Fosinopril	   had	   no	   significant	   effect	   on	   autophagy	   at	   3	  
months	   compared	   to	   placebo.	   Median	  MSTN	   mRNA	   expression	   levels	   were	   increased	   in	  
patients	  given	  fosinopril	  compared	  to	  placebo	  after	  3	  months	  however,	  the	  increase	  was	  not	  
significant	  (Placebo	  1.00	  ±	  0.397,	  Fosinopril	  12.2	  ±	  6.69,	  p=0.081,	  Table	  15,	  Figure	  42).	  
	  
Table	  15	  Change	  in	  gene	  expression	  in	  the	  placebo	  group	  compared	  fosinopril	  group	  trial	  
at	  3	  months	  
Relative	   gene	   expression	   values	   of	   COPD	   patients	   in	   the	   fosinopril	   trial	   at	   3	   months	   for	  
autophagy	   related	   and	   TGF-­‐β	   signalling	   genes.	   The	   expression	   of	   the	   fosinopril	   group	   is	  
normalised	   to	   placebo	   group	   (n=20	   fosinopril	   group,	   n=29	   placebo	   group,	   ns=	   non-­‐
significant).	  
	  








ATG4B	   1.00	  ±	  0.121	   1.74	  ±	  0.569	  	   ns	  
ATG12L	   1.00	  ±	  0.288	  	   2.22	  ±	  0.981	   ns	  
BECLIN	   1.00	  ±	  0.138	   0.796	  ±	  0.171	   ns	  
LC3B	   1.00	  ±	  0.221	   1.55	  ±	  0.450	   ns	  
TGF-­‐β 	  
signalling	  
MYOSTATIN	   1.00	  ±	  0.397	   12.2	  ±	  6.69	  	   0.081	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Figure	   42	  Myostatin	   expression	   in	   COPD	   patients	   given	   fosinopril	   compared	   to	   placebo	  
after	  3	  months	  
Median	   levels	   of	   myostatin	   expression	   were	   increased	   in	   COPD	   patients	   given	   fosinopril	  
compared	   to	  placebo	  at	  3	  months;	  however,	   this	  did	  not	   reach	   significance.	  Graphs	   show	  
each	   patient	   represent	   as	   a	   logged	   data	   point.	   Significance	   analysed	   by	  Mann	  Whitney	  U	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5.2.3.4 	  Effect	  of	  time	  on	  gene	  expression	  in	  patients	  given	  placebo	  and	  fosinpril	  
A	   longitudinal	   analysis	   of	   the	   effect	   of	   time	   on	   each	   treatment	   group	   (placebo	   or	  
fosinopril)	  revealed	  that	  levels	  of	  MSTN	  and	  PAI-­‐1	  mRNA	  both	  increased	  from	  baseline	  to	  3	  
months	   regardless	   of	   whether	   patients	   were	   given	   fosinopril	   or	   placebo	   (MSTN:	   placebo	  
baseline	  1.00	  ±	  0.191,	  3	  months	  4.30	  ±	  1.71,	  p=0.0104,	   fosinopril	  baseline	  1.00	  ±	  0.261,	  3	  
months	  48.1	  ±	  26.4,	  p=0.0103),	  (PAI-­‐1:	  placebo	  baseline	  1.00	  ±	  0.175,	  3	  months	  4.48	  ±	  1.22	  
p=0.001,	   fosinopril	  baseline	  1.00	  ±	   0.282,	  3	  months	  15.3	  ±	   9.33,	  p=0.023,	  Table	  16,	  Table	  
17).	  There	  was	  also	  a	  trend	  to	  an	  increase	  in	  the	  expression	  of	  ATG12l	  in	  the	  placebo	  group	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Table	  16	  Change	  in	  gene	  expression	  in	  the	  COPD	  patients	  given	  placebo	  from	  baseline	  to	  
Day	  90	  
Relative	  gene	  expression	  values	  of	  COPD	  patients	  given	  placebo	  at	  baseline	  and	  3	  months	  
for	  autophagy	   related	  and	  TGF-­‐β	  signalling	  genes.	  The	  expression	  of	   the	  placebo	  group	  at	  



























ATG4B	   1.00	  ±	  0.177	   0.932	  ±	  0.113	   ns	  
ATG12L	   1.00	  ±	  0.202	  	   2.70	  ±	  0.778	   0.059	  
BECLIN	   1.00	  ±	  0.156	   1.06	  ±	  0.146	   ns	  
LC3B	   1.00	  ±	  0.246	   1.07	  ±	  0.238	   ns	  
TGF-­‐β 	  
signalling	  
MYOSTATIN	   1.00	  ±	  0.191	   4.30	  ±	  1.71	   0.01	  
PAI-­‐1	   1.00	  ±	  0.175	   4.48	  ±	  1.22	   0.001	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Table	  17	  Change	  in	  gene	  expression	  in	  the	  COPD	  patients	  given	  fosinopril	  from	  baseline	  to	  
Day	  90	  
Relative	  gene	  expression	  values	  of	  COPD	  patients	  given	  fosinopril	  at	  baseline	  and	  3	  months	  
for	  autophagy	   related	  and	  TGF-­‐β	  signalling	  genes.	  The	  expression	  of	   the	  placebo	  group	  at	  
day	   90	   is	   normalised	   to	   baseline	   measurements	   within	   the	   same	   group	   (n=20	   fosinpril	  














ATG4B	   1.00	  ±	  0.207	   1.90	  ±	  0.621	   ns	  
ATG12L	   1.00	  ±	  0.296	  	   4.79	  ±	  2.12	   ns	  
BECLIN	   1.00	  ±	  0.189	  	   0.906	  ±	  0.195	   ns	  
LC3B	   1.00	  ±	  0.259	   2.26	  ±	  0.656	   ns	  
TGF-­‐β 	  
signalling	  
MYOSTATIN	   1.00	  ±	  0.261	   48.1	  ±	  26.4	   0.013	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5.2.3.5 Analysis	  of	  interaction	  between	  treatment	  and	  time	  
Analysis	  of	  the	  data	  using	  a	  two-­‐way	  ANOVA	  revealed	  that	  the	  effect	  of	  time	  had	  a	  
greater	  effect	  on	  MSTN,	  PAI-­‐1	  and	  ATG12L	  gene	  expression	  than	  that	  of	  fosinopril	  treatment	  
(Figure	   43,	   Figure	   44,	   Figure	   45).	   There	   was	   greater	   increase	   i.e.	   a	   greater	   change	   from	  
baseline	  to	  3	  months	  in	  MSTN	  mRNA	  levels	  in	  the	  fosinopril	  group	  compared	  to	  the	  placebo	  
group	  which	  did	  not	  reach	  significance	  (placebo	  Δchange	  0.276	  ±	  0.099,	   fosinopril	  0.762	  ±	  
0.274,	   p=0.072).	   There	   were	   no	   other	   significant	   differences	   in	   the	   change	   in	   gene	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Figure	  43	  Analysis	   of	   the	  effect	   of	   time	   compared	   to	   the	  effect	   of	   fosinopril	   on	  ATG12L	  
expression	  
There	  was	  a	  significant	  change	  on	  ATG12l	  expression	  in	  the	  placebo	  group	  from	  day	  0	  to	  day	  
90.	   There	  was	   no	   significant	   effect	   of	   fosinopril	   treatment.	   There	  was	   a	   greater	   effect	   of	  
time	  than	  of	  fosinopril	  treatment.	  Data	  analysed	  by	  two-­‐way	  to	  compare	  the	  effect	  of	  time	  
compared	   to	   treatment,	   with	   data	   points	   representing	   mean	   ±	   SEM	   and	   significance	   of	  


















































































Interaction p=0.586  ns
Time          p=0.008   **
Treatment p=0.564  ns
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Figure	  44	  Analysis	  of	  the	  effect	  of	  time	  compared	  to	  the	  effect	  of	  fosinopril	  on	  Myostatin	  
expression	  
There	  was	  a	  significant	  change	  on	  myostatin	  mRNA	  expression	  in	  the	  placebo	  and	  fosinopril	  
group	  from	  day	  0	  to	  day	  90.	  There	  was	  no	  significant	  effect	  of	   fosinopril	   treatment.	  There	  
was	   a	   greater	   effect	   of	   time	   than	   of	   fosinopril	   treatment.	   Data	   analysed	   by	   two-­‐way	   to	  
compare	  the	  effect	  of	  time	  compared	  to	  treatment,	  with	  data	  points	  representing	  mean	  ±	  



















































































Interaction p=0.0911  ns
Time          p=0.0001   **
Treatment p=0.1668  ns
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Figure	   45	   Analysis	   of	   the	   effect	   of	   time	   compared	   to	   the	   effect	   of	   fosinopril	   on	   PAI-­‐1	  
expression	  
There	  was	  a	  significant	  change	  on	  PAI-­‐1	  expression	  in	  the	  placebo	  and	  fosinopril	  group	  from	  
day	  0	  to	  day	  90.	  There	  was	  no	  significant	  effect	  of	  fosinopril	  treatment.	  There	  was	  a	  greater	  
effect	  of	  time	  than	  of	  fosinopril	  treatment.	  Data	  analysed	  by	  two-­‐way	  to	  compare	  the	  effect	  
of	  time	  compared	  to	  treatment,	  with	  data	  points	  representing	  mean	  ±	  SEM	  and	  significance	  































































Interaction p=0.5719  ns
Time          p=0.0004   **
Treatment p=0.4815  ns
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5.3 Discussion	  
The	   data	   presented	   above	   shows	   the	   complexity	   of	   the	   effect	   of	   chronic	   smoke	  
exposure	  on	  skeletal	  muscle.	  Muscle	  mass	   loss	  was	  observed	   in	   the	  smoke	  exposed	  mice,	  
and	   increased	   autophagy	   gene	   expression	   was	   observed.	   In	   COPD	   patients	   compared	   to	  
healthy	   controls,	   there	  was	  no	   significant	   difference	   in	   autophagy	   gene	  expression	   levels.	  	  
As	   the	   in	   vivo	   model	   is	   a	   simplified	   model	   of	   chronic	   cigarette	   smoke,	   it	   is	   not	   directly	  
comparable	  to	  the	  COPD	  disease	  state	  in	  humans.	  The	  data	  above	  has	  shown	  that	  there	  are	  
inherent	  differences	  between	  this	  chronic	  smoke	  exposure	  animal	  model	  and	  the	  disease	  in	  
man.	   Thus,	   inferences	   made	   from	   this	   in	   vivo	   model	   must	   be	   made	   with	   caution.	   One	  
example	   of	   a	   therapeutic	   target	   derived	   from	   animal	   model	   of	   a	   human	   disease	   not	  
translating	   directly	   in	   humans,	   is	   the	   anti-­‐TNF-­‐α	   therapy	  which	   although	  was	   effective	   in	  
murine	  emphysema,	  proved	  to	  be	  ineffective	  in	  humans	  (Barnes,	  2007,	  Churg	  et	  al.,	  2004).	  	  
It	   is	  difficult	   to	  distinguish	  the	  effect	  of	  smoke	  from	  that	  of	   the	  smoking	  apparatus	  
given	  the	   loss	   in	  body	  weight	  and	  also	  the	  significant	   increase	   in	  myostatin	   in	  both	  forced	  
and	   smoke	   air	   groups.	   It	   seems	   highly	   likely	   that	   the	   restraint	   of	   the	  mice	   in	   the	   smoke	  
exposure	  tower	  caused	  stress,	  which	  may	  have	   increased	  cortisol	   levels	  and	   induced	  body	  
weight	  loss	  (Simmons	  et	  al.,	  1984).	  Furthermore,	  these	  elevated	  stress	  levels	  may	  have	  also	  
increased	  myostatin	  levels,	  which	  would	  be	  consistent	  with	  cortisol	  induction	  of	  myostatin.	  
The	   correlation	   between	   myostatin	   and	   its	   purported	   target	   genes	   showed	   that	   the	  
signalling	  was	  indeed	  functional.	  This	  would	  strongly	  suggest	  that	  another	  mechanism	  was	  
involved	  in	  the	  smoke	  induced	  wasting	  in	  this	  model.	  Although	  no	  growth	  data	  was	  provided	  
in	  this	  model,	  the	  loss	   in	  body	  weight	   in	  both	  groups	  placed	  in	  the	  smoking	  apparatus	  has	  
been	  observed	  in	  a	  previous	  batch	  of	  samples	  from	  a	  smaller	  study	  (Figure	  47).	  
Examining	  the	  effect	  on	  smoke	  in	  vivo	  is	  in	  itself	  difficult	  due	  to	  species	  differences.	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Nevertheless,	  loss	  of	  muscle	  weight	  at	  least	  as	  measured	  by	  mass	  of	  the	  gastrocnemius	  was	  
restricted	  to	  the	  smoke	  air	  group.	  A	  number	  of	  COPD	  models	   in	  mice	  have	  also	  examined	  
the	   role	   of	   chronic	   cigarette	   smoke	   exposure	   on	  muscle	  mass	   and	   function	   (Caron	   et	   al.,	  
2013,	  Rinaldi	  et	  al.,	  2012,	  Gosker	  et	  al.,	  2009).	  	  Using	  a	  whole	  body	  exposure	  method	  for	  6	  
months,	  Caron	  et	  al.	  observed	  increased	  mRNA	  and	  protein	  levels	  of	  MuRF1	  and	  Atrogin-­‐1,	  
with	   a	   concomitant	   decrease	   in	   protein	   synthesis,	   phospho-­‐Akt/total	  Akt	   protein	   levels	   in	  
the	  gastrocnemius	  after	  6	  months.	  Gosker	  et	  al.	  performed	  a	  similar	  study	  exposing	  mice	  to	  
passive	  smoke	  in	  a	  whole	  body	  chamber	  for	  6	  months,	  where	  they	  observed	  a	  reduction	  in	  
body	  weight	  gain	  only	  in	  the	  smoke	  group.	  However,	  they	  observed	  a	  trend	  to	  a	  loss	  of	  mass	  
in	  the	  soleus	  muscle,	  and	  only	  in	  the	  soleus	  was	  a	  decrease	  in	  type	  IIA	  fibre	  type	  observed.	  
Gosker	  et	   al.	   showed	   that	   sham	  exposed	  mice	   did	   not	   lose	  weight	   using	   the	  whole	   body	  
method,	   nor	   was	   there	   a	   loss	   in	   any	   of	   the	   muscle	   groups	   examined	   including	   the	  
gastrocnemius.	   However,	   the	   model	   used	   here	   in	   this	   chapter,	   produced	   a	   greater	   and	  
significant	  loss	  of	  gastrocnemius	  muscle	  weight,	  whether	  the	  loss	  in	  muscle	  mass	  is	  global	  is	  
unknown	   as	   the	   other	   muscles	   were	   not	   examined.	   Additionally,	   whether	   there	   was	   a	  
significant	  effect	  on	  fibre	  type	  cannot	  be	  determined	  as	  the	  samples	  prepared	  for	  histology	  
were	  of	  poor	  quality.	  	  
Rinaldi	   et	   al.	   used	   a	   similar	   nose	   only	   smoking	   device	   to	   that	   used	   by	   GSK,	   and	  
observed	  only	   a	  mild	   dysfunction	   in	   the	   soleus	  with	   a	   fibre	   type	   change	   from	   IIA	   to	   IIB/X	  
after	   6	  months	   of	   exposure;	   however	   they	   did	   not	   observe	   any	   skeletal	  muscle	   atrophy.	  	  
Beckett	  et	  al.	  employed	  a	  high	   intensity	  nose	  only	  method,	  over	  a	  much	  shorter	  time	  of	  2	  
months	   and	   showed	   this	   smoke	   exposure	   was	   sufficient	   to	   cause	   COPD	   and	   quadriceps	  
wasting	   (Beckett	   et	   al.,	   2013).	   The	  data	   from	   the	  model	   studied	   in	   this	   chapter	  may	   vary	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from	   others	   as	   due	   to	   the	   duration	   of	   the	   exposure	   smoke	   and	   the	   method	   of	   smoke	  
exposure.	  
An	  increase	  in	  expression	  of	  all	  MyHC	  isoforms	  was	  observed	  in	  the	  smoke	  air	  group	  
compared	  to	  the	  forced	  air	  group	  and	  this	  is	  consistent	  with	  analyses	  from	  the	  smaller	  study	  
(n=8-­‐9)	  using	  the	  same	  smoke	  exposure	  model.	  This	   increase	  in	  the	  expression	  of	  some	  of	  
the	  myosin	  heavy	  chain	  genes	  may	  be	  a	  compensatory	  mechanism	  by	  which	   the	  muscles,	  
which	  have	  wasted,	  are	  attempting	  to	  regenerate	  and	  synthesise	  new	  myosins.	  
	   Smoking	   suppressed	   Tgf-­‐β	   and	   Myostatin,	   with	   the	   down	   regulation	   of	   TGF-­‐β	  
signalling	   components-­‐	   Vegf-­‐C	   and	   Pai-­‐1.	   Concomitantly	   there	   was	   an	   increase	   the	  
expression	  of	  the	  inhibitory	  Smad7	  (Kollias	  et	  al.,	  2006).	  PAI-­‐1	  is	  a	  well-­‐known	  target	  of	  TGF-­‐
β	  signalling,	  and	  SMAD7	  has	  been	  shown	  previously	  to	  antagonise	  TGF-­‐β	  signalling	  (Keeton	  
et	  al.,	  1991,	  Kavsak	  et	  al.,	  2000).	  The	   reduction	   in	  myostatin	  expression	  may	  have	  caused	  
the	   reduction	   in	   downstream	   signalling;	   alternatively	   the	   increase	   in	   Smad7	   may	   have	  
resulted	   in	   a	   reduction	   in	   the	   activity	   of	   the	   TGF-­‐β	   signalling	   pathway.	   However,	   as	  
myostatin	  is	  increased	  by	  TGF-­‐β	  (Budasz-­‐Rwiderska	  et	  al.,	  2005),	  it	  is	  also	  possible	  that	  the	  
increase	  in	  SMAD7	  is	  the	  cause	  of	  the	  reduction	  in	  all	  of	  the	  factors.	   It	   is	  possible	  that	  the	  
down	  regulation	  of	  TGF-­‐β	  signalling	  and	  increase	  in	  SMAD	  7	  expression	  observed	  after	  the	  
period	  of	  cigarette	  exposure	   is	  due	  to	  the	  negative	   feedback	  mechanism	  between	  SMAD7	  
and	  myostatin	  (Forbes	  et	  al.,	  2006,	  Zhu	  et	  al.,	  2004).	  As	  there	  are	  no	  other	  time	  points	  in	  the	  
experiment,	  myostatin	   expression	  may	   have	   peaked	   earlier	   in	   the	   study	   thus	   the	   role	   of	  
myostatin	  in	  causing	  the	  loss	  of	  muscle	  cannot	  be	  ruled	  out.	  	  
VEGF-­‐C	   is	   a	   factor	   shown	   to	   be	   inducible	   by	   TGF-­‐β	   signalling	   (Suzuki	   et	   al.,	   2012),	  
furthermore	   the	   decrease	   in	   Vegf-­‐C	   observed	   in	   the	   model	   may	   indicate	   a	   decrease	   in	  
angiogenesis	   and	   vascularisation	   of	   skeletal	   muscle	   in	   the	   smoke	   mice	   (Anisimov	   et	   al.,	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2009).	  The	  decrease	  in	  Vegf-­‐C	  may	  indicate	  that	  smoke	  prevents	  muscle	  from	  repair	  caused	  
by	   its	   hypoxic	   effects	   (Anisimov	   et	   al.,	   2009).	   A	   decrease	   in	   another	   vascular	   endothelial	  
factor	   –VEGF-­‐A	   has	   also	   been	  observed	   in	   the	   lung	   in	   in	   vitro	  models	   of	   smoke	   exposure	  
(Thaikoottathil	  et	  al.,	  2009,	  Basic	  et	  al.,	  2012).	  Basic	  et	  al.	  have	  also	  observed	  a	  reduction	  in	  
capillarisation	   in	   gastrocnemius	   muscle	   with	   a	   reduced	   fibre	   cross	   sectional	   area	   and	  
exercise	  tolerance	  in	  smoke	  exposed	  mice	  (Basic	  et	  al.,	  2012).	  Thus,	  the	  reduction	  in	  Vegf-­‐C	  
observed	   here	  may	   indicate	   that	   the	   smoke	   exposed	  mice	   in	   this	  model	   also	   had	  muscle	  
dysfunction	   similar	   to	   that	   found	   in	   COPD	   patients,	   where	   reduced	   capillarisation	   is	   also	  
observed	  (Jobin	  et	  al.,	  1998).	  
There	  was	  an	  increase	  in	  mRNA	  expression	  of	  a	  number	  of	  autophagy	  related	  genes,	  
Atg12l,	  Ulk-­‐2	  and	  Beclin,	  but	   there	  was	  a	   significant	  decrease	   in	  Atg4b.	  All	   the	  autophagy	  
genes	  analysed	  are	  required	  in	  autophagosome	  formation,	  with	  the	  exception	  of	  Gabarap1l,	  
which	  is	  also	  a	  homolog	  of	  Lc3b	  (Mizushima	  et	  al.,	  2011).	  One	  explanation	  for	  the	  reduction	  
in	   Atg4b	   is	   the	   association	   of	   Atg4B	   with	   myostatin	   expression	   and	   the	   suppression	   of	  
myostatin	  in	  the	  smoke	  exposed	  animals.	  However,	  as	  there	  was	  no	  uniform	  change	  in	  the	  
expression	  of	  the	  autophagy	  related	  genes,	  and	  as	  mRNA	  expression	  does	  not	  directly	  relate	  
to	   protein	   expression;	   no	   definite	   conclusion	   can	   be	   drawn.	   Furthermore	   examination	   of	  
autophagosomes	  in	  situ	  was	  not	  possible	  due	  to	  the	  poor	  condition	  of	  the	  sections.	  
There	   was	   no	   change	   in	   the	   other	   protein	   degradation	   pathways-­‐	   apoptosis	   and	  
proteasomal	  degradation.	  Whilst	   the	   lack	  of	   change	   in	  expression	  may	   suggest	   that	   these	  
pathways	   are	   not	   involved	   in	   the	   atrophy	   observed,	   the	   role	   of	   the	   pathways	   cannot	   be	  
excluded	  at	  the	  earlier	  stages	  in	  smoking	  model.	  Given	  that	  Gosker	  et	  al.	  observed	  changes	  
in	   proteasomal	   degradation	   at	   6	   months,	   the	   pathways	   examined	   may	   have	   been	   more	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active	   at	   earlier	   time	   points	   in	   the	   study.	   	   Furthermore	  measuring	  mRNA	   levels	   does	   not	  
equate	  to	  measuring	  pathway	  activity.	  
Comparing	   the	   COPD	   patients	   and	   healthy	   controls,	   Dr	   Shrikrishna	   reported	   a	  
significant	   reduction	   in	   IGF-­‐1	  mRNA	   and	  MyoD	   in	   COPD	   patients,	   however	   there	   was	   no	  
change	   in	   Atrogin1	   or	   MuRF-­‐1	   mRNA	   expression	   (Shrikrishnapalasuriyar,	   2013).	   Dr	  
Shrikrishna	  also	  reported	  a	  significant	  reduction	  in	  MHC	  type	  I	   in	  COPD	  patients	  compared	  
to	   healthy	   controls,	   but	   no	   other	   changes	   were	   observed	   in	   the	   other	   isoforms.	   In	   this	  
present	   study	   of	   autophagy	   and	   myostatin	   gene	   expression,	   there	   were	   no	   significant	  
differences	   between	   the	   patient	   cohort	   and	   healthy	   controls.	   Patients	  were	   recruited	   for	  
this	   study	   specifically	   with	   the	   presence	   of	   weakness,	   which	   was	   defined	   as	   a	   having	   a	  
strength	   measurement	   of	   less	   than	   120%	   of	   the	   patient’s	   body	   mass	   index	  
(Shrikrishnapalasuriyar,	  2013).	   These	  patients	  did	  not	  necessarily	  have	  muscle	  wasting	   i.e.	  
low	  FFMI,	  which	  was	  calculated	  by	  dividing	  fat	  free	  mass	  by	  height	  squared	  in	  metres.	  Perhaps	  
in	  patients	  with	  more	  pronounced	  loss	  of	  muscle	  mass,	  greater	  molecular	  changes	  would	  be	  
detected.	   The	   lack	   of	   changes	   observed	   otherwise	   in	   autophagy	   related	   gene	   expression	  
might	  suggest	  in	  fact	  that	  autophagy	  does	  not	  play	  a	  key	  role	  in	  COPD.	  	  
	   Physiological	  changes	  between	  the	  patients	  groups	  (data	  gathered	  by	  Dr	  Shrikrishna)	  
showed	   that	   although	   the	   fosinopril	   group	   did	   increase	   in	   strength	   (QVMC)	   compared	  
baseline	   measurements,	   the	   placebo	   group	   showed	   a	   greater	   improvement.	   Directly	  
comparing	   the	   groups	   at	   3	   months,	   the	   fosinopril	   group	   was	   weaker	   compared	   to	   the	  
placebo	   group,	   which	  may	   be	   a	   result	   of	   the	  mild	   increase	   in	  myostatin	   observed	   in	   the	  
fosinopril	  group.	  A	  longitudinal	  analysis	  of	  the	  two	  time	  points	  within	  the	  treatment	  groups,	  
showed	  that	  in	  both	  groups,	  patients	  showed	  an	  increase	  in	  myostatin	  and	  PAI-­‐1	  expression,	  
however,	  the	  implications	  of	  this	  increase	  is	  unclear	  as	  the	  patients	  showed	  no	  deterioration	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in	  health	   (Table	  19).	   There	  was	  a	   trend	   to	  an	   increase	   in	  ATG12l	  mRNA	  expression	   in	   the	  
placebo	  group	  between	  baseline	  and	  day	  90.	  	  
	   Overall	  the	  data	  herein	  suggests	  that	  whilst	  autophagy	  gene	  expression	  is	  increased	  
in	  a	  chronic	  smoke	  exposure	  model	  in	  mice,	  autophagy	  gene	  expression	  does	  not	  appear	  to	  
be	   increased	   in	  COPD	  patients.	  The	  attenuation	  of	  angiotensin	  signalling	  by	  ACE	   inhibition	  
had	  no	  effect	  on	  autophagy.	  The	  data	  presented	  here	  suggests	  that	  autophagy	  may	  not	  be	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6.1 Summary	  of	  results	  
The	  work	  in	  this	  thesis	  has	  explored	  the	  mechanisms	  by	  which	  myostatin	  contributes	  
to	  muscle	  wasting	  and	  the	  role	  of	  autophagy	  in	  muscle	  atrophy	  with	  particular	  reference	  to	  
COPD.	  The	  work	  in	  chapter	  3	  showed	  that	  myostatin,	  a	  protein	  known	  to	  be	  increased	  and	  
associated	  with	  weakness	   in	   COPD,	   induces	   autophagy	   in	  muscle	   cells	   in	   vitro,	   suggesting	  
that	   at	   least	   part	   of	   the	   mechanism	   by	   which	   myostatin	   causes	   muscle	   wasting	   is	   by	  
increasing	   this	  pathway.	   In	   the	   fourth	  chapter	  a	  novel	  mechanism	  by	  which	   the	  effects	  of	  
myostatin	  may	  be	  amplified	  in	  a	  specific	  fibre-­‐type	  were	  examined.	  	  This	  data	  showed	  that	  
the	  protein	  FHL1	  amplifies	  the	  effects	  of	  myostatin	  in	  vitro	  and	  in	  vivo.	  	  As	  FHL1	  expression	  
is	  higher	  in	  type	  II	  fibres	  this	  data	  suggests	  that	  myostatin	  function	  will	  be	  amplified	  in	  type	  
II	   fibres.	   	  Consequently,	   in	  COPD	  where	  there	  is	  a	  fibre-­‐shift	  towards	  type	  II	   fibres,	  FHL1	  is	  
likely	  to	  contribute	  to	  muscle	  wasting.	  	  Finally,	  in	  chapter	  5,	  the	  contribution	  of	  autophagy	  
to	   muscle	   wasting	   in	   response	   to	   smoking	   and	   COPD	   was	   examined	   by	   comparing	   the	  
expression	  of	   components	  of	   the	  autophagy	  pathway	   in	  mice	  exposed	   to	  cigarette	   smoke	  
over	  a	  19	  month	  period	  and	  in	  patients	  with	  COPD	  before	  and	  after	  treatment	  with	  an	  ACE	  
inhibitor.	  Consistent	  changes	  in	  the	  expression	  of	  genes	  associated	  with	  autophagy	  were	  not	  
observed	   in	   either	   study	   and	   the	   absence	   of	   protein	   data	   make	   it	   difficult	   to	   make	   any	  
conclusions	   on	   the	   contribution	   of	   autophagy	   to	   muscle	   wasting	   in	   these	   situations.	  
Furthermore,	   the	   smoke	  exposure	  mouse	  model	   showed	  a	  marked	   stress	   response	   in	   the	  
control	   animals	   probably	   due	   to	   restraint.	   These	   studies	  were	   further	   limited	   by	   the	   low	  
availability	   of	   tissue	   and	   to	   the	   poor	   quality	   of	   sections	   obtained	   from	   both	   studies	  
preventing	   appropriate	   in	   situ	   analysis	   of	   proteins.	   The	   wider	   relevance	   of	   the	   work	   is	  
analysed	  below	  individually	  and	  then	  as	  a	  whole.	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6.2 Induction	  of	  autophagy	  by	  myostatin	  	  
Myostatin	   has	   been	   shown	   to	   increase	  MuRF1	   in	  muscle	   (McFarlane	   et	   al.,	   2006),	  
however,	  studies	  of	  muscle	  biopsies	  from	  COPD	  patients	  with	  atrophy	  have	  not	  observed	  an	  
significant	   changes	   in	  MuRF1	   protein	   levels	   compared	   to	   patients	  with	   preserved	  muscle	  
mass	   (Doucet	   et	   al.,	   2007,	   Natanek	   et	   al.,	   2013b),	   thus	   myostatin	   may	   induce	   other	  
mechanisms	   to	   bring	   about	   its	   atrophy	   effects.	   The	   data	   in	   Chapter	   3	   has	   shown	   that	  
myostatin	   is	   a	   novel	   inducer	   of	   autophagy	   in	   skeletal	   muscle.	   Although	   autophagy	   is	   a	  
constituently	  active	  process,	  the	  rate	  of	  autophagy	  is	  regulated	  and	  myostatin	  may	  further	  
enhance	   autophagy	   above	   the	   basal	   rate,	   to	   contribute	   to	   the	   loss	   of	   protein	   and	   thus	  
muscle	   mass	   in	   diseases	   such	   as	   COPD.	   The	   induction	   of	   autophagy	   by	  myostatin	   would	  
provide	   a	   potential	   mechanism	   for	   the	   loss	   of	   muscle	   mass	   in	   COPD	   other	   than	   the	  
ubiquitin-­‐proteasomal	  pathway	  that	  has	  proved	  not	  to	  be	  involved.	  	  
Several	   lines	   of	   evidence	   showed	   that	   myostatin	   increased	   autophagy;	   increased	  
gene	   expression,	   LC3-­‐II	   turnover	   and	   as	   well	   as	   number	   of	   LC3-­‐GFP	   transfected	  
autophagosomes	  were	  all	  observed	  in	  murine	  skeletal	  muscle	  cells.	  In	  the	  field	  of	  autophagy	  
research,	   a	   number	   of	   techniques	   must	   be	   employed	   to	   ensure	   reliability	   in	   observing	  
changes	  in	  autophagy	  (Barth	  et	  al.,	  2010,	  Mizushima	  et	  al.,	  2010).	  Whilst	  other	  techniques	  
such	  as	  p62	  protein	  degradation	  could	  have	  been	  used,	   the	  use	  of	   several	   techniques	  has	  
added	  consistency	  to	  the	  theory	  presented	  here.	  	  
The	  signalling	  pathway	  by	  which	  myostatin	  induces	  autophagy	  has	  yet	  to	  be	  clarified	  
in	  skeletal	  muscle.	  Kiyono	  et	  al.	  have	  shown	  that	  the	  knock	  down	  of	  SMAD	  proteins	  as	  well	  
as	   inhibition	  of	  JNK	  attenuated	  TGF-­‐β	  induced	  autophagy	  in	  hepatocellular	  carcinoma	  cells	  
(Kiyono	   et	   al.,	   2009,	   Suzuki	   et	   al.,	   2010). However,	   another	   likely	   pathway	   is	   via	   the	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inhibition	   of	   AKT/mTOR	   signalling,	   as	   TGF-­‐β	   has	   been	   shown	   to	   induce	   autophagy	   by	   the	  
induction	   of	   PI3K-­‐Akt-­‐mTOR-­‐S6K	   signalling	  in	   mesangial	   cells	   (Ding	   et	   al.,	   2010).	   AKT	  
activates	  two	  pathways,	  it	  is	  associated	  with	  protein	  synthesis	  and	  growth	  in	  skeletal	  muscle	  
through	   mTOR	   and	   secondly	   AKT	   inhibits	   protein	   degradation	   by	   inhibiting	   FoxO	  
transcription	   factors	   (Bodine	   et	   al.,	   2001b,	   Pallafacchina	   et	   al.,	   2002,	   Sandri	   et	   al.,	   2004).	  
Autophagosome	  formation	  has	  shown	  to	  be	  regulated	  by	  AKT	  in	  skeletal	  muscle	  and	  FoxO3	  
has	   been	   shown	   to	   regulate	   autophagy	   (Mammucari	   et	   al.,	   2007b). Myostatin	   has	   been	  
shown	  to	  inhibit	  protein	  synthesis	  by	  inhibiting	  AKT	  (Trendelenburg	  et	  al.,	  2009).	  Myostatin	  
has	   also	   been	   shown	   to	   up-­‐regulate	   the	   transcription	   factor	   FoxO3	   in	   human	   myotubes	  
(Lokireddy	   et	   al.,	   2011).	   Thus	   by	   inhibiting	   AKT,	   myostatin	   would	   be	   able	   to	   induce	  
autophagy.	  	  
These	  suggestions	  could	  be	  further	  explored	  for	  example	  with	  use	  of	  AKT	  inhibitors	  
or	   knocking	  down	  FoxO3	  expression	  with	   siRNA	  and	   then	   treating	   cells	  with	  myostatin	   to	  
see	   if	  autophagy	   is	   still	   enhanced	   in	  cell	   culture.	  Similarly,	  experiments	  attenuating	  SMAD	  
proteins	  and	  MAP	  kinases	  such	  as	  the	  ones	  previously	  mentioned	  would	  also	  clarify	  whether	  
SMAD	  and/or	  MAP	  kinase	  signalling	  is	  also	  involved	  in	  myostatin	  induced	  autophagy.	  	  
	   Lokireddy	  et	  al.	   recently	   showed	   that	  myostatin	   induced	   the	  protein	  expression	  of	  
Mul1,	   a	  mitochondrial	   E3	   ubiquitin	   ligase	   expression,	   and	   lead	   to	   increase	  mitochondrial	  
fragmentation	   and	   degradation	   (Lokireddy	   et	   al.,	   2012b).	   The	   induction	   of	   mitophagy	  
(selective	   degradation	   of	   mitochondria	   by	   the	   autophagy	   lysosomal	   pathway)	   by	   Mul1	  
(Youle	   and	   Narendra,	   2011)	   could	   therefore	   add	   to	   the	   increased	   degradation	   of	  muscle	  
fibres	   and	   perhaps	   the	   loss	   of	  muscle	  mass	   in	   COPD.	   	   Furthermore,	   loss	   of	  mitochondria	  
occurs	  as	  part	  the	  fibre	  shift	  from	  type	  I-­‐	  to	  type	  II	  fibres	  that	  occur	  in	  COPD	  patients.	  This	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response	  will	   require	  both	  proteolysis	  of	  mitochondrial	  proteins	  as	  well	  as	   the	   removal	  of	  
the	  mitochondria	  by	  autophagy.	   It	   is	  therefore	  possible	  that	   in	  COPD	  that	  the	  induction	  of	  
autophagy	  by	  myostatin	  contributes	  to	  the	  reduction	  in	  mitochondrial	  number	  that	  occurs	  
in	  COPD.	  	  Given	  that	  myostatin	  signalling	  is	  stronger	  in	  type	  II	  fibres	  (see	  section	  1.4.2.4)	  it	  is	  
seems	  more	  likely	  that	  myostatin	  contributes	  to	  the	  loss	  of	  mitochondria	  in	  fibres	  that	  have	  
already	  switched	  to	  a	  type	  II	  phenotype	  or	  at	  least	  have	  started	  to	  increase	  the	  expression	  
of	  FHL1.	  	  
The	  data	  suggests	  that	  myostatin	  may	  use	  autophagy	  to	  cause	  wasting	   in	  vitro.	  The	  
induction	  of	  autophagy	  by	  myostatin	  in	  vivo	  was	  further	  explored	  in	  Chapter	  4.	  
	  
6.3 Interaction	  of	  Myostatin	  and	  FHL1	  in	  skeletal	  muscle	  
FHL1	  is	  another	  important	  protein	  in	  muscle	  mass	  regulation,	  and	  its	  function	  appears	  
to	  be	  context	  dependent.	  When	  over-­‐expressed	  alone,	  FHL1	  causes	  hypertrophy	  (Cowling	  et	  
al.,	  2008),	  however	  the	  data	  in	  Chapter	  4	  has	  shown	  that	  in	  the	  presence	  of	  myostatin,	  FHL1	  
enhances	  myostatin	  signalling	  both	   in	  vitro	  and	   in	  vivo.	  FHL1	  enhanced	  myostatin	   induced	  
myotube	  atrophy.	  Furthermore,	  of	  the	  3	  groups	  studied	  in	  the	  electroporation	  model,	  only	  
the	  myostatin	  +	   FHL1	  over-­‐expressing	  group	   showed	   significant	   changes	   in	   all	   the	  protein	  
degradation	  pathways	   that	  were	  examined.	  This	  would	   strongly	   suggest	   that	  FHL1	  plays	  a	  
different	   role	   in	   the	   regulation	   of	  muscle	  mass	   depending	   on	   the	   signalling	   environment	  
within	  the	  cell.	  	  Furthermore	  the	  data	  raise	  the	  possibility	  of	  FHL1	  contributing	  to	  the	  fibre-­‐
specific	  effects	  of	  myostatin	  as	  FHL1	   is	  preferentially	  expressed	   in	  type	   II	   fibres,	  which	  are	  
the	  fibres	  that	  are	  most	  susceptible	  to	  myostatin	  induced	  atrophy.	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   The	  data	  are	  limited	  by	  the	  number	  of	  mice	  analysed	  in	  each	  group	  so	  it	  would	  be	  of	  
interest	  to	  repeat	  the	  experiment	  in	  a	  larger	  group	  of	  mice,	  to	  confirm	  protein	  expression	  of	  
FHL1	  and	  myostatin	  as	  well	  as	  fibre	  type	  changes.	  Much	  of	  the	  data	  presented	  displaying	  the	  
interaction	  between	  FHL1	  and	  myostatin	  has	  been	  gene	  expression.	  The	  argument	  would	  be	  
further	   strengthened	   by	   perhaps	   using	   immuno-­‐precipitation	   to	   show	   the	   physical	  
interaction	  between	  FHL1	  and	  myostatin	  signalling	  pathway	  components	  in	  skeletal	  muscle.	  
In	   addition,	   immuno-­‐staining	   or	   western	   blotting	   confirming	   the	   over-­‐expression	   of	   FHL1	  
and	  myostatin	  expression	  (via	  SMAD	  signalling)	  would	  be	  useful.	  	  
	   Measurements	  such	  as	  the	  tetanic	  and	  twitch	  force	  of	  the	  electroporated	  TA	  might	  
also	   show	  differences	  between	   the	   strength	  of	   the	  myostatin	   +	   FHL1	  over-­‐expressing	   TAs	  
and	   the	   other	   groups	   (Hakim	   et	   al.,	   2011).	   An	   improved	   method	   such	   as	   an	   automated	  
program	  of	  counting	  the	  different	   fibre	  types	  may	  also	  show	  more	  subtle	  changes	   in	   fibre	  
proportion.	  Further	  to	  this,	  an	  automated	  method	  of	  fibre	  diameter	  and/or	  area	  measuring	  
would	  also	  increase	  consistency,	  accuracy	  and	  output	  if	  a	  larger	  group	  were	  studied.	  
	   	  The	  data	  presented	  in	  Chapter	  4	  proposes	  a	  mechanism	  for	  the	  association	  of	  FHL1	  
with	  weakness	  and	  inactivity	  observed	  in	  the	  cohort	  of	  COPD	  patients	  previously	  studied	  in	  
the	  group	  (Lewis	  et	  al.,	  2010).	  FHL1	  over-­‐expression	  has	  been	  shown	  to	  cause	  an	  increase	  in	  
type	   IIA	   fibres,	   thus	   indicating	   that	   FHL1	   can	   drive	   fibre	   shift	   (Cowling	   2008).	   As	   COPD	  
patients	   become	   more	   inactive,	   FHL1	   expression	   increases,	   resulting	   in	   an	   increase	  
proportion	   of	   fast	   twitch	   type	   II	   fibres.	   Aside	   from	   the	   increase	   in	   proportion	   of	   type	   II	  
fibres,	  the	  type	  II	  fibres	  have	  a	  reduced	  fibre	  diameter	  (Gosker	  et	  al.,	  2002a,	  Natanek	  et	  al.,	  
2013a),	   suggesting	   that	   perhaps	   type	   II	   fibres	   have	   increased	   susceptibility	   to	   atrophy	  
signals.	  As	  both	  myostatin	  and	  FHL1	  expression	  is	  associated	  with	  type	  II	  fibres	  (Lewis	  et	  al.,	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2010,	  Hennebry	  et	  al.,	  2009);	  the	  data	  presented	  here	  would	  suggest	  that	  the	  atrophy	  effect	  
of	   myostatin	   is	   enhanced	   in	   fast	   twitch	   fibres	   as	   these	   fibres	   also	   express	   more	   FHL1,	  
causing	   increased	   protein	   degradation	   and	  wasting	   in	   these	   fibres.	   The	   shift	   in	   fibre	   type	  
may	  drive	  a	  positive	  feedback	  mechanism	  as	  there	  are	  more	  type	  II	  fibres	  expressing	  more	  
FHL1,	  enhancing	  fibre	  atrophy	  and	  muscle	  dysfunction.	  	  In	  addition,	  the	  increased	  activity	  of	  
Mul1	  due	  to	  increased	  myostatin	  signalling	  in	  type	  II	  fibres	  may	  also	  contribute	  to	  increased	  
loss	  of	  mitochondria	   in	   these	  muscle	   fibres	  during	  atrophy	  and	  also	  add	   to	   the	   fibre	   shift	  
observed	  in	  COPD.	   	   	  	  
	   It	   is	   difficult	   to	   confirm	   the	   in	   vitro	   observations	   in	   patients	   as	   it	   is	   challenging	   to	  
measure	  changes	  caused	  by	  the	  augmentation	  of	  myostatin	  signalling	  by	  FHL1.	  For	  example,	  
no	  changes	  in	  FHL1	  mRNA	  levels	  were	  detected	  in	  patients	  compared	  to	  control,	  however,	  
this	  may	  not	  necessarily	  imply	  that	  FHL1	  does	  not	  potentiate	  myostatin	  signalling,	  FHL1	  may	  
be	  more	  available	   (i.e.	  not	  bound	   to	  other	  proteins	   in	   the	   cell)	   to	  act	  upon	   the	   increased	  
myostatin	   signalling	  within	   the	   fibre.	  Thus	   it	  would	  be	  of	   interest	   to	  verify	   the	   location	  of	  
FHL1	  within	  patient	  muscle	  biopsies	  with	   immuno-­‐staining	  and	   to	  co-­‐stain	   for	  SMADs	  and	  
phospho-­‐SMADs	   to	  examine	   if	   the	   two	  proteins	   co-­‐localise	  within	   the	   fibres.	  Despite	   this,	  
the	  results	  of	  myostatin	  signalling	  enhancement	  may	  only	  be	  detectable	  as	   fibre	   type	  and	  
diameter	  changes,	  as	  it	  is	  unknown	  when	  the	  changes	  in	  myostatin	  signalling	  occur	  in	  COPD.	  
Laser	   capture	  micro-­‐dissection	   (LCM)	   can	   be	   used	   to	   dissect	   out	   specific	   fibres	   based	   on	  
immuno-­‐fluorescent	  staining	  from	  PFA	  fixed	  muscle	  biopsies	  to	  isolate	  only	  type	  II	  fibres	  for	  
mRNA	  and	  protein	  analysis	  (Vanderburg	  and	  Clarke,	  2013).	  Type	  II	  enriched	  samples	  could	  
then	   be	   used	   to	   examine	   if	   more	   FHL1	   was	   present	   in	   patients	   samples	   compared	   to	  
controls	   and	   if	   the	   expression	   of	   downstream	   signalling	   targets	   of	  myostatin	   (i.e.	   targets	  
measurement	  in	  Chapter	  4)	  were	  enhanced.	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6.4 GDF-­‐15,	  autophagy	  and	  skeletal	  muscle	  wasting	  
	   The	   experiments	   with	   GDF-­‐15	   have	   highlighted	   that	   not	   all	   TGF-­‐β	   superfamily	  
members	  behave	  in	  a	  similar	  manner.	  Unlike	  myostatin	  and	  TGF-­‐β,	  GDF-­‐15	  was	  not	  a	  strong	  
inducer	  of	  autophagy.	  GDF-­‐15	  did	  not	  appear	  to	  interact	  with	  FHL1	  unlike	  myostatin.	  Indeed	  
FHL1	  did	  not	  enhance	  the	  atrophy	  effect	  of	  GDF-­‐15	  in	  myotubes.	  A	  number	  of	  studies	  have	  
examined	  the	  link	  between	  GDF-­‐15	  and	  reduced	  body	  weight	  (Macia	  et	  al.,	  2012,	  Johnen	  et	  
al.,	  2007),	   in	  mice	  and	  cachexia	   in	  cancer,	  chronic	  heart	   failure	  and	   ICU	  acquired	  cachexia	  
(Kempf	  et	  al.,	  2007,	  Wakchoure	  et	  al.,	  2009,	  Pfitzenmaier	  et	  al.,	  2003,	  Johnen	  et	  al.,	  2007,	  
Bloch	  et	  al.,	  2013).	  	  	  
In	   the	   studies	   of	   Johnen	  et	   al.,	   the	   authors	   concluded	   that	   the	   cachectic	   effect	   of	  
GDF-­‐15	  occurred	  in	  response	  to	  effects	  of	  GDF-­‐15	  on	  the	  hypothalamus	  leading	  to	  reduced	  
appetite.	   	  However,	  the	   in	  vitro	  data	  presented	  here	  strongly	  suggests	  that	  GDF-­‐15	  causes	  
atrophy	   in	   skeletal	   muscle	   suggesting	   a	   more	   direct	   effect	   of	   GDF-­‐15	   in	   muscle.	   This	  
observation	  would	  be	  consistent	  with	   the	  association	  of	  GDF-­‐15	  with	  muscle	  wasting	   that	  
we	  demonstrated	   in	   ICU	  acquired	  weakness	  because	   in	   these	  patients	   the	   rate	  of	  muscle	  
loss	   was	   too	   fast	   for	   a	   suppression	   of	   appetite	   to	   be	   the	   cause,	   as	   suggested	   by	   animal	  
studies.	  Thus,	  the	  effect	  of	  GDF-­‐15	  over-­‐expression	  via	  TA	  electroporation	  method	  in	  mice	  
(in	   the	  same	  manner	  as	   the	  myostatin	  and	  FHL1	  model	  used	  here)	  could	  be	  quantified	  by	  
measuring	  fibre	  type	  and	  diameter	  to	  provide	  evidence	  for	  this	  theory.	  
	   It	  has	  been	  reported	  that	  GDF-­‐15	  binds	  TGF-­‐β	  RII	  (Kempf	  et	  al.,	  2011)	  but	  this	  has	  yet	  
to	   be	   verified	   in	  muscle.	   The	   signalling	   pathways	   activated	   by	   GDF-­‐15	   are	   still	   unclear;	   it	  
would	  also	  be	  of	  great	   interest	  to	  examine	  the	  pathways	  that	  are	  up	  regulated	  by	  GDF-­‐15	  
with	  the	  muscle	  samples	  obtained	  from	  the	  GDF-­‐15	  over-­‐expression	  model	  and	  examining	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the	  gene	  expression	  in	  an	  mRNA	  array.	  However,	  analysis	  of	  autophagy	  gene	  expression	  and	  
LC3-­‐II	  protein	  levels	  in	  cell	  culture	  suggest	  that	  GDF-­‐15	  does	  not	  induce	  autophagy	  to	  bring	  
about	  its	  atrophy	  effects.	  
	   Additionally,	  levels	  of	  GDF-­‐15	  have	  yet	  to	  be	  measured	  in	  COPD	  patients	  with	  muscle	  
atrophy.	  Analysis	  of	  muscle	  and	  serum	  GDF-­‐15	  levels	  would	  consolidate	  the	  data	  from	  other	  
diseases	  with	  muscle	  wasting	  as	  co-­‐morbidity.	  Furthermore,	  given	  that	  myostatin	  and	  TGF-­‐β	  
associate	   with	   fast	   fibre	   types,	   it	   would	   also	   be	   interesting	   to	   examine	   if	   there	   is	   an	  
association	  between	  GDF-­‐15	  and	  fibre	  type	  in	  COPD	  muscle	  samples.	  
	  
6.5 Ang-­‐II	  and	  autophagy	  in	  skeletal	  muscle	  wasting	  	  
While	  ang-­‐II	  has	  been	  shown	  to	  cause	  muscle	  wasting	  (Sanders	  et	  al.,	  2005,	  Brink	  et	  
al.,	  1996,	  Russell	  et	  al.,	  2006),	  the	  data	  presented	  here	  suggests	  that	  this	  is	  not	  induced	  via	  
autophagy.	  Ang-­‐II	  induced	  LC3-­‐II	  expression	  only	  to	  a	  small	  degree	  in	  skeletal	  muscle	  in	  vitro	  
although	   it	   has	   previously	   been	   shown	   to	   induce	   autophagy	   in	   podocytes	   (Yadav	   et	   al.,	  
2010).	  Similar	  to	  other	  studies,	  ang-­‐II	  caused	  wasting	  of	  myotubes	  in	  cell	  culture;	  however,	  
this	  was	  not	  augmented	  by	  FHL1.	  	  Attenuation	  of	  ang-­‐II	  signalling	  via	  ACE	  inhibition	  did	  not	  
affect	  autophagy	  gene	  expression	  in	  COPD	  patients	  after	  3	  months	  of	  fosinopril	  treatment.	  
Overall,	  these	  results	  imply	  that	  ang-­‐II	  uses	  other	  pathways	  of	  protein	  degradation	  such	  as	  
the	   ubiquitin-­‐proteasome	   and/or	   apoptosis	   as	   well	   as	   the	   inhibition	   of	   protein	   synthesis	  
(Fabris	  et	  al.,	  2007,	  Sanders	  et	  al.,	  2005,	  Russell	  et	  al.,	  2006)	  to	  induce	  muscle	  wasting.	  
Ang-­‐II	   did	   not	   interact	   with	   FHL1	   and	   the	   ang-­‐II	   induced	   wasting	   was	   not	   further	  
enhanced	  by	  FHL1.	  The	  role	  of	  ang-­‐II	   in	  muscle	  atrophy	  has	  been	  explored	  with	  the	  use	  of	  
ACE	  inhibitors	  in	  several	  trials	  in	  the	  elderly	  (Sumukadas	  et	  al.,	  2007,	  Carter	  et	  al.,	  2005).	  The	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effect	  of	  ang-­‐II	   signalling	   inhibition	  on	  autophagy	   in	   skeletal	  muscle	   in	  COPD	  patients	  was	  
examined	  in	  Chapter	  5.	  
Autophagy	  may	  be	  perturbed	  in	  other	  ways	  in	  COPD.	  Exercise	  has	  been	  shown	  to	  up-­‐
regulate	   autophagy	   (He	   et	   al.,	   2012).	   Perhaps	   autophagy	   is	   impaired	   or	   impeded	   from	  
removing	  damaged	  proteins	  in	  muscle	  caused	  by	  exercise	  in	  COPD	  patients.	  The	  build-­‐up	  of	  
damaged	  proteins	  may	  lead	  to	  muscle	  dysfunction	  in	  COPD.	  Thus,	  it	  would	  be	  of	  interest	  to	  
examine	  the	  effect	  of	  exercise	  on	  autophagy	  in	  patients.	  	  
Indeed,	  it	  would	  be	  of	  interest	  to	  examine	  changes	  in	  autophagy	  levels	  after	  exercise	  
in	  COPD	  patients	  without	   intervention	  as	   it	  has	  recently	  been	  suggested	  that	  autophagy	   is	  
required	   for	   exercise	   induced	  muscle	   adaptations	   (Lira	   et	   al.,	   2013).	   Denervation	   induced	  
disuse	   in	  rats	  has	  been	  shown	  to	  cause	   increased	  ROS	  production	  and	  autophagy	  (O'Leary	  
and	  Hood,	  2008).	  O’Leary	  et	  al.	  also	  found	  LC3-­‐II	  translocation	  to	  mitochondrial	  membrane	  
suggesting	  that	  mitochondria	  are	  targeted	  for	  death	  (O'Leary	  and	  Hood,	  2009).	  
	  
6.6 Cigarette	  smoke	  and	  autophagy	  in	  skeletal	  muscle	  
Cigarette	  smoke,	  the	  main	  cause	  of	  COPD	  in	  the	  developed	  world	  (Buist	  et	  al.,	  2008),	  
may	   also	   have	   a	   role	   in	   the	   mechanism	   of	   muscle	   wasting	   in	   COPD.	   The	   GSK	   model	   of	  
chronic	   smoke	   exposure	   in	  mice	   revealed	   that	   only	   the	   smoke	   exposed	  mice	   lost	  muscle	  
mass,	   and	   that	   perhaps	   autophagy	   contributed	   to	   the	   loss.	   However,	   the	   changes	   in	  
autophagy	  do	  not	  appear	  to	  be	  due	  to	  myostatin	  or	  TGF-­‐β	  superfamily	  signalling.	  Given	  that	  
the	  mice	   were	   exposed	   for	   19	  months,	   it	   would	   be	   interesting	   to	   examine	   the	   effect	   of	  
smoke	  at	  12	  months	  to	  ascertain	  if	  the	  same	  signalling	  pathways	  were	  altered	  perhaps	  to	  an	  
even	  greater	  degree.	  Measurement	  of	  whole	  body	  lean	  mass	  of	  the	  mice	  using	  quantitative	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magnetic	  resonance	  (QMR)	  (Johnson	  et	  al.,	  2009)	  to	  examine	  muscle	  mass	  changes	  would	  
also	  be	  of	  importance.	  As	  the	  OCT	  embedded	  samples	  from	  this	  model	  were	  too	  damaged	  
to	   analyse,	   it	   would	   be	   particularly	   interesting	   to	   examine	   the	   effect	   of	   smoke	   on	   fibre	  
phenotype	   and	   fibre	   wasting.	   However,	   the	   restraint	   used	   in	   this	  model	   complicates	   the	  
findings	   significantly	  as	   there	  was	  a	  marked	  activation	  of	  myostatin	  expression	  and	  TGF-­‐β	  
signalling	  in	  the	  mice	  exposed	  to	  forced	  air	  compared	  to	  those	  exposed	  to	  room	  air.	  	  
Examination	  of	   the	  human	   samples	   from	  both	  healthy	   controls	   and	  COPD	  patients	  
showed	  that	  there	  was	  no	  change	  in	  autophagy	  levels	  in	  the	  vastus	  lateralis	  samples.	  Muscle	  
wasting	  has	  been	  shown	  to	  occur	  even	  at	  the	  early	  stages	  of	  COPD	  (Shrikrishna	  et	  al.,	  2012)	  
thus	   it	   would	   interesting	   to	   measure	   autophagy	   (at	   an	   mRNA	   and	   protein	   level)	   at	   the	  
various	   different	   stages	   of	   COPD	   as	   well	   as	   healthy	   smokers.	   This	   would	   give	   a	   more	  
dynamic	  perspective	  of	  autophagy	  during	  the	  progression	  of	  COPD.	  It	  would	  be	  of	  particular	  
interest	  to	  perhaps	  examine	  patient	  biopsies	  using	  electron	  microscopy	  for	  the	  presence	  of	  
autophagic	  vacuoles	  within	  muscle	  as	  another	  indicator	  of	  autophagy	  levels.	  
	  
6.7 Therapeutic	  Possibilities	  	  
There	   is	   still	   a	   need	   for	   effective	   drugs	   to	   target	   muscle	   atrophy	   in	   COPD.	   The	  
implications	   from	  the	  data	  presented	  here	   for	   therapeutics	   for	  skeletal	  muscle	  are	  varied.	  
Currently,	  myostatin	   inhibitors	   targeting	   the	   loss	  of	  muscle	  mass	  are	   in	  clinical	   trial,	   these	  
include	  antibodies	  to	  myostatin	  that	  bind	  and	   inactivate	  myostatin	   in	   the	  circulation	  (Lilly,	  
2013)	  and	  myostatin	  inhibitors	  that	  bind	  to	  the	  myostatin	  receptor.	  However,	  as	  these	  drugs	  
are	  not	  directly	   targeted	  to	  the	  muscle,	   they	  may	  also	  have	  side	  effects,	  such	  as	  ACE-­‐031,	  
which	  is	  a	  decoy	  receptor	  for	  myostatin	  by	  Acceleron	  Pharma	  and	  Shire	  for	  which	  the	  clinical	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trials	   were	   halted	   due	   to	   side	   effects	   from	   the	   drug	   (Wahl,	   2013,	   Wahl,	   2011).	   Equally,	  
others	  have	  shown	  efficacy	  in	  in	  vitro	  studies,	  which	  has	  not	  translated	  in	  humans	  such	  as	  in	  
the	  case	  of	  the	  moystatin	  antibody	  MYO-­‐029(MDA,	  2008).	  Currently,	  follistatin	  is	  also	  being	  
tested	   in	   vitro	   as	   a	   potential	   drug	   as	   it	   is	   a	  myostatin	   antagonist,	  which	   binds	   directly	   to	  
myostatin,	   preventing	   its	  binding	   to	   the	  activin	   receptor	   (Kota	  et	   al.,	   2009,	  Amthor	  et	   al.,	  
2004).	   The	   increasing	   evidence	   of	   the	   role	   of	   GDF-­‐15	   in	   muscle	   mass	   regulation	   would	  
indicate	  GDF-­‐15	  as	  a	  potential	  target	  for	  pharmacotherapy.	  	  
Although	   there	   are	   a	   number	   of	   FHL1	   related	   myopathies,	   currently	   it	   is	   not	   a	  
pharmacological	   drug	   target	   given	   the	   functional	   role	   of	   FHL1	   in	  muscle	  mass	   regulation	  
(Windpassinger	   et	   al.,	   2008,	   Schessl	   et	   al.,	   2008,	   Domenighetti	   et	   al.,	   2013).	   There	   are	   a	  
number	  of	  studies	  aimed	  at	  both	  inducing	  and	  inhibiting	  autophagy	  in	  a	  disease	  dependant	  
context.	  	  There	  are	  a	  number	  of	  autophagy	  inhibitors	  in	  existence	  undergoing	  clinical	  trials	  
such	   as	   hydroxychloroquine	   as	   a	   chemotherapeutic	   for	   breast	   cancer	   and	   chloroquine,	  
which	   is	  being	  used	   to	   treat	  Duchenne’s	  muscular	  dystrophy	   (Choi	  et	  al.,	  2013).	  However,	  
autophagy	  inhibitors	  must	  be	  rigorously	  tested	  as	  many	  autophagy	  proteins	  are	  involved	  in	  
other	  pathways,	   furthermore	  the	  pathogenesis	  of	  a	  disease	   in	   relation	  to	  autophagy	  must	  
be	  fully	  understood.	  For	  example,	  there	  are	  also	  studies	  attempting	  to	  promote	  autophagy,	  
as	  defective	  autophagy	  has	  resulted	  in	  myopathy	  (Lee	  et	  al.,	  2012).	  
Although	   there	   is	   a	   great	  need	   for	  drugs	   to	   target	  muscle	   atrophy,	   the	  delivery	  of	  
such	  drugs	  to	  the	  skeletal	  muscle	  only	  is	  one	  of	  the	  greatest	  challenges	  facing	  researchers.	  
Gene	  therapy	  is	  one	  such	  method	  of	  delivering	  myostatin	  inhibitors	  to	  skeletal	  muscle	  and	  
maintaining	   expression.	   One	   follistatin	   drug	   AAV1-­‐FS344,	   uses	   an	   adenoviral	   vector	   to	  
express	   the	   inhibitor	   in	   skeletal	   muscle	   and	   was	   shown	   to	   increase	  muscle	   strength	   and	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mass	   in	  non-­‐human	  primates	  (Kota	  et	  al.,	  2009).	  The	  trial	  has	   is	  now	  progressing	  to	  Phase	  
1/2	  safety	  with	  initial	  efficacy	  clinical	  trials	  in	  Becker	  muscular	  dystrophy	  and	  inclusion	  body	  
myositis	  patients	  (Pogorelc,	  2013).	  However,	  whether	  the	  adenoviral	  delivery	  will	  cause	  an	  
immunogenic	  reaction	  in	  humans	  remains	  to	  be	  seen.	  
Although	   the	   main	   focus	   of	   drug	   therapies	   has	   been	   targeted	   towards	   muscular	  
dystrophies	  such	  as	  Duchenne’s,	  Becker’s	  and	  limb	  girdle	  dystrophy,	  such	  drugs	  could	  easily	  
be	   given	   to	   COPD	   patients	   with	  muscle	   atrophy,	   provided	   the	   correct	   safety	   testing	   was	  
performed	   particularly	   with	   the	   medication	   that	   COPD	   patients	   use.	   Any	   form	   of	  
pharmocotherapy	   should	   be	   administered	   in	   a	   combination	   therapy	   with	   a	   pulmonary	  
rehabilitation	  program	  to	  reap	  the	  full	  benefits	  on	  muscle	  function.	  
	  
6.8 Conclusions	  
The	   data	   herein	   has	   shown	   for	   the	   first	   time	   that	   myostatin	   induces	   autophagy	  
providing	  a	  potential	  mechanism	  for	  myostatin	  to	  induce	  protein	  degradation	  and	  atrophy.	  
FHL1	   augmented	   myostatin	   signalling	   both	   in	   vitro	   and	   in	   vivo	   suggests	   a	   potential	  
mechanism	   for	  muscle	  wasting	   that	  amplifies	  myostatin	   signalling	   in	   the	   subset	  of	  muscle	  
fibres	  that	  express	  more	  FHL1	  (type	  II	  fibres,	  Figure	  46).	  	  Thus,	  as	  FHL1	  expression	  increases	  
due	   to	   inactivity,	   the	   fibre	   type	   proportion	   is	   shifted	   to	   predominantly	   type	   II	   fibres.	   The	  
greater	   presence	   of	   FHL1	   in	   type	   II	   fibres	   sensitises	   these	   fibres	   to	   myostatin-­‐induced	  
atrophy,	  thus,	  type	  II	  fibres	  atrophy	  to	  a	  greater	  extent	  than	  type	  I	  fibres.	  GDF-­‐15	  may	  be	  a	  
significant	  cytokine	  involved	  in	  atrophy	  that	  warrants	  further	  analysis.	  The	  role	  of	  cigarette	  
smoke	   does	   not	   appear	   to	   induce	   autophagy	   in	   skeletal	   muscle,	   however	   further	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investigation	  is	  required	  to	  clarify	  this.	  Ang-­‐II	  signalling	  does	  not	  appear	  to	  induce	  autophagy	  
and	  ACE	  blockade	  does	  not	  alter	  autophagy	  levels	  in	  COPD	  patients.	  
	   FHL1	   is	   another	   important	   protein	   in	   muscle	   mass	   regulation,	   and	   its	   function	  
appears	   to	   be	   context	   dependent.	  When	   over-­‐expressed	   alone,	   FHL1	   causes	   hypertrophy	  
(Cowling	   et	   al.,	   2008),	   however	   the	   data	   in	   Chapter	   4	   has	   shown	   that	   in	   the	   presence	   of	  
myostatin,	  FHL1	  enhances	  myostatin	  signalling	  both	  in	  vitro	  and	  in	  vivo.	  Furthermore,	  of	  the	  
3	  groups	  studied	   in	  the	  electroporation	  model,	  only	  the	  myostatin	  +	  FHL1	  over-­‐expressing	  
group	   showed	   significant	   changes	   in	   all	   the	   protein	   degradation	   pathways	   that	   were	  
examined.	  This	  would	  strongly	  suggest	  that	  FHL1	  plays	  a	  different	  role	   in	  the	  regulation	  of	  
muscle	  mass	  depending	  on	  the	  signalling	  environment	  within	  the	  cell.	  	  Furthermore	  the	  data	  
raise	  the	  possibility	  of	  FHL1	  contributing	  to	  the	  fibre-­‐specific	  effects	  of	  myostatin	  as	  FHL1	  is	  
preferentially	  expressed	   in	  type	   II	   fibres,	  which	  are	  the	  fibres	  that	  are	  most	  susceptible	  to	  
myostatin	  induced	  atrophy.	  
	   The	  data	  are	  limited	  by	  the	  number	  of	  mice	  analysed	  in	  each	  group	  so	  it	  would	  be	  of	  
interest	  to	  repeat	  the	  experiment	  in	  a	  larger	  group	  of	  mice,	  to	  confirm	  protein	  expression	  of	  
FHL1	  and	  myostatin	  as	  well	   as	   fibre	   type	  changes.	  Much	  of	  data	  presented	  displaying	   the	  
interaction	  between	  FHL1	  and	  myostatin	  has	  been	  gene	  expression.	  The	  argument	  would	  be	  
further	   strengthened	   by	   perhaps	   using	   immuno-­‐precipitation	   to	   show	   the	   physical	  
interaction	  between	  FHL1	  and	  myostatin	  in	  skeletal	  muscle.	  In	  addition,	  immuno-­‐staining	  or	  
western	   blotting	   confirming	   the	   over-­‐expression	   of	   FHL1	   and	   myostatin	   expression	   (via	  
SMAD	  signalling)	  would	  be	  useful.	  	  
	   Measurements	  such	  as	  the	  tetanic	  and	  twitch	  force	  of	  the	  electroporated	  TA	  might	  
also	   show	  differences	  between	   the	   strength	  of	   the	  myostatin	   +	   FHL1	  over-­‐expressing	   TAs	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and	   the	   other	   groups	   (Hakim	   et	   al.,	   2011).	   An	   improved	   method	   such	   as	   an	   automated	  
program	  of	  counting	  the	  different	   fibre	  types	  may	  also	  show	  more	  subtle	  changes	   in	   fibre	  
proportion.	  Further	  to	  this,	  an	  automated	  method	  of	  fibre	  diameter	  and/or	  area	  measuring	  
would	  also	  increase	  consistency,	  accuracy	  and	  output	  if	  a	  larger	  group	  were	  studied.	  
	   	  The	  data	  presented	  in	  Chapter	  4	  proposes	  a	  mechanism	  for	  the	  association	  of	  FHL1	  
with	  weakness	  and	  inactivity	  observed	  in	  the	  cohort	  of	  COPD	  patients	  previously	  studied	  in	  
the	  group	  (Lewis	  et	  al.,	  2010).	  FHL1	  over-­‐expression	  has	  been	  shown	  to	  cause	  an	  increase	  in	  
type	  IIA	  fibres,	  thus	  indicating	  that	  FHL1	  can	  drive	  fibre	  shift	  (Cowling	  et	  al.,	  2008).	  As	  COPD	  
patients	   become	   more	   inactive,	   FHL1	   expression	   increases,	   resulting	   in	   an	   increase	  
proportion	   of	   fast	   twitch	   type	   II	   fibres.	   Aside	   from	   the	   increase	   in	   proportion	   of	   type	   II	  
fibres,	   but	   the	   type	   II	   fibres	   also	   have	   a	   reduced	   fibre	   diameter	   (Gosker	   et	   al.,	   2002a,	  
Natanek	  et	  al.,	  2013a),	  suggesting	  that	  perhaps	  type	  II	  fibres	  have	  increased	  susceptibility	  to	  
atrophy	   signals.	   As	   both	   myostatin	   and	   FHL1	   expression	   is	   associated	   with	   type	   II	   fibres	  
(Lewis	  et	  al.,	  2010,	  Hennebry	  et	  al.,	  2009);	  the	  data	  presented	  here	  would	  suggest	  that	  the	  
atrophy	   effect	   of	  myostatin	   is	   enhanced	   in	   fast	   twitch	   fibres	   as	   these	   fibres	   also	   express	  
more	  FHL1,	  causing	  increased	  protein	  degradation	  and	  wasting	  in	  these	  fibres.	  The	  shift	   in	  
fibre	   type	   may	   drive	   a	   positive	   feedback	   mechanism	   as	   there	   are	   more	   type	   II	   fibres	  
expressing	  more	   FHL1,	   enhancing	   fibre	   atrophy	   and	  muscle	   dysfunction.	   	   In	   addition,	   the	  
increased	  activity	  of	  Mul1	  due	   to	   increased	  myostatin	   signalling	   in	   type	   II	   fibres	  may	  also	  
contribute	  to	  increased	  loss	  of	  mitochondria	  in	  these	  muscle	  fibres	  during	  atrophy	  and	  also	  
add	  to	  the	  fibre	  shift	  observed	  in	  COPD.	   	   	  	  
	   It	   is	   difficult	   to	   confirm	   the	   in	   vitro	   observations	   in	   patients	   as	   it	   is	   challenging	   to	  
measure	  changes	  caused	  by	  the	  augmentation	  of	  myostatin	  signalling	  by	  FHL1.	  For	  example,	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no	  changes	  in	  FHL1	  mRNA	  levels	  were	  detected	  in	  patients	  compared	  to	  control,	  however,	  
this	  may	  not	  necessarily	  imply	  that	  FHL1	  is	  not	  potentiating	  myostatin	  signalling,	  FHL1	  may	  
be	  more	  available	   (i.e.	  not	  bound	   to	  other	  proteins	   in	   the	   cell)	   to	  act	  upon	   the	   increased	  
myostatin	   signalling	  within	   the	   fibre.	  Thus	   it	  would	  be	  of	   interest	   to	  verify	   the	   location	  of	  
FHL1	  within	  patient	  muscle	  biopsies	  with	   immuno-­‐staining	  and	   to	  co-­‐stain	   for	  SMADs	  and	  
phospho-­‐SMADs	   to	  examine	   if	   the	   two	  proteins	   co-­‐localise	  within	   the	   fibres.	  Despite	   this,	  
the	  results	  of	  myostatin	  signalling	  enhancement	  may	  only	  be	  detectable	  as	   fibre	   type	  and	  
diameter	  changes,	  as	  it	  is	  unknown	  when	  the	  changes	  in	  myostatin	  signalling	  occur	  in	  COPD.	  
Laser	  capture	  micro-­‐	  dissection	  (LCM)	  could	  be	  used	  to	  dissect	  out	  specific	  fibres	  based	  on	  
immuno-­‐fluorescent	   staining	   from	  muscle	   biopsies	   to	   isolate	   only	   type	   II	   fibres	   for	  mRNA	  
and	  protein	  analysis	  (Vanderburg	  and	  Clarke,	  2013).	  Type	  II	  enriched	  samples	  could	  then	  be	  
used	  to	  examine	  if	  more	  FHL1	  was	  present	  in	  patients	  samples	  compared	  to	  controls	  and	  if	  
the	  expression	  of	  downstream	  signalling	  targets	  of	  myostatin	   (i.e.	   targets	  measurement	   in	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Figure	  46	  Diagram	  of	  the	  interplay	  between	  myostatin	  signalling	  and	  FHL1	  on	  autophagy	  
in	  type	  II	  fibres	  in	  COPD	  muscle	  atrophy	  
As	  inactivity	  drives	  a	  fibre	  type	  shift	  to	  a	  predominantly	  type	  II	  fibre	  type,	  these	  fibres	  also	  
atrophy	  to	  a	  greater	  extent	  than	  type	  I	  fibres.	  The	  higher	  expression	  of	  FHL1	  in	  type	  II	  fibres	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Appendix	  
Table	  18	  ATG	  genes	  involved	  in	  autophagy	  
Table	  of	  functions	  of	  human	  ATG	  genes,	  interacting	  proteins	  and	  yeast	  homolog	  genes.	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Figure	  47	  Growth	  curves	  of	  mice	  from	  a	  smaller	  19	  month	  smoke	  study	  
Growth	  data	  kindly	  provided	  by	  GSK	  from	  a	  similar	  study	  performed	  with	  a	  smaller	  number	  
of	  mice	  showed	  growth	  retardation	  in	  both	  forced	  air	  mice	  and	  smoke	  air	  mice	  compared	  to	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Table	   19	   Change	   in	   physiological	   and	   HRQOL	   outcomes	   following	   3	   months	   of	   ACE-­‐
inhibition	  








Endurance	  half-­‐time	  (s)	   4.6	  (28.0)	   5.1	  (24.2)	   0.94	  
QMVC	  (kg)	   3.6	  (4.3)	   1.1	  (2.9)	   0.009	  
TwQ	  (kg)	   0.6	  (1.5)	   -­‐0.3	  (1.8)	   0.06	  
MTCSA	  (cm2)	   1.0	  (3.7)	   -­‐0.6	  (4.1)	   0.09	  
ISWT	  (m)	   17.1	  (75.6)	   7.1	  (34.5)	   0.51	  
FEV1%	  pred	   2.7	  (5.6)	   1.7	  (6.8)	   0.50	  
TLco%	  pred	   1.2	  (4.7)	   -­‐0.23	  (4.3)	   0.20	  
RV%TLC	  ratio	   -­‐3.7	  (14.0)	   -­‐1.2	  (4.3)	   0.35	  
PaO2	  (kPa)	   -­‐0.12	  (0.8)	   -­‐0.05	  (1.1)	   0.77	  
PaCO2	  (kPa)	   -­‐0.02	  (0.5)	   -­‐0.05	  (0.4)	   0.79	  
SGRQ	  (Symptoms)	   -­‐1.8	  (19.4)	   4.0	  (21.0)	   0.25	  
SGRQ	  (Activity)	   -­‐1.5	  (9.9)	   -­‐1.5	  (11.9)	   0.99	  
SGRQ	  (Impacts)	   -­‐0.7	  (12.2)	   2.3	  (9.4)	   0.28	  
SGRQ	  (Total)	   -­‐1.1	  (10.1)	   1.5	  (7.9)	   0.25	  
CAT	  score	   -­‐2.6	  (5.7)	   -­‐0.3	  (6.2)	   0.18	  
	  
